{"title": "PDF", "author": "PDF", "url": "http://docs.saludchiapas.gob.mx/transparencia/pot/f01/F01_412.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 1/23NORMA\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad006\u00adSSA2\u00ad2013,\u00a0Para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\u00a0tuberculosis.\nA l \u00a0 m a r g e n \u00a0 u n \u00a0 s e l l o \u00a0 c o n \u00a0 e l \u00a0 E s c u d o \u00a0 N a c i o n a l , \u00a0 q u e \u00a0 d i c e : \u00a0 E s t a d o s \u00a0 U n i d o s \u00a0 M e x i c a n o s . \u00ad \u00a0 S e c r e t a r \u00ed a \u00a0 d e \u00a0 S a l u d .\nPABLO\u00a0ANTONIO\u00a0KURI\u00a0MORALES,\u00a0Subsecretario\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Promoci\u00f3n\u00a0de\u00a0la\u00a0Salud\u00a0y\u00a0Presidente\u00a0del\u00a0Comit\u00e9\nConsultivo\u00a0Nacional\u00a0de\u00a0Normalizaci\u00f3n\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades,\u00a0con\u00a0fundamento\u00a0en\u00a0los\u00a0art\u00edculos\u00a039,\u00a0de\u00a0la\u00a0Ley\nOrg\u00e1nica\u00a0de\u00a0la\u00a0Administraci\u00f3n\u00a0P\u00fablica\u00a0Federal\u037e\u00a04\u00a0de\u00a0la\u00a0Ley\u00a0Federal\u00a0de\u00a0Procedimiento\u00a0Administrativo\u037e\u00a03o,\u00a0fracci\u00f3n\u00a0XV,\u00a013,\napartado\u00a0A,\u00a0fracci\u00f3n\u00a0I,\u00a0133,\u00a0fracci\u00f3n\u00a0I,\u00a0134,\u00a0fracci\u00f3n\u00a0III,\u00a0135,\u00a0137,\u00a0139,\u00a0140,\u00a0145,\u00a0146,\u00a0351\u00a0y\u00a0393,\u00a0de\u00a0la\u00a0Ley\u00a0General\u00a0de\u00a0Salud\u037e\u00a038,\nfracci\u00f3n\u00a0II,\u00a040,\u00a0fracciones\u00a0III\u00a0y\u00a0XI,\u00a041,\u00a043\u00a0y\u00a047,\u00a0fracci\u00f3n\u00a0IV,\u00a0de\u00a0la\u00a0Ley\u00a0Federal\u00a0sobre\u00a0Metrolog\u00eda\u00a0y\u00a0Normalizaci\u00f3n\u037e\u00a04,\u00a08\u00a0y\u00a019,\u00a0del\nReglamento\u00a0de\u00a0la\u00a0Ley\u00a0General\u00a0de\u00a0Salud\u00a0en\u00a0materia\u00a0de\u00a0prestaci\u00f3n\u00a0de\u00a0servicios\u00a0de\u00a0atenci\u00f3n\u00a0m\u00e9dica\u037e\u00a028,\u00a0del\u00a0Reglamento\u00a0de\u00a0la\u00a0Ley\nFederal\u00a0sobre\u00a0Metrolog\u00eda\u00a0y\u00a0Normalizaci\u00f3n\u037e\u00a08,\u00a0fracci\u00f3n\u00a0V\u00a0y\u00a010,\u00a0fracciones\u00a0VII\u00a0y\u00a0XVI,\u00a0del\u00a0Reglamento\u00a0Interior\u00a0de\u00a0la\u00a0Secretar\u00eda\u00a0de\nSalud,\u00a0he\u00a0tenido\u00a0a\u00a0bien\u00a0expedir\u00a0y\u00a0ordenar\u00a0la\u00a0publicaci\u00f3n\u00a0en\u00a0el\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n,\u00a0de\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\nNOM\u00ad006\u00adSSA2\u00ad2013,\u00a0Para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\u00a0tuberculosis.\nCONSIDERANDO\nQue\u00a0con\u00a0fecha\u00a013\u00a0de\u00a0septiembre\u00a0de\u00a02012,\u00a0en\u00a0cumplimiento\u00a0al\u00a0acuerdo\u00a0del\u00a0Comit\u00e9\u00a0Consultivo\u00a0Nacional\u00a0de\u00a0Normalizaci\u00f3n\u00a0de\nPrevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades\u00a0y\u00a0a\u00a0lo\u00a0previsto\u00a0en\u00a0el\u00a0art\u00edculo\u00a047,\u00a0fracci\u00f3n\u00a0I,\u00a0de\u00a0la\u00a0Ley\u00a0Federal\u00a0sobre\u00a0Metrolog\u00eda\u00a0y\nNormalizaci\u00f3n,\u00a0se\u00a0public\u00f3\u00a0en\u00a0el\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n,\u00a0el\u00a0Proyecto\u00a0de\u00a0Modificaci\u00f3n\u00a0a\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad\n006\u00adSSA2\u00ad1993,\u00a0para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\u00a0tuberculosis\u00a0en\u00a0la\u00a0atenci\u00f3n\u00a0primaria\u00a0a\u00a0la\u00a0salud,\u00a0para\u00a0quedar\u00a0como\u00a0Proyecto\nde\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0PROY\u00adNOM\u00ad006\u00adSSA2\u00ad2010,\u00a0Para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\u00a0tuberculosis,\u00a0a\u00a0efecto\u00a0de\u00a0que\u00a0dentro\nde\u00a0los\u00a0siguientes\u00a060\u00a0d\u00edas\u00a0naturales\u00a0posteriores\u00a0a\u00a0dicha\u00a0publicaci\u00f3n,\u00a0los\u00a0interesados\u00a0presentaran\u00a0sus\u00a0comentarios\u00a0ante\u00a0dicho\nComit\u00e9.\nQue\u00a0de\u00a0conformidad\u00a0con\u00a0el\u00a0art\u00edculo\u00a045,\u00a0fracci\u00f3n\u00a0VI,\u00a0del\u00a0Reglamento\u00a0Interior\u00a0de\u00a0la\u00a0Secretar\u00eda\u00a0de\u00a0Salud,\u00a0el\u00a0Centro\u00a0Nacional\u00a0de\nProgramas\u00a0Preventivos\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades\u00a0(antes\u00a0Centro\u00a0Nacional\u00a0de\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0y\u00a0Control\u00a0de\nEnfermedades),\u00a0ha\u00a0realizado\u00a0el\u00a0seguimiento\u00a0de\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0en\u00a0cuesti\u00f3n\u00a0y\u00a0ha\u00a0decidido,\u00a0despu\u00e9s\u00a0de\u00a0los\u00a0an\u00e1lisis\ncient\u00edficos\u00a0necesarios,\u00a0proponer\u00a0la\u00a0actualizaci\u00f3n\u00a0del\u00a0contenido\u00a0de\u00a0la\u00a0Norma\u00a0de\u00a0m\u00e9rito\u00a0ante\u00a0el\u00a0Comit\u00e9\u00a0Consultivo\u00a0Nacional\u00a0de\nNormalizaci\u00f3n\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades,\u00a0especialmente\u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0prevenci\u00f3n,\u00a0detecci\u00f3n,\u00a0diagn\u00f3stico,\ntratamiento\u00a0y\u00a0atenci\u00f3n\u00a0integral\u00a0de\u00a0la\u00a0tuberculosis.\nQue\u00a0con\u00a0fecha\u00a0previa\u00a0fueron\u00a0publicados\u00a0en\u00a0el\u00a0Diario\u00a0oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\u00a0las\u00a0respuestas\u00a0a\u00a0los\u00a0comentarios\u00a0recibidos\u00a0por\u00a0el\nmencionado\u00a0Comit\u00e9,\u00a0en\u00a0t\u00e9rminos\u00a0de\u00a0lo\u00a0establecido\u00a0por\u00a0el\u00a0art\u00edculo\u00a047,\u00a0fracci\u00f3n\u00a0III,\u00a0de\u00a0la\u00a0Ley\u00a0Federal\u00a0sobre\u00a0Metrolog\u00eda\u00a0y\nNormalizaci\u00f3n.\nQue\u00a0en\u00a0atenci\u00f3n\u00a0a\u00a0las\u00a0anteriores\u00a0consideraciones,\u00a0contando\u00a0con\u00a0la\u00a0aprobaci\u00f3n\u00a0del\u00a0Comit\u00e9\u00a0Consultivo\u00a0Nacional\u00a0de\nNormalizaci\u00f3n\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades,\u00a0se\u00a0expide\u00a0la\u00a0siguiente:\nNorma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad006\u00adSSA2\u00ad2013,\u00a0Para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\u00a0tuberculosis\nPREFACIO\nEn\u00a0la\u00a0elaboraci\u00f3n\u00a0de\u00a0esta\u00a0Norma\u00a0participaron\u00a0las\u00a0unidades\u00a0administrativas\u00a0e\u00a0instituciones\u00a0siguientes:\nSECRETAR\u00cdA\u00a0DE\u00a0SALUD.\nCentro\u00a0Nacional\u00a0de\u00a0Programas\u00a0Preventivos\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades.\nDirecci\u00f3n\u00a0General\u00a0de\u00a0Epidemiolog\u00eda.\nInstituto\u00a0de\u00a0Diagn\u00f3stico\u00a0y\u00a0Referencia\u00a0Epidemiol\u00f3gicos.\nDirecci\u00f3n\u00a0General\u00a0de\u00a0Promoci\u00f3n\u00a0de\u00a0la\u00a0Salud.\nCentro\u00a0Nacional\u00a0para\u00a0la\u00a0Salud\u00a0de\u00a0la\u00a0Infancia\u00a0y\u00a0la\u00a0Adolescencia.\nCentro\u00a0Nacional\u00a0para\u00a0la\u00a0Prevenci\u00f3n\u00a0y\u00a0el\u00a0Control\u00a0del\u00a0VIH/SIDA.\nHOSPITAL\u00a0GENERAL\u00a0DE\u00a0M\u00c9XICO.\nHOSPITAL\u00a0INFANTIL\u00a0DE\u00a0M\u00c9XICO\u00a0FEDERICO\u00a0G\u00d3MEZ.\nINSTITUTO\u00a0NACIONAL\u00a0DE\u00a0ENFERMEDADES\u00a0RESPIRATORIAS\u00a0ISMAEL\u00a0COS\u00cdO\u00a0VILLEGAS.\nINSTITUTO\u00a0NACIONAL\u00a0DE\u00a0CIENCIAS\u00a0M\u00c9DICAS\u00a0Y\u00a0NUTRICI\u00d3N\u00a0SALVADOR\u00a0ZUBIR\u00c1N.\nINSTITUTO\u00a0NACIONAL\u00a0DE\u00a0PEDIATR\u00cdA.\nLABORATORIOS\u00a0DE\u00a0BIOL\u00d3GICOS\u00a0Y\u00a0REACTIVOS\u00a0DE\u00a0M\u00c9XICO,\u00a0S.A.\u00a0DE\u00a0C.V.\nSECRETAR\u00cdA\u00a0DE\u00a0LA\u00a0DEFENSA\u00a0NACIONAL.\nDirecci\u00f3n\u00a0General\u00a0de\u00a0Sanidad\u00a0Militar.\n\u00a0\nSECRETAR\u00cdA\u00a0DE\u00a0MARINA.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 2/23SECRETAR\u00cdA\u00a0DE\u00a0MARINA.\nDirecci\u00f3n\u00a0General\u00a0de\u00a0Sanidad\u00a0Naval.\nINSTITUTO\u00a0MEXICANO\u00a0DEL\u00a0SEGURO\u00a0SOCIAL.\nUnidad\u00a0IMSS\u00adOportunidades.\nUnidad\u00a0de\u00a0Salud\u00a0P\u00fablica,\u00a0Coordinaci\u00f3n\u00a0de\u00a0Programas\u00a0Integrados\u00a0de\u00a0Salud.\nINSTITUTO\u00a0DE\u00a0SEGURIDAD\u00a0Y\u00a0SERVICIOS\u00a0SOCIALES\u00a0DE\u00a0LOS\u00a0TRABAJADORES\u00a0DEL\u00a0ESTADO.\nCoordinaci\u00f3n\u00a0de\u00a0Asesores,\u00a0Direcci\u00f3n\u00a0M\u00e9dica.\nSubdirecci\u00f3n\u00a0de\u00a0Promoci\u00f3n\u00a0y\u00a0Prevenci\u00f3n\u00a0de\u00a0la\u00a0Salud.\nPETR\u00d3LEOS\u00a0MEXICANOS.\nGerencia\u00a0de\u00a0Servicios\u00a0M\u00e9dicos.\nSISTEMA\u00a0NACIONAL\u00a0PARA\u00a0EL\u00a0DESARROLLO\u00a0INTEGRAL\u00a0DE\u00a0LA\u00a0FAMILIA.\nDirecci\u00f3n\u00a0de\u00a0Atenci\u00f3n\u00a0M\u00e9dica.\nUNIVERSIDAD\u00a0NACIONAL\u00a0AUT\u00d3NOMA\u00a0DE\u00a0M\u00c9XICO.\nFacultad\u00a0de\u00a0Medicina.\nEscuela\u00a0Nacional\u00a0de\u00a0Enfermer\u00eda\u00a0y\u00a0Obstetricia.\nINSTITUTO\u00a0POLIT\u00c9CNICO\u00a0NACIONAL.\nEscuela\u00a0Superior\u00a0de\u00a0Medicina.\nASOCIACI\u00d3N\u00a0NACIONAL\u00a0DE\u00a0HOSPITALES\u00a0PRIVADOS\u00a0A.C.\nORGANIZACI\u00d3N\u00a0PANAMERICANA\u00a0DE\u00a0LA\u00a0SALUD/ORGANIZACI\u00d3N\u00a0MUNDIAL\u00a0DE\u00a0LA\u00a0SALUD.\nRepresentaci\u00f3n\u00a0en\u00a0M\u00e9xico.\nUNI\u00d3N\u00a0INTERNACIONAL\u00a0CONTRA\u00a0LA\u00a0TUBERCULOSIS\u00a0Y\u00a0ENFERMEDADES\u00a0RESPIRATORIAS.\nCOMIT\u00c9\u00a0NACIONAL\u00a0DE\u00a0LUCHA\u00a0CONTRA\u00a0LA\u00a0TUBERCULOSIS\u00a0Y\u00a0ENFERMEDADES\u00a0DEL\u00a0APARATO\u00a0RESPIRATORIO.\n\u00cdNDICE\n0 .\u00a0Introducci\u00f3n.\n1 .\u00a0Objetivo\u00a0y\u00a0Campo\u00a0de\u00a0aplicaci\u00f3n.\n2 .\u00a0Referencias.\n3 .\u00a0Definiciones.\n4 .\u00a0Abreviaturas.\n5 .\u00a0Clasificaci\u00f3n,\u00a0registro\u00a0y\u00a0notificaci\u00f3n.\n6 .\u00a0Especificaciones.\n7 .\u00a0Tuberculosis\u00a0y\u00a0otros\u00a0padecimientos.\n8 .\u00a0Tuberculosis\u00a0farmacorresistente.\n9 .\u00a0Bibliograf\u00eda.\n1 0 .\u00a0Concordancia\u00a0con\u00a0normas\u00a0internacionales\u00a0y\u00a0normas\u00a0mexicanas.\n1 1 .\u00a0Observancia\u00a0de\u00a0la\u00a0Norma.\n1 2 .\u00a0Vigencia.\n0 . \u00a0 I n t r o d u c c i \u00f3 n\nLa\u00a0tuberculosis\u00a0es\u00a0una\u00a0enfermedad\u00a0infecciosa,\u00a0causada\u00a0por\u00a0un\u00a0grupo\u00a0de\u00a0bacterias\u00a0del\u00a0orden\u00a0Actinomicetales\u00a0de\u00a0la\u00a0familia\nMycobacteriaceae\u037e\u00a0el\u00a0complejo\u00a0M.\u00a0tuberculosis\u00a0se\u00a0compone\u00a0por:\u00a0M.\u00a0tuberculosis,\u00a0M.\u00a0bovis,\u00a0M.\u00a0africanum,\u00a0M.\u00a0microti,\u00a0M.\u00a0canettii,\u00a0M.\ncaprae\u00a0y\u00a0M.\u00a0pinnipedii\u00a0y\u00a0se\u00a0adquiere\u00a0por\u00a0v\u00eda\u00a0a\u00e9rea,\u00a0principalmente.\u00a0Es\u00a0una\u00a0enfermedad\u00a0sist\u00e9mica\u00a0que\u00a0afecta\u00a0mayoritariamente\u00a0al\nsistema\u00a0respiratorio.\u00a0Ataca\u00a0al\u00a0estado\u00a0general\u00a0y\u00a0de\u00a0no\u00a0tratarse\u00a0oportuna\u00a0y\u00a0eficientemente,\u00a0puede\u00a0causar\u00a0la\u00a0muerte\u00a0a\u00a0quien\u00a0la\npadece.\nLa\u00a0Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud,\u00a0informa\u00a0que\u00a0un\u00a0tercio\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0mundial\u00a0est\u00e1\u00a0infectada\u00a0por\u00a0el\u00a0Mycobacterium\ntuberculosis\u037e\u00a0cada\u00a0a\u00f1o\u00a0se\u00a0estima\u00a0una\u00a0ocurrencia\u00a0cercana\u00a0a\u00a09\u00a0millones\u00a0de\u00a0casos\u00a0nuevos\u00a0y\u00a01.7\u00a0millones\u00a0de\u00a0defunciones\u00a0por\ntuberculosis.\u00a0En\u00a0M\u00e9xico,\u00a0se\u00a0diagnosticaron\u00a0en\u00a02010\u00a0m\u00e1s\u00a0de\u00a018\u00a0mil\u00a0casos\u00a0nuevos\u00a0y\u00a0cerca\u00a0de\u00a02,000\u00a0defunciones\u00a0por\u00a0esta\u00a0causa.\nEs\u00a0sabido\u00a0que\u00a0factores\u00a0como:\u00a0la\u00a0desnutrici\u00f3n,\u00a0el\u00a0alcoholismo,\u00a0las\u00a0adicciones,\u00a0las\u00a0afecciones\u00a0de\u00a0la\u00a0respuesta\u00a0inmunol\u00f3gica\u00a0e,\nincluso,\u00a0las\u00a0condiciones\u00a0deficientes\u00a0de\u00a0vivienda,\u00a0influyen\u00a0en\u00a0el\u00a0desarrollo\u00a0de\u00a0la\u00a0enfermedad\u00a0tuberculosa.\nLo\u00a0anterior\u00a0se\u00a0relaciona\u00a0con\u00a0las\u00a0enfermedades\u00a0m\u00e1s\u00a0frecuentemente\u00a0asociadas\u00a0con\u00a0la\u00a0tuberculosis\u00a0en\u00a0M\u00e9xico,\u00a0que\u00a0en\u00a0orden\nde\u00a0frecuencia\u00a0son:\u00a0diabetes\u00a0(20%),\u00a0desnutrici\u00f3n\u00a0(13%),\u00a0VIH/SIDA\u00a0(10%)\u00a0y\u00a0alcoholismo\u00a0(6%).\u00a0La\u00a0importancia\u00a0de\u00a0esta\u00a0relaci\u00f3n\nradica\u00a0en\u00a0que\u00a0estas\u00a0enfermedades\u00a0no\u00a0son\u00a0s\u00f3lo\u00a0condicionantes\u00a0de\u00a0infecci\u00f3n\u00a0tuberculosa,\u00a0sino\u00a0que\u00a0adem\u00e1s\u00a0pueden\u00a0afectar\u00a0la\ncuraci\u00f3n\u00a0y\u00a0la\u00a0sobrevida\u00a0de\u00a0las\u00a0personas\u00a0afectadas\u00a0por\u00a0la\u00a0tuberculosis.\nEs\u00a0de\u00a0particular\u00a0importancia\u00a0la\u00a0relaci\u00f3n\u00a0simbi\u00f3tica\u00a0con\u00a0el\u00a0VIH/SIDA,\u00a0debido\u00a0a\u00a0que\u00a0ambas\u00a0son\u00a0enfermedades\u00a0que\u00a0se\u00a0impulsan\nmutuamente:\u00a0la\u00a0tuberculosis\u00a0es\u00a0la\u00a0enfermedad\u00a0infecciosa\u00a0por\u00a0la\u00a0que\u00a0fallece\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0personas\u00a0que\u00a0viven\u00a0con\u00a0VIH\u00a0en\nel\u00a0mundo\u00a0y\u00a0el\u00a0VIH\u00a0activa\u00a0la\u00a0tuberculosis\u00a0latente\u00a0de\u00a0una\u00a0persona\u00a0infectada.\nDestaca\u00a0la\u00a0tuberculosis\u00a0farmacorresistente,\u00a0debido\u00a0a\u00a0los\u00a0m\u00faltiples\u00a0factores\u00a0que\u00a0la\u00a0condicionan\u00a0y\u00a0al\u00a0problema\u00a0terap\u00e9utico\u00a0que\nrepresenta\u00a0su\u00a0tratamiento,\u00a0aun\u00a0cuando\u00a0en\u00a0M\u00e9xico\u00a0representa\u00a0una\u00a0peque\u00f1a\u00a0proporci\u00f3n\u00a0del\u00a0total\u00a0de\u00a0los\u00a0enfermos.\u00a0Al\u00a0respecto,\u00a0el\napego\u00a0al\u00a0tratamiento\u00a0acortado\u00a0estrictamente\u00a0supervisado\u00a0es\u00a0la\u00a0principal\u00a0estrategia\u00a0que\u00a0garantiza\u00a0la\u00a0curaci\u00f3n\u00a0y\u00a0previene\u00a0en\nconsecuencia\u00a0la\u00a0aparici\u00f3n\u00a0de\u00a0casos\u00a0de\u00a0resistencia\u00a0bacteriana.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 3/23En\u00a0M\u00e9xico,\u00a0el\u00a0Programa\u00a0de\u00a0Acci\u00f3n\u00a0de\u00a0Tuberculosis,\u00a0tiene\u00a0como\u00a0misi\u00f3n\u00a0contribuir\u00a0a\u00a0alcanzar\u00a0una\u00a0mejor\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0las\npersonas\u00a0afectadas\u00a0por\u00a0la\u00a0tuberculosis\u00a0y\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0en\u00a0riesgo,\u00a0mediante\u00a0acciones\u00a0permanentes\u00a0e\u00a0integradas\u00a0de\u00a0promoci\u00f3n,\nprevenci\u00f3n,\u00a0tratamiento\u00a0y\u00a0vigilancia\u00a0de\u00a0la\u00a0tuberculosis,\u00a0reduciendo\u00a0los\u00a0riesgos\u00a0de\u00a0enfermar\u00a0y\u00a0morir\u00a0por\u00a0esta\u00a0causa.\nPara\u00a0enfrentar\u00a0el\u00a0problema\u00a0de\u00a0salud\u00a0p\u00fablica\u00a0que\u00a0representa\u00a0la\u00a0tuberculosis,\u00a0las\u00a0instituciones\u00a0que\u00a0forman\u00a0parte\u00a0del\u00a0Sistema\nNacional\u00a0de\u00a0Salud,\u00a0han\u00a0unificado\u00a0criterios\u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0para,\u00a0mediante\u00a0un\u00a0frente\u00a0com\u00fan\u00a0ante\u00a0esta\nproblem\u00e1tica,\u00a0avanzar\u00a0hacia\u00a0un\u00a0\"M\u00e9xico\u00a0Libre\u00a0de\u00a0Tuberculosis\".\n1 . \u00a0 O b j e t i v o \u00a0 y \u00a0 c a m p o \u00a0 d e \u00a0 a p l i c a c i \u00f3 n\n\u00a0\u00a0\u00a0Esta\u00a0Norma\u00a0tiene\u00a0por\u00a0objeto\u00a0establecer\u00a0y\u00a0uniformar\u00a0los\u00a0criterios,\u00a0procedimientos\u00a0y\u00a0lineamientos\u00a0para\u00a0la\u00a0prevenci\u00f3n,\u00a0detecci\u00f3n,\ndiagn\u00f3stico,\u00a0tratamiento\u00a0y\u00a0atenci\u00f3n\u00a0integral\u00a0de\u00a0la\u00a0tuberculosis,\u00a0as\u00ed\u00a0como,\u00a0las\u00a0medidas\u00a0de\u00a0control\u00a0necesarias\u00a0en\u00a0materia\u00a0de\u00a0salud\np\u00fablica,\u00a0que\u00a0deben\u00a0realizarse\u00a0en\u00a0todos\u00a0los\u00a0establecimientos\u00a0de\u00a0prestaci\u00f3n\u00a0de\u00a0servicios\u00a0de\u00a0atenci\u00f3n\u00a0m\u00e9dica\u00a0de\u00a0los\u00a0sectores\np\u00fablico,\u00a0social\u00a0y\u00a0privado\u00a0del\u00a0Sistema\u00a0Nacional\u00a0de\u00a0Salud.\n\u00a0\u00a0\u00a0Esta\u00a0Norma\u00a0ser\u00e1\u00a0obligatoria\u00a0en\u00a0todo\u00a0el\u00a0territorio\u00a0nacional,\u00a0para\u00a0todos\u00a0los\u00a0establecimientos\u00a0de\u00a0los\u00a0sectores\u00a0p\u00fablico,\u00a0social\u00a0y\nprivado\u00a0del\u00a0Sistema\u00a0Nacional\u00a0de\u00a0Salud\u00a0en\u00a0los\u00a0que\u00a0se\u00a0realicen\u00a0actividades\u00a0para\u00a0la\u00a0prevenci\u00f3n,\u00a0detecci\u00f3n,\u00a0diagn\u00f3stico,\u00a0tratamiento\ny\u00a0atenci\u00f3n\u00a0integral\u00a0de\u00a0la\u00a0tuberculosis.\n2 . \u00a0 R e f e r e n c i a s\nPara\u00a0la\u00a0correcta\u00a0aplicaci\u00f3n\u00a0de\u00a0esta\u00a0Norma\u00a0es\u00a0necesario\u00a0consultar\u00a0las\u00a0siguientes\u00a0Normas\u00a0Oficiales\u00a0Mexicanas\u00a0o\u00a0las\u00a0que\u00a0la\nsustituyan:\n2 . 1\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad004\u00adSSA3\u00ad2012,\u00a0Del\u00a0expediente\u00a0cl\u00ednico.\n2 . 2\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad010\u00adSSA2\u00ad2010,\u00a0Para\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0el\u00a0control\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0Virus\u00a0de\u00a0la\nInmunodeficiencia\u00a0Humana.\n2 . 3 \u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad015\u00adSSA2\u00ad2010,\u00a0Para\u00a0la\u00a0prevenci\u00f3n,\u00a0tratamiento\u00a0y\u00a0control\u00a0de\u00a0la\u00a0diabetes\u00a0mellitus.\n2 . 4 \u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad017\u00adSSA2\u00ad2012,\u00a0Para\u00a0la\u00a0vigilancia\u00a0epidemiol\u00f3gica.\n2 . 5\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad031\u00adSSA2\u00ad1999,\u00a0Para\u00a0la\u00a0atenci\u00f3n\u00a0a\u00a0la\u00a0salud\u00a0del\u00a0ni\u00f1o.\n2 . 6 \u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad036\u00adSSA2\u00ad2012,\u00a0Prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0enfermedades.\u00a0Aplicaci\u00f3n\u00a0de\u00a0vacunas,\u00a0toxoides,\nfaboter\u00e1picos\u00a0(sueros),\u00a0e\u00a0inmunoglobulinas\u00a0en\u00a0el\u00a0humano.\n2 . 7\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad043\u00adSSA2\u00ad2012,\u00a0Servicios\u00a0b\u00e1sicos\u00a0de\u00a0salud.\u00a0Promoci\u00f3n\u00a0y\u00a0educaci\u00f3n\u00a0para\u00a0la\u00a0salud\u00a0en\nmateria\u00a0alimentaria.\u00a0Criterios\u00a0para\u00a0brindar\u00a0orientaci\u00f3n.\n2 . 8\u00a0Modificaci\u00f3n\u00a0a\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad028\u00adSSA2\u00ad1999,Para\u00a0la\u00a0prevenci\u00f3n,\u00a0tratamiento\u00a0y\u00a0control\u00a0de\u00a0las\nadicciones,\u00a0para\u00a0quedar\u00a0como\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad028\u00adSSA2\u00ad2009,\u00a0Para\u00a0la\u00a0prevenci\u00f3n,\u00a0tratamiento\u00a0y\u00a0control\u00a0de\u00a0las\nadicciones.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 4/232 . 9\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0NOM\u00ad045\u00adSSA2\u00ad2005,\u00a0Para\u00a0la\u00a0vigilancia\u00a0epidemiol\u00f3gica,\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0las\u00a0infecciones\nnosocomiales.\n3 . \u00a0 D e f i n i c i o n e s\nPara\u00a0efectos\u00a0de\u00a0esta\u00a0Norma\u00a0se\u00a0entiende\u00a0por:\n3 . 1 \u00a0 A b a n d o n o \u00a0 e n \u00a0 t r a t a m i e n t o \u00a0 p r i m a r i o :\u00a0a\u00a0la\u00a0interrupci\u00f3n\u00a0del\u00a0tratamiento\u00a0contra\u00a0la\u00a0tuberculosis\u00a0durante\u00a0treinta\u00a0o\u00a0m\u00e1s\u00a0d\u00edas\nconsecutivos.\n3 . 2\u00a0 A b a n d o n o \u00a0 e n \u00a0 t u b e r c u l o s i s \u00a0 f a r m a c o r r e s i s t e n t e :\u00a0al\u00a0paciente\u00a0que\u00a0interrumpi\u00f3\u00a0el\u00a0tratamiento\u00a0durante\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0meses\nconsecutivos.\n3 . 3 \u00a0 A b o g a c \u00ed a \u00a0 p a r a \u00a0 l a \u00a0 s a l u d :\u00a0a\u00a0la\u00a0combinaci\u00f3n\u00a0de\u00a0acciones\u00a0individuales\u00a0y\u00a0sociales\u00a0destinadas\u00a0a\u00a0obtener\u00a0compromisos\npol\u00edticos,\u00a0aceptaci\u00f3n\u00a0social\u00a0y\u00a0apoyo\u00a0de\u00a0los\u00a0sistemas\u00a0para\u00a0un\u00a0determinado\u00a0objetivo\u00a0o\u00a0programa\u00a0de\u00a0salud.\n3 . 4\u00a0 A d i c c i o n e s : \u00a0a\u00a0los\u00a0h\u00e1bitos\u00a0o\u00a0actividades\u00a0que\u00a0desarrolla\u00a0un\u00a0individuo\u00a0a\u00a0fin\u00a0de\u00a0mantener\u00a0el\u00a0uso\u00a0y/o\u00a0abuso\u00a0de\u00a0alguna\u00a0droga,\ngeneralmente\u00a0t\u00f3xica,\u00a0que\u00a0afectan\u00a0negativamente\u00a0su\u00a0salud\u00a0f\u00edsica\u00a0y\u00a0mental.\n3 . 5\u00a0 A l c o h o l i s m o :\u00a0a\u00a0la\u00a0adicci\u00f3n\u00a0al\u00a0alcohol.\n3 . 6\u00a0 B a c i l o s c o p i a :\u00a0a\u00a0la\u00a0t\u00e9cnica\u00a0de\u00a0laboratorio\u00a0que\u00a0mediante\u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0Ziehl\u00a0Neelsen,\u00a0preferentemente,\u00a0permite\u00a0observar\u00a0en\nun\u00a0frotis\u00a0bacilos\u00a0\u00e1cido\u00a0alcohol\u00a0resistentes\u00a0puede\u00a0ser\u00a0para\u00a0detecci\u00f3n,\u00a0diagn\u00f3stico\u00a0o\u00a0control.\n3 . 7\u00a0 B a c i l o s c o p i a \u00a0 n e g a t i v a :\u00a0a\u00a0la\u00a0ausencia\u00a0de\u00a0bacilos\u00a0\u00e1cido\u00a0alcohol\u00a0resistentes,\u00a0en\u00a0la\u00a0lectura\u00a0de\u00a0100\u00a0campos\u00a0microsc\u00f3picos\n\u00fatiles\u00a0del\u00a0frotis\u00a0de\u00a0la\u00a0expectoraci\u00f3n\u00a0o\u00a0de\u00a0cualquier\u00a0otro\u00a0esp\u00e9cimen.\n3 . 8\u00a0 B a c i l o s c o p i a \u00a0 p o s i t i v a :\u00a0a\u00a0la\u00a0demostraci\u00f3n\u00a0de\u00a0uno\u00a0o\u00a0m\u00e1s\u00a0bacilos\u00a0\u00e1cido\u00a0alcohol\u00a0resistentes,\u00a0en\u00a0la\u00a0lectura\u00a0de\u00a0100\u00a0campos\ndel\u00a0frotis\u00a0de\u00a0la\u00a0expectoraci\u00f3n\u00a0o\u00a0de\u00a0cualquier\u00a0otro\u00a0esp\u00e9cimen.\n3 . 9\u00a0 B a c i l o s c o p i a \u00a0 d e \u00a0 c o n t r o l :\u00a0a\u00a0la\u00a0que\u00a0se\u00a0realiza\u00a0mensualmente\u00a0durante\u00a0el\u00a0tratamiento\u00a0del\u00a0paciente\u00a0con\u00a0tuberculosis\npulmonar\u00a0para\u00a0evaluar\u00a0su\u00a0evoluci\u00f3n.\n3 . 1 0\u00a0 C a s o \u00a0 d e \u00a0 t u b e r c u l o s i s :\u00a0a\u00a0la\u00a0persona\u00a0en\u00a0quien\u00a0se\u00a0establece\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0tuberculosis\u00a0pulmonar\u00a0o\u00a0extrapulmonar\u00a0y\nse\u00a0clasifica\u00a0en\u00a0caso\u00a0confirmado\u00a0o\u00a0caso\u00a0no\u00a0confirmado.\n3 . 1 1\u00a0 C a s o \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 c o n f i r m a d o :\u00a0a\u00a0la\u00a0persona\u00a0en\u00a0quien\u00a0se\u00a0ha\u00a0identificado\u00a0por\u00a0laboratorio\u00a0el\u00a0complejo\u00a0Mycobacterium\ntuberculosis\u00a0en\u00a0cualquier\u00a0muestra\u00a0biol\u00f3gica\u00a0ya\u00a0sea\u00a0por\u00a0cultivo,\u00a0baciloscopia\u00a0o\u00a0por\u00a0m\u00e9todos\u00a0moleculares.\n3 . 1 2 \u00a0 C a s o \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 n o \u00a0 c o n f i r m a d o :\u00a0a\u00a0la\u00a0persona\u00a0con\u00a0tuberculosis\u00a0en\u00a0quien\u00a0la\u00a0sintomatolog\u00eda,\u00a0signos\u00a0f\u00edsicos,\nelementos\u00a0auxiliares\u00a0de\u00a0diagn\u00f3stico,\u00a0respuesta\u00a0terap\u00e9utica,\u00a0sugieren\u00a0la\u00a0evidencia\u00a0de\u00a0tuberculosis\u00a0y\u00a0la\u00a0baciloscopia,\u00a0cultivo\u00a0o\nm\u00e9todos\u00a0moleculares\u00a0fueron\u00a0negativos.\n3 . 1 3\u00a0 C a s o \u00a0 n u e v o :\u00a0a\u00a0la\u00a0persona\u00a0en\u00a0quien\u00a0se\u00a0establece\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0tuberculosis\u00a0por\u00a0primera\u00a0vez\u00a0o\u00a0si\u00a0recibi\u00f3\u00a0tratamiento,\nfue\u00a0por\u00a0menos\u00a0de\u00a0treinta\u00a0d\u00edas.\n3 . 1 4\u00a0 C a s o \u00a0 p r e v i a m e n t e \u00a0 t r a t a d o :\u00a0al\u00a0enfermo\u00a0que\u00a0ha\u00a0recibido\u00a0al\u00a0menos\u00a0un\u00a0esquema\u00a0de\u00a0tratamiento\u00a0anti\u00a0tuberculosis\u00a0por\u00a0lo\nmenos\u00a0durante\u00a0un\u00a0mes.\n3 . 1 5\u00a0 C a s o \u00a0 p r o b a b l e \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 p u l m o n a r \u00a0 ( s i n t o m \u00e1 t i c o \u00a0 r e s p i r a t o r i o ) :\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0presenta\u00a0tos\u00a0con\u00a0expectoraci\u00f3n\no\u00a0hemoptisis,\u00a0de\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0semanas\u00a0de\u00a0evoluci\u00f3n,\u00a0en\u00a0las\u00a0cuales\u00a0deben\u00a0agotarse\u00a0los\u00a0recursos\u00a0de\u00a0diagn\u00f3stico\u00a0previo\u00a0a\u00a0iniciar\u00a0el\ntratamiento.\u00a0En\u00a0ni\u00f1as\u00a0y\u00a0ni\u00f1os,\u00a0todo\u00a0caso\u00a0que\u00a0presenta\u00a0tos\u00a0con\u00a0o\u00a0sin\u00a0expectoraci\u00f3n\u00a0durante\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0semanas,\u00a0fiebre,\u00a0diaforesis\nnocturna,\u00a0detenci\u00f3n\u00a0o\u00a0baja\u00a0de\u00a0peso.\n3 . 1 6 \u00a0 C a s o \u00a0 p r o b a b l e \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 m e n \u00ed n g e a :\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0presente\u00a0cualquiera\u00a0de\u00a0los\u00a0s\u00edndromes:\u00a0men\u00edngeo,\u00a0cr\u00e1neo\nhipertensivo\u00a0o\u00a0encef\u00e1lico,\u00a0de\u00a0manera\u00a0individual\u00a0o\u00a0combinada\u00a0y\u00a0que\u00a0pueden\u00a0acompa\u00f1arse\u00a0de\u00a0manifestaciones\u00a0generales\u00a0de\ninfecci\u00f3n.\u00a0En\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0de\u00a0edad:\u00a0los\u00a0que\u00a0presenten\u00a0rechazo\u00a0al\u00a0alimento,\u00a0somnolencia\u00a0e\u00a0irritabilidad,\u00a0aunado\u00a0a\u00a0los\ns\u00edndromes\u00a0arriba\u00a0mencionados.\u00a0Con\u00a0o\u00a0sin\u00a0antecedente\u00a0de\u00a0contacto\u00a0con\u00a0alg\u00fan\u00a0caso\u00a0de\u00a0tuberculosis\u00a0pulmonar,\u00a0con\u00a0sospecha\u00a0por\ncualquier\u00a0auxiliar\u00a0de\u00a0diagn\u00f3stico\u00a0(por\u00a0ejemplo,\u00a0citoqu\u00edmico\u00a0de\u00a0LCR,\u00a0imagenolog\u00eda,\u00a0entre\u00a0otros).\n3 . 1 7\u00a0 C a s o \u00a0 p r o b a b l e \u00a0 d e \u00a0 T u b e r c u l o s i s \u00a0 M u l t i f a r m a c o r r e s i s t e n t e :\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0recibi\u00f3\u00a0retratamiento\u00a0primario\u00a0o\u00a0f\u00e1rmacos\nde\u00a0segunda\u00a0l\u00ednea\u00a0o\u00a0contactos\u00a0con\u00a0caso\u00a0conocido\u00a0de\u00a0Multifarmacorresistencia.\n3 . 1 8\u00a0 C a s o \u00a0 c o n f i r m a d o \u00a0 d e \u00a0 T u b e r c u l o s i s \u00a0 M u l t i f a r m a c o r r e s i s t e n t e : \u00a0al\u00a0caso\u00a0en\u00a0el\u00a0que\u00a0se\u00a0confirma\u00a0que\u00a0las\u00a0cepas\u00a0infectantes\nde\u00a0M.\u00a0tuberculosis\u00a0son\u00a0resistentes\u00a0in\u00a0vitro\u00a0como\u00a0m\u00ednimo\u00a0a\u00a0la\u00a0isoniacida\u00a0y\u00a0a\u00a0la\u00a0rifampicina,\u00a0simult\u00e1neamente.\n3 . 1 9 \u00a0 C a s o \u00a0 c o n f i r m a d o \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 m e n \u00ed n g e a :\u00a0al\u00a0caso\u00a0probable\u00a0de\u00a0tuberculosis\u00a0men\u00edngea\u00a0que\u00a0cuenta\u00a0con\u00a0confirmaci\u00f3n\npor\u00a0laboratorio\u00a0de\u00a0la\u00a0presencia\u00a0de\u00a0Mycobacterium\u00a0tuberculosis,\u00a0en\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0baciloscopia,\u00a0cultivo\u00a0o\nm\u00e9todos\u00a0moleculares.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 5/233 . 2 0\u00a0 C a s o \u00a0 d e \u00a0 t u b e r c u l o s i s \u00a0 d e s c a r t a d o :\u00a0al\u00a0caso\u00a0probable\u00a0de\u00a0tuberculosis\u00a0en\u00a0quien\u00a0se\u00a0compruebe\u00a0otra\u00a0etiolog\u00eda.\n3 . 2 1 \u00a0 C o m i t \u00e9 \u00a0 E s t a t a l \u00a0 d e \u00a0 F a r m a c o r r e s i s t e n c i a :\u00a0a\u00a0los\u00a0grupos\u00a0de\u00a0apoyo\u00a0al\u00a0Programa\u00a0de\u00a0Acci\u00f3n\u00a0de\u00a0Tuberculosis\u00a0en\u00a0cada\u00a0una\nde\u00a0las\u00a032\u00a0entidades\u00a0federativas\u00a0de\u00a0la\u00a0Rep\u00fablica\u00a0Mexicana\u00a0y\u00a0que\u00a0est\u00e1\u00a0conformado\u00a0por\u00a0el\u00a0coordinador\u00a0del\u00a0Programa\u00a0de\nTuberculosis\u00a0en\u00a0el\u00a0estado,\u00a0m\u00e9dicos\u00a0consultores\u00a0(neum\u00f3logo,\u00a0internista,\u00a0infect\u00f3logo,\u00a0pediatra),tratantes\u00a0de\u00a0casos\u00a0TB\u00adMFR\nidentificados\u00a0por\u00a0el\u00a0estado,\u00a0responsables\u00a0de\u00a0la\u00a0Red\u00a0TAES,\u00a0responsables\u00a0de\u00a0la\u00a0Red\u00a0estatal\u00a0de\u00a0laboratorios,\u00a0autoridades\u00a0sanitarias\nencargadas\u00a0de\u00a0revisar,\u00a0dictaminar,\u00a0tratar\u00a0y\u00a0dar\u00a0seguimiento\u00a0a\u00a0los\u00a0casos\u00a0complicados\u00a0de\u00a0tuberculosis\u00a0y\u00a0los\u00a0no\u00a0previstos.\n3 . 2 2\u00a0 C o n t a c t o :\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0convive\u00a0o\u00a0ha\u00a0convivido\u00a0con\u00a0un\u00a0enfermo\u00a0de\u00a0tuberculosis\u00a0bacil\u00edfero\u00a0de\u00a0manera\u00a0intra\u00a0o\u00a0extra\ndomiciliaria\u00a0y\u00a0que\u00a0tiene\u00a0la\u00a0posibilidad\u00a0de\u00a0contraer\u00a0la\u00a0infecci\u00f3n.\n3 . 2 3\u00a0 C o n v e r s i \u00f3 n \u00a0 a \u00a0 l a \u00a0 p r u e b a \u00a0 d e \u00a0 l a \u00a0 t u b e r c u l i n a \u00a0 ( P P D ) :\u00a0a\u00a0la\u00a0reactividad\u00a0al\u00a0PPD\u00a0en\u00a0una\u00a0persona\u00a0previamente\u00a0PPD\u00a0negativo.\n3 . 2 4\u00a0 C u l t i v o :\u00a0a\u00a0la\u00a0t\u00e9cnica\u00a0de\u00a0laboratorio\u00a0que\u00a0permite\u00a0el\u00a0aislamiento\u00a0de\u00a0M.\u00a0tuberculosis\u00a0en\u00a0medio\u00a0s\u00f3lido\u00a0o\u00a0l\u00edquido.\n3 . 2 5\u00a0 C u l t i v o \u00a0 n e g a t i v o :\u00a0a\u00a0la\u00a0ausencia\u00a0de\u00a0desarrollo\u00a0de\u00a0bacilos\u00a0\u00e1cido\u00a0alcohol\u00a0resistentes\u00a0despu\u00e9s\u00a0de\u00a0ocho\u00a0semanas\u00a0de\nobservaci\u00f3n,\u00a0en\u00a0medio\u00a0s\u00f3lido\u00a0o\u00a0despu\u00e9s\u00a0de\u00a0seis\u00a0semanas\u00a0en\u00a0medio\u00a0l\u00edquido.\n3 . 2 6\u00a0 C u l t i v o \u00a0 p o s i t i v o :\u00a0a\u00a0la\u00a0demostraci\u00f3n\u00a0de\u00a0desarrollo\u00a0con\u00a0caracter\u00edsticas\u00a0del\u00a0Complejo\u00a0Mycobacterium\u00a0tuberculosis.\n3 . 2 7\u00a0 C u r a c i \u00f3 n \u00a0 d e \u00a0 c a s o \u00a0 c o n f i r m a d o \u00a0 b a c t e r i o l \u00f3 g i c a m e n t e :\u00a0al\u00a0caso\u00a0de\u00a0tuberculosis\u00a0que\u00a0termina\u00a0su\u00a0tratamiento,\u00a0desaparecen\nlos\u00a0signos\u00a0cl\u00ednicos\u00a0y\u00a0tiene\u00a0baciloscopia\u00a0negativa\u00a0en\u00a0los\u00a0dos\u00a0\u00faltimos\u00a0meses\u00a0de\u00a0tratamiento\u00a0o\u00a0cultivo\u00a0negativo\u00a0al\u00a0final\u00a0del\ntratamiento.\n3 . 2 8 \u00a0 C u r a c i \u00f3 n \u00a0 d e \u00a0 c a s o \u00a0 n o \u00a0 c o n f i r m a d o \u00a0 b a c t e r i o l \u00f3 g i c a m e n t e :\u00a0al\u00a0caso\u00a0de\u00a0tuberculosis\u00a0que\u00a0termina\u00a0el\u00a0tratamiento,\ndesaparecen\u00a0los\u00a0signos\u00a0cl\u00ednicos\u00a0y\u00a0se\u00a0observa\u00a0mejora\u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0gabinete.\n3 . 2 9\u00a0 C u r a c i \u00f3 n \u00a0 d e \u00a0 c a s o \u00a0 d e \u00a0 T u b e r c u l o s i s \u00a0 r e s i s t e n t e :\u00a0al\u00a0paciente\u00a0con\u00a0Tuberculosis\u00a0Multifarmacorresistente\u00a0que\u00a0complet\u00f3\u00a0el\ntratamiento\u00a0indicado\u00a0y\u00a0presenta\u00a0al\u00a0menos\u00a0cinco\u00a0cultivos\u00a0consecutivos\u00a0negativos\u00a0con\u00a0intervalo\u00a0m\u00ednimo\u00a0de\u00a0sesenta\u00a0d\u00edas\u00a0durante\u00a0los\n\u00faltimos\u00a0doce\u00a0meses\u00a0de\u00a0tratamiento.\u00a0Si\u00a0en\u00a0este\u00a0lapso\u00a0se\u00a0notifica\u00a0un\u00a0solo\u00a0cultivo\u00a0positivo\u00a0y\u00a0no\u00a0ocurre\u00a0ning\u00fan\u00a0otro\u00a0signo\u00a0cl\u00ednico\u00a0de\ndeterioro,\u00a0todav\u00eda\u00a0el\u00a0paciente\u00a0puede\u00a0considerarse\u00a0curado\u00a0si\u00a0dicho\u00a0cultivo\u00a0va\u00a0seguido\u00a0de\u00a0un\u00a0m\u00ednimo\u00a0de\u00a0tres\u00a0cultivos\u00a0consecutivos\nnegativos\u00a0con\u00a0intervalo\u00a0cada\u00a0uno\u00a0de\u00a0treinta\u00a0d\u00edas.\n3 . 3 0\u00a0 D e f u n c i \u00f3 n \u00a0 p o r \u00a0 t u b e r c u l o s i s :\u00a0a\u00a0la\u00a0defunci\u00f3n\u00a0en\u00a0la\u00a0que\u00a0la\u00a0tuberculosis\u00a0inicia\u00a0la\u00a0serie\u00a0de\u00a0acontecimientos\u00a0que\u00a0llevan\u00a0a\u00a0la\nmuerte.\n3 . 3 1 \u00a0 D e s a r r o l l o \u00a0 d e \u00a0 c o m p e t e n c i a s \u00a0 e n \u00a0 s a l u d :\u00a0a\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0conocimientos\u00a0y\u00a0fomento\u00a0de\u00a0aptitudes,\u00a0actitudes\u00a0y\u00a0valores\npara\u00a0que\u00a0las\u00a0personas\u00a0salvaguarden\u00a0su\u00a0salud,\u00a0fortaleciendo\u00a0los\u00a0determinantes\u00a0positivos.\n3 . 3 2 \u00a0 D e t e r m i n a n t e s \u00a0 d e \u00a0 l a \u00a0 s a l u d :\u00a0al\u00a0conjunto\u00a0de\u00a0condiciones\u00a0biol\u00f3gicas,\u00a0ambientales,\u00a0sociales,\u00a0econ\u00f3micas,\u00a0culturales,\u00a0estilo\nde\u00a0vida\u00a0y\u00a0servicios\u00a0de\u00a0salud,\u00a0que\u00a0afectan\u00a0o\u00a0favorecen\u00a0la\u00a0salud\u00a0de\u00a0los\u00a0individuos\u00a0y/o\u00a0comunidades.\n3 . 3 3\u00a0 E m p o d e r a m i e n t o \u00a0 p a r a \u00a0 l a \u00a0 s a l u d \u00a0 ( a u t o c u i d a d o ) :\u00a0al\u00a0proceso\u00a0mediante\u00a0el\u00a0cual\u00a0la\u00a0persona\u00a0o\u00a0comunidad\u00a0adquieren\u00a0mayor\ncontrol\u00a0sobre\u00a0las\u00a0acciones\u00a0y\u00a0decisiones\u00a0que\u00a0afectan\u00a0su\u00a0salud.\n3 . 3 4\u00a0 E n t o r n o \u00a0 f a v o r a b l e :\u00a0al\u00a0proceso\u00a0mediante\u00a0el\u00a0cual\u00a0se\u00a0propician\u00a0espacios\u00a0f\u00edsicos\u00a0y\u00a0sociales,\u00a0donde\u00a0se\u00a0promueve\u00a0la\u00a0salud\u00a0y\nse\u00a0mejora\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0las\u00a0personas\u00a0o\u00a0de\u00a0una\u00a0comunidad.\n3 . 3 5 \u00a0 E s t i l o \u00a0 d e \u00a0 v i d a :\u00a0al\u00a0patr\u00f3n\u00a0de\u00a0comportamiento\u00a0identificable\u00a0por\u00a0las\u00a0interacciones\u00a0entre\u00a0caracter\u00edsticas\u00a0personales,\ninteracci\u00f3n\u00a0social\u00a0y\u00a0condiciones\u00a0de\u00a0vida\u00a0socioecon\u00f3mica\u00a0y\u00a0ambiental.\n3 . 3 6\u00a0 E s t u d i o \u00a0 d e \u00a0 c o n t a c t o s :\u00a0a\u00a0las\u00a0acciones\u00a0dirigidas\u00a0para\u00a0identificar\u00a0personas\u00a0infectadas\u00a0o\u00a0enfermos\u00a0que\u00a0conviven\u00a0o\u00a0han\nconvivido\u00a0con\u00a0un\u00a0enfermo\u00a0de\u00a0tuberculosis.\n3 . 3 7\u00a0 E x a m e n \u00a0 b a c t e r i o l \u00f3 g i c o :\u00a0a\u00a0la\u00a0b\u00fasqueda\u00a0de\u00a0bacilos\u00a0\u00e1cido\u00a0alcohol\u00a0resistentes\u00a0mediante\u00a0baciloscopia\u00a0o\u00a0cultivo\u00a0de\nmuestras\u00a0de\u00a0expectoraci\u00f3n\u00a0u\u00a0otros\u00a0espec\u00edmenes.\n3 . 3 8\u00a0 F a r m a c o r r e s i s t e n c i a :\u00a0al\u00a0concepto\u00a0microbiol\u00f3gico\u00a0en\u00a0el\u00a0cual\u00a0un\u00a0microorganismo\u00a0del\u00a0complejo\u00a0M.\u00a0tuberculosis\u00a0se\nconfirma\u00a0resistente\u00a0por\u00a0pruebas\u00a0de\u00a0f\u00e1rmaco\u00a0sensibilidad\u00a0in\u00a0vitro\u00a0a\u00a0uno\u00a0o\u00a0m\u00e1s\u00a0medicamentos\u00a0anti\u00a0tuberculosis\u00a0de\u00a0primera\u00a0o\nsegunda\u00a0l\u00ednea.\n3 . 3 9\u00a0 F \u00e1 r m a c o s \u00a0 d e \u00a0 p r i m e r a \u00a0 l \u00ed n e a :\u00a0a\u00a0los\u00a0que\u00a0se\u00a0utilizan\u00a0en\u00a0el\u00a0tratamiento\u00a0primario\u00a0de\u00a0la\u00a0tuberculosis:\u00a0isoniacida,\u00a0rifampicina,\npirazinamida,\u00a0estreptomicina\u00a0y\u00a0etambutol.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 6/233 . 4 0\u00a0 F r a c a s o \u00a0 d e \u00a0 t r a t a m i e n t o :\u00a0a\u00a0la\u00a0persistencia\u00a0de\u00a0bacilos\u00a0en\u00a0la\u00a0expectoraci\u00f3n\u00a0o\u00a0en\u00a0otros\u00a0espec\u00edmenes,\u00a0al\u00a0t\u00e9rmino\u00a0de\ntratamiento,\u00a0confirmada\u00a0por\u00a0cultivo\u00a0o\u00a0a\u00a0quien\u00a0despu\u00e9s\u00a0de\u00a0un\u00a0periodo\u00a0de\u00a0negativizaci\u00f3n\u00a0durante\u00a0el\u00a0tratamiento,\u00a0tiene\u00a0baciloscopia\npositiva\u00a0confirmada\u00a0por\u00a0cultivo.\n3 . 4 1\u00a0 F r a c a s o \u00a0 e n \u00a0 p a c i e n t e s \u00a0 c o n \u00a0 T u b e r c u l o s i s \u00a0 M u l t i f a r m a c o r r e s i s t e n t e :\u00a0cuando\u00a0en\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0de\u00a0los\u00a0cinco\u00a0\u00faltimos\u00a0cultivos\nconsecutivos\u00a0durante\u00a0los\u00a0\u00faltimos\u00a0doce\u00a0meses\u00a0es\u00a0positivo\u00a0o\u00a0si\u00a0uno\u00a0de\u00a0los\u00a0tres\u00a0\u00faltimos\u00a0cultivos\u00a0es\u00a0positivo.\u00a0Tambi\u00e9n\u00a0se\u00a0considera\nfracaso\u00a0si\u00a0tuvo\u00a0que\u00a0suspender\u00a0el\u00a0tratamiento\u00a0tempranamente,\u00a0ya\u00a0sea\u00a0por\u00a0deterioro\u00a0cl\u00ednico\u00a0o\u00a0radiol\u00f3gico\u00a0o\u00a0presencia\u00a0de\nreacciones\u00a0adversas.\n3 . 4 2\u00a0 G r u p o s \u00a0 e n \u00a0 r i e s g o :\u00a0a\u00a0los\u00a0individuos\u00a0susceptibles\u00a0y\u00a0a\u00a0quienes\u00a0por\u00a0sus\u00a0condiciones\u00a0de\u00a0trabajo,\u00a0ocupaci\u00f3n\u00a0o\u00a0vivienda,\ntienen\u00a0una\u00a0alta\u00a0probabilidad\u00a0de\u00a0entrar\u00a0en\u00a0contacto\u00a0con\u00a0la\u00a0bacteria\u00a0y\u00a0adquirir\u00a0la\u00a0infecci\u00f3n.\n3 . 4 3 \u00a0 I n m u n o c o m p e t e n c i a : \u00a0al\u00a0estado\u00a0del\u00a0sistema\u00a0inmunol\u00f3gico,\u00a0que\u00a0se\u00a0traduce\u00a0en\u00a0resolver\u00a0adecuadamente\u00a0los\u00a0encuentros\ncon\u00a0las\u00a0infecciones.\n3 . 4 4 \u00a0 I n m u n o c o m p r o m i s o :\u00a0a\u00a0la\u00a0condici\u00f3n\u00a0en\u00a0la\u00a0que\u00a0el\u00a0sistema\u00a0inmunol\u00f3gico\u00a0presenta\u00a0deficiencia\u00a0cualitativa\u00a0de\u00a0su\u00a0funci\u00f3n,\ndebida\u00a0a\u00a0enfermedades\u00a0sist\u00e9micas\u00a0o\u00a0uso\u00a0de\u00a0f\u00e1rmacos.\n3 . 4 5 \u00a0 M e d i d a s \u00a0 d e \u00a0 c o n t r o l \u00a0 a m b i e n t a l :\u00a0a\u00a0los\u00a0sistemas\u00a0y/o\u00a0equipos\u00a0que\u00a0se\u00a0pueden\u00a0utilizar\u00a0en\u00a0las\u00a0\u00e1reas\u00a0de\u00a0mayor\u00a0riesgo\u00a0de\ntransmisi\u00f3n\u00a0de\u00a0tuberculosis\u00a0para\u00a0reducir\u00a0la\u00a0concentraci\u00f3n\u00a0de\u00a0part\u00edculas\u00a0infecciosas\u00a0dentro\u00a0de\u00a0los\u00a0establecimientos\u00a0de\u00a0salud,\nincluyen\u00a0ventilaci\u00f3n,\u00a0uso\u00a0de\u00a0filtros\u00a0de\u00a0alta\u00a0eficiencia\u00a0(HEPA)\u00a0y\u00a0l\u00e1mparas\u00a0germicidas\u00a0de\u00a0rayos\u00a0ultravioleta.\n3 . 4 6\u00a0 M e d i d a s \u00a0 d e \u00a0 p r o t e c c i \u00f3 n \u00a0 r e s p i r a t o r i a :\u00a0a\u00a0las\u00a0medidas\u00a0que\u00a0tienen\u00a0por\u00a0objetivo\u00a0proteger\u00a0a\u00a0las\u00a0personas\u00a0en\u00a0\u00e1reas\u00a0donde\u00a0la\nconcentraci\u00f3n\u00a0de\u00a0part\u00edculas\u00a0infectantes\u00a0no\u00a0pueden\u00a0ser\u00a0reducida\u00a0por\u00a0las\u00a0medidas\u00a0de\u00a0control\u00a0gerenciales\u00adadministrativas\u00a0y\nambientales.\n3 . 4 7\u00a0 M e d i d a s \u00a0 g e r e n c i a l e s \u00ad a d m i n i s t r a t i v a s :\u00a0a\u00a0las\u00a0medidas\u00a0de\u00a0control\u00a0m\u00e1s\u00a0importantes\u00a0para\u00a0disminuir\u00a0el\u00a0riesgo\u00a0de\ntransmisi\u00f3n\u00a0de\u00a0tuberculosis\u00a0y\u00a0que\u00a0tienen\u00a0por\u00a0objetivo\u00a0reducir\u00a0la\u00a0exposici\u00f3n\u00a0de\u00a0los\u00a0trabajadores\u00a0de\u00a0la\u00a0salud\u00a0al\u00a0M.\u00a0tuberculosis,\u00a0las\ncuales\u00a0est\u00e1n\u00a0asociadas\u00a0a\u00a0la\u00a0separaci\u00f3n,\u00a0detecci\u00f3n\u00a0temprana\u00a0e\u00a0inicio\u00a0inmediato\u00a0del\u00a0tratamiento\u00a0a\u00a0las\u00a0personas\u00a0con\u00a0tuberculosis,\neducaci\u00f3n\u00a0al\u00a0afectado\u00a0por\u00a0la\u00a0tuberculosis\u00a0y\u00a0a\u00a0los\u00a0trabajadores\u00a0de\u00a0la\u00a0salud.\n3 . 4 8\u00a0 M e d i d a s \u00a0 p a r a \u00a0 p r e v e n i r \u00a0 l a \u00a0 t r a n s m i s i \u00f3 n \u00a0 d e \u00a0 l a \u00a0 t u b e r c u l o s i s \u00a0 e n \u00a0 e s t a b l e c i m i e n t o s \u00a0 d e \u00a0 s a l u d \u00a0 ( c o n t r o l \u00a0 d e \u00a0 i n f e c c i o n e s \u00a0 e n\nt u b e r c u l o s i s ) :\u00a0a\u00a0las\u00a0medidas\u00a0que\u00a0tienen\u00a0por\u00a0objetivo\u00a0limitar,\u00a0disminuir\u00a0y\u00a0controlar\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0M.\u00a0tuberculosis.\u00a0Estas\nmedidas\u00a0tambi\u00e9n\u00a0pueden\u00a0ser\u00a0aplicadas\u00a0en\u00a0sitios\u00a0de\u00a0concentraci\u00f3n\u00a0(c\u00e1rceles,\u00a0entre\u00a0otros)\u00a0y\u00a0domicilios.\u00a0Se\u00a0dividen\u00a0en:\n\u00a0\u00a0\u00a0\u00a0Medidas\u00a0gerenciales\u00a0administrativas.\n\u00a0\u00a0\u00a0\u00a0Medidas\u00a0de\u00a0control\u00a0ambiental.\n\u00a0\u00a0\u00a0\u00a0Medidas\u00a0de\u00a0protecci\u00f3n\u00a0respiratoria.\n3 . 4 9 \u00a0 P a r t i c i p a c i \u00f3 n \u00a0 s o c i a l \u00a0 p a r a \u00a0 l a \u00a0 a c c i \u00f3 n \u00a0 c o m u n i t a r i a :\u00a0a\u00a0la\u00a0acci\u00f3n\u00a0organizada\u00a0e\u00a0informada\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0para\u00a0participar\ncon\u00a0autoridades\u00a0locales,\u00a0otros\u00a0sectores\u00a0y\u00a0organizaciones\u00a0sociales\u00a0en\u00a0tareas\u00a0encaminadas\u00a0a\u00a0posibilitar\u00a0instrumentos\u00a0y\u00a0facilitar\nestrategias\u00a0de\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud,\u00a0desde\u00a0una\u00a0base\u00a0social\u00a0para\u00a0el\u00a0empoderamiento\u00a0de\u00a0las\u00a0comunidades.\n3 . 5 0\u00a0 P r u e b a s \u00a0 d e \u00a0 f a r m a c o s e n s i b i l i d a d :\u00a0a\u00a0las\u00a0t\u00e9cnicas\u00a0de\u00a0laboratorio\u00a0que\u00a0permiten\u00a0determinar\u00a0in\u00a0vitro\u00a0si\u00a0el\u00a0crecimiento\u00a0de\u00a0los\nbacilos\u00a0de\u00a0M.\u00a0tuberculosis\u00a0aislados\u00a0de\u00a0un\u00a0paciente\u00a0son\u00a0inhibidos\u00a0(sensibles)\u00a0o\u00a0no\u00a0(resistentes)\u00a0por\u00a0un\u00a0f\u00e1rmaco.\n3 . 5 1\u00a0 Q u i m i o p r o f i l a x i s \u00a0 ( t e r a p i a \u00a0 p r e v e n t i v a ) :\u00a0a\u00a0la\u00a0administraci\u00f3n\u00a0de\u00a0isoniacida\u00a0a\u00a0contactos\u00a0u\u00a0otras\u00a0personas\u00a0con\u00a0alto\u00a0riesgo\u00a0y\nque\u00a0lo\u00a0requieran,\u00a0con\u00a0objeto\u00a0de\u00a0prevenir\u00a0la\u00a0infecci\u00f3n\u00a0primaria\u00a0o\u00a0el\u00a0desarrollo\u00a0de\u00a0la\u00a0enfermedad\u00a0tuberculosa.\n3 . 5 2\u00a0 R e a c t o r \u00a0 a l \u00a0 P P D :\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0a\u00a0las\u00a0setenta\u00a0y\u00a0dos\u00a0horas\u00a0de\u00a0aplicar\u00a0la\u00a0prueba\u00a0presenta\u00a0en\u00a0el\u00a0sitio\u00a0de\u00a0la\u00a0aplicaci\u00f3n\ninduraci\u00f3n\u00a0intrad\u00e9rmica\u00a0de\u00a010\u00a0mm\u00a0o\u00a0m\u00e1s.\u00a0En\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0con\u00a0o\u00a0sin\u00a0vacuna\u00a0Bacilo\u00a0de\u00a0Calmette\u00a0y\u00a0Gu\u00e9rin\u00a0y\u00a0en\nparticular\u00a0los\u00a0reci\u00e9n\u00a0nacidos,\u00a0as\u00ed\u00a0como,\u00a0enfermos\u00a0con\u00a0desnutrici\u00f3n\u00a0y\u00a0con\u00a0inmunodeficiencia,\u00a0se\u00a0considera\u00a0reactor\u00a0a\u00a0quien\npresente\u00a0induraci\u00f3n\u00a0de\u00a05\u00a0mm\u00a0o\u00a0m\u00e1s.\n3 . 5 3 \u00a0 R e c a \u00ed d a :\u00a0a\u00a0la\u00a0reaparici\u00f3n\u00a0de\u00a0signos\u00a0y\u00a0s\u00edntomas\u00a0en\u00a0un\u00a0paciente\u00a0que\u00a0habiendo\u00a0sido\u00a0declarado\u00a0como\u00a0curado\u00a0o\u00a0con\ntratamiento\u00a0terminado,\u00a0presenta\u00a0nuevamente\u00a0baciloscopia\u00a0y/o\u00a0cultivo\u00a0positivo.\n3 . 5 4\u00a0 R e c a m b i o \u00a0 d e \u00a0 a i r e :\u00a0a\u00a0la\u00a0expulsi\u00f3n\u00a0del\u00a0aire\u00a0viciado\u00a0y\u00a0su\u00a0sustituci\u00f3n\u00a0por\u00a0aire\u00a0fresco\u00a0en\u00a0un\u00a0determinado\u00a0tiempo\u00a0por\u00a0medio\nde\u00a0ventilaci\u00f3n\u00a0natural\u00a0o\u00a0mec\u00e1nica.\n3 . 5 5\u00a0 R e i n g r e s o :\u00a0al\u00a0caso\u00a0de\u00a0tuberculosis\u00a0que\u00a0ingresa\u00a0nuevamente\u00a0a\u00a0un\u00a0tratamiento\u00a0y\u00a0por\u00a0tanto\u00a0al\u00a0sistema\u00a0de\u00a0registro,\u00a0despu\u00e9s\nde\u00a0abandono,\u00a0reca\u00edda\u00a0o\u00a0fracaso.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 7/233 . 5 6\u00a0 R e t r a t a m i e n t o \u00a0 p r i m a r i o :\u00a0al\u00a0esquema\u00a0de\u00a0tratamiento\u00a0que\u00a0se\u00a0instituye\u00a0a\u00a0los\u00a0pacientes\u00a0con\u00a0reca\u00edda\u00a0o\u00a0abandono\u00a0de\u00a0un\ntratamiento\u00a0primario\u00a0acortado.\u00a0Se\u00a0sugiere\u00a0la\u00a0administraci\u00f3n\u00a0de\u00a0cinco\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea\u00a0durante\u00a0ocho\u00a0meses,\u00a0dividido\u00a0en\ntres\u00a0fases.\n3 . 5 7 \u00a0 R e t r a t a m i e n t o \u00a0 e s t a n d a r i z a d o :\u00a0al\u00a0esquema\u00a0de\u00a0tratamiento\u00a0que\u00a0se\u00a0instituye\u00a0a\u00a0un\u00a0enfermo\u00a0con\u00a0fracaso\u00a0a\u00a0un\u00a0esquema\u00a0de\nretratamiento\u00a0primario\u00a0o\u00a0con\u00a0tuberculosis\u00a0multifarmacorresistente\u00a0que\u00a0no\u00a0haya\u00a0recibido\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0previamente,\nque\u00a0es\u00a0confirmado\u00a0por\u00a0cultivo\u00a0y\u00a0pruebas\u00a0de\u00a0farmacosensibilidad\u00a0y\u00a0es\u00a0avalado\u00a0por\u00a0el\u00a0Comit\u00e9\u00a0Estatal\u00a0de\u00a0Farmacorresistencia\ncorrespondiente.\n3 . 5 8\u00a0 R e t r a t a m i e n t o \u00a0 i n d i v i d u a l i z a d o :\u00a0al\u00a0esquema\u00a0de\u00a0tratamiento\u00a0que\u00a0se\u00a0instituye\u00a0a\u00a0un\u00a0enfermo\u00a0con\u00a0TB\u00adMFR\u00a0multitratado\u00a0o\ncon\u00a0fracaso\u00a0a\u00a0un\u00a0esquema\u00a0de\u00a0retratamiento\u00a0estandarizado,\u00a0fundamentado\u00a0en\u00a0el\u00a0resultado\u00a0del\u00a0estudio\u00a0de\u00a0farmacosensibilidad.\nComprende\u00a0la\u00a0administraci\u00f3n\u00a0de\u00a0un\u00a0tratamiento\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea.\u00a0La\u00a0combinaci\u00f3n\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos\u00a0ser\u00e1n\ndefinidos\u00a0por\u00a0el\u00a0Comit\u00e9\u00a0Estatal\u00a0de\u00a0Farmacorresistencia\u00a0o\u00a0por\u00a0el\u00a0Grupo\u00a0Asesor\u00a0Nacional\u00a0de\u00a0Farmacorresistencia.\n3 . 5 9\u00a0 S e r v i c i o \u00a0 i n t e g r a d o \u00a0 d e \u00a0 p r o m o c i \u00f3 n \u00a0 d e \u00a0 l a \u00a0 s a l u d :\u00a0a\u00a0la\u00a0estrategia\u00a0mediante\u00a0la\u00a0cual\u00a0se\u00a0cumplen\u00a0las\u00a0funciones\u00a0de\u00a0promoci\u00f3n\nde\u00a0la\u00a0salud,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0siete\u00a0componentes:\u00a0manejo\u00a0de\u00a0riesgos\u00a0personales,\u00a0desarrollo\u00a0de\u00a0competencias\u00a0en\u00a0salud,\u00a0participaci\u00f3n\npara\u00a0la\u00a0acci\u00f3n\u00a0comunitaria,\u00a0entornos\u00a0favorables,\u00a0comunicaci\u00f3n\u00a0educativa,\u00a0abogac\u00eda\u00a0para\u00a0la\u00a0salud\u00a0y\u00a0evidencias\u00a0para\u00a0la\u00a0salud\u037e\ncuyas\u00a0intervenciones\u00a0van\u00a0de\u00a0lo\u00a0individual\u00a0a\u00a0lo\u00a0poblacional\u00a0y\u00a0tiene\u00a0como\u00a0finalidad\u00a0la\u00a0entrega\u00a0de\u00a0acciones\u00a0de\u00a0promoci\u00f3n\u00a0de\u00a0la\nsalud\u00a0en\u00a0el\u00a0nivel\u00a0local\u00a0con\u00a0enfoque\u00a0de\u00a0interculturalidad,\u00a0g\u00e9nero\u00a0y\u00a0equidad.\n3 . 6 0\u00a0 T \u00e9 r m i n o \u00a0 d e \u00a0 t r a t a m i e n t o : \u00a0al\u00a0caso\u00a0de\u00a0tuberculosis\u00a0que\u00a0ha\u00a0completado\u00a0el\u00a0esquema\u00a0de\u00a0tratamiento,\u00a0han\u00a0desaparecido\u00a0los\nsignos\u00a0cl\u00ednicos\u00a0y\u00a0no\u00a0se\u00a0realiz\u00f3\u00a0baciloscopia\u00a0o\u00a0cultivo\u00a0al\u00a0finalizar\u00a0el\u00a0tratamiento.\n3 . 6 1 \u00a0 T r a t a m i e n t o \u00a0 e s t r i c t a m e n t e \u00a0 s u p e r v i s a d o :\u00a0al\u00a0que\u00a0administra\u00a0el\u00a0personal\u00a0de\u00a0salud\u00a0o\u00a0personal\u00a0capacitado\u00a0por\u00a0el\u00a0mismo,\nquien\u00a0confirma\u00a0la\u00a0ingesta\u00a0y\u00a0degluci\u00f3n\u00a0del\u00a0f\u00e1rmaco\u00a0para\u00a0garantizar\u00a0el\u00a0cumplimiento\u00a0del\u00a0tratamiento.\n3 . 6 2\u00a0 T r a t a m i e n t o \u00a0 p r i m a r i o \u00a0 a c o r t a d o :\u00a0al\u00a0tratamiento\u00a0que\u00a0se\u00a0aplica\u00a0a\u00a0todos\u00a0los\u00a0casos\u00a0nuevos.\u00a0Comprende\u00a0la\u00a0administraci\u00f3n\u00a0de\nmedicamentos\u00a0de\u00a0primera\u00a0l\u00ednea:\u00a0isoniacida,\u00a0rifampicina,\u00a0pirazinamida\u00a0y\u00a0etambutol.\n3 . 6 3\u00a0 T u b e r c u l o s i s :\u00a0a\u00a0la\u00a0enfermedad\u00a0infecciosa,\u00a0causada\u00a0por\u00a0el\u00a0complejo\u00a0Mycobacterium\u00a0tuberculosis\u00a0(M.\u00a0tuberculosis,\u00a0M.\nbovis,\u00a0M.\u00a0microti,\u00a0M.\u00a0africanum,\u00a0M.\u00a0canettii,\u00a0M.\u00a0caprae\u00a0y\u00a0M.\u00a0pinnipedii),\u00a0que\u00a0se\u00a0transmite\u00a0del\u00a0enfermo\u00a0al\u00a0sujeto\u00a0sano\u00a0por\u00a0inhalaci\u00f3n\nde\u00a0material\u00a0infectante\u037e\u00a0de\u00a0madre\u00a0infectada\u00a0al\u00a0producto,\u00a0ingesti\u00f3n\u00a0de\u00a0leche\u00a0contaminada,\u00a0contacto\u00a0con\u00a0personas\u00a0enfermas\nbacil\u00edferas\u00a0o\u00a0animales\u00a0enfermos.\u00a0Puede\u00a0ser\u00a0de\u00a0localizaci\u00f3n\u00a0pulmonar\u00a0o\u00a0extra\u00a0pulmonar.\n3 . 6 4\u00a0 T u b e r c u l o s i s \u00a0 l a t e n t e \u00a0 o \u00a0 i n f e c c i \u00f3 n \u00a0 t u b e r c u l o s a :\u00a0a\u00a0la\u00a0condici\u00f3n\u00a0de\u00a0la\u00a0persona\u00a0ya\u00a0infectada\u00a0con\u00a0M.\u00a0tuberculosis,\ndemostrada\u00a0por\u00a0su\u00a0reactividad\u00a0al\u00a0PPD,\u00a0que\u00a0no\u00a0presenta\u00a0signos\u00a0y\u00a0s\u00edntomas,\u00a0ni\u00a0datos\u00a0radiol\u00f3gicos\u00a0compatibles\u00a0con\u00a0enfermedad\nactiva.\n3 . 6 5\u00a0 T u b e r c u l o s i s \u00a0 m o n o r r e s i s t e n t e :\u00a0al\u00a0caso\u00a0con\u00a0tuberculosis\u00a0confirmada,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0identifica\u00a0que\u00a0la\u00a0cepa\u00a0del\u00a0complejo\u00a0M.\ntuberculosis\u00a0es\u00a0resistente\u00a0in\u00a0vitro\u00a0a\u00a0s\u00f3lo\u00a0uno\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0anti\u00a0tuberculosis.\n3 . 6 6\u00a0 T u b e r c u l o s i s \u00a0 m u l t i f a r m a c o r r e s i s t e n t e :\u00a0al\u00a0caso\u00a0con\u00a0tuberculosis\u00a0confirmada,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0identifica\u00a0que\u00a0la\u00a0cepa\u00a0del\ncomplejo\u00a0M.\u00a0tuberculosis\u00a0es\u00a0resistente\u00a0in\u00a0vitro\u00a0a\u00a0isoniacida\u00a0y\u00a0rifampicina\u00a0de\u00a0forma\u00a0simult\u00e1nea.\n3 . 6 7\u00a0 T u b e r c u l o s i s \u00a0 p o l i r r e s i s t e n t e :\u00a0al\u00a0caso\u00a0con\u00a0tuberculosis\u00a0confirmada,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0identifica\u00a0que\u00a0la\u00a0cepa\u00a0del\u00a0complejo\u00a0M.\ntuberculosis\u00a0es\u00a0resistente\u00a0in\u00a0vitro\u00a0a\u00a0m\u00e1s\u00a0de\u00a0uno\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0anti\u00a0tuberculosis\u00a0de\u00a0primera\u00a0l\u00ednea,\u00a0menos\u00a0a\u00a0la\u00a0isoniacida\u00a0y\u00a0a\u00a0la\nrifampicina\u00a0de\u00a0manera\u00a0simult\u00e1nea.\n3 . 6 8\u00a0 T u b e r c u l o s i s \u00a0 c o n \u00a0 r e s i s t e n c i a \u00a0 e x t e n d i d a :\u00a0al\u00a0caso\u00a0con\u00a0tuberculosis\u00a0confirmada,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0identifica\u00a0que\u00a0la\u00a0cepa\u00a0del\ncomplejo\u00a0M.\u00a0tuberculosis\u00a0es\u00a0resistente\u00a0in\u00a0vitro\u00a0a\u00a0la\u00a0isoniacida\u00a0y\u00a0rifampicina\u00a0de\u00a0manera\u00a0simult\u00e1nea,\u00a0adem\u00e1s\u00a0de\u00a0la\u00a0resistencia\u00a0a\u00a0un\nf\u00e1rmaco\u00a0del\u00a0grupo\u00a0de\u00a0las\u00a0fluroquinolonas\u00a0y\u00a0a\u00a0uno\u00a0o\u00a0m\u00e1s\u00a0de\u00a0los\u00a0tres\u00a0f\u00e1rmacos\u00a0inyectables\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0(kanamicina,\namikacina\u00a0y\u00a0capreomicina).\n4 . \u00a0 A b r e v i a t u r a s .\nPara\u00a0efectos\u00a0de\u00a0esta\u00a0Norma\u00a0se\u00a0utilizar\u00e1n\u00a0las\u00a0abreviaturas\u00a0siguientes:\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Amikacina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bacilo\u00a0de\u00a0Calmette\u00a0y\u00a0Gu\u00e9rin.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Examen\u00a0de\u00a0nitr\u00f3geno\u00a0ureico\u00a0en\u00a0la\u00a0sangre.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0C\u00famulo\u00a0de\u00a0diferenciaci\u00f3n\u00a04\u037e\u00a0es\u00a0una\u00a0mol\u00e9cula\u00a0que\u00a0se\u00a0expresa\u00a0en\u00a0la\u00a0superficie\u00a0de\u00a0algunas\u00a0c\u00e9lulas\u00a0T.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Linfocitos\u00a0T\u00a0que\u00a0expresan\u00a0activamente\u00a0su\u00a0CD4.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 8/23\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Centro\u00a0Nacional\u00a0de\u00a0Programas\u00a0Preventivos\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Comit\u00e9\u00a0Estatal\u00a0de\u00a0Farmacorresistencia.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Capreomicina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Cicloserina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Etambutol.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Electrolitos\u00a0s\u00e9ricos.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Etionamida.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Grupo\u00a0Asesor\u00a0Nacional\u00a0de\u00a0Farmacorresistencia.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Gramo.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Isoniacida.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Filtros\u00a0de\u00a0Alta\u00a0Eficiencia\u00a0de\u00a0Part\u00edculas.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Intramuscular.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Kanamicina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Kilogramo.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0La\u00a0Uni\u00f3n\u00a0Internacional\u00a0Contra\u00a0la\u00a0Tuberculosis\u00a0y\u00a0las\u00a0Enfermedades\u00a0Respiratorias.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0L\u00edquido\u00a0cefalorraqu\u00eddeo.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Levofloxacina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0M\u00e1ximo.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Moxifloxacina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Multifarmacorresistente.Moxifloxacina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Miligramo.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mililitro.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mil\u00edmetro.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mil\u00edmetro\u00a0c\u00fabico.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Ofloxacina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Organizaci\u00f3n\u00a0Panamericana\u00a0de\u00a0la\u00a0Salud.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Acido\u00a0para\u00adamino\u00adsalic\u00edlico.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pruebas\u00a0de\u00a0Funcionamiento\u00a0Hep\u00e1tico.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pruebas\u00a0de\u00a0farmacosensibilidad\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pruebas\u00a0de\u00a0Funcionamiento\u00a0Tiroideo..\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Derivado\u00a0proteico\u00a0purificado.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Derivado\u00a0proteico\u00a0purificado\u00a0lote\u00a0RT23.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Derivado\u00a0proteico\u00a0purificado\u00a0est\u00e1ndar.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Protionamida.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Rifampicina\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Recambios\u00a0de\u00a0aire\u00a0por\u00a0hora.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Estreptomicina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0S\u00edndrome\u00a0de\u00a0inmunodeficiencia\u00a0adquirida.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sistema\u00a0Nacional\u00a0de\u00a0Vigilancia\u00a0Epidemiol\u00f3gica.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sistema\u00a0Nervioso\u00a0Central.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0S\u00edndrome.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 9/23\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tuberculosis\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tratamiento\u00a0Acortado\u00a0Estrictamente\u00a0Supervisado.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tuberculosis\u00a0Multifarmacorresistente.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tratamiento.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Unidad\u00a0de\u00a0Especialidad\u00a0M\u00e9dica\u00a0en\u00a0Enfermedades\u00a0Cr\u00f3nica.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Unidades\u00a0de\u00a0tuberculina.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Virus\u00a0de\u00a0la\u00a0inmunodeficiencia\u00a0humana.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pirazinamida.\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Por\u00a0ciento.\n5 . \u00a0 C l a s i f i c a c i \u00f3 n , \u00a0 r e g i s t r o \u00a0 y \u00a0 n o t i f i c a c i \u00f3 n\n5 . 1\u00a0Esta\u00a0Norma\u00a0se\u00a0apega\u00a0a\u00a0la\u00a0Clasificaci\u00f3n\u00a0Estad\u00edstica\u00a0Internacional\u00a0de\u00a0Enfermedades\u00a0y\u00a0Problemas\u00a0relacionados\u00a0con\u00a0la\nSalud\u00a0de\u00a0la\u00a0OPS/OMS\u00a0en\u00a0su\u00a010a.\u00a0revisi\u00f3n,\u00a0en\u00a0la\u00a0codificaci\u00f3n\u00a0de\u00a0la\u00a0tuberculosis\u00a0de\u00a0la\u00a0A\u00a015\u00a0a\u00a0la\u00a0A\u00a019.\n5 . 2\u00a0Todo\u00a0caso\u00a0de\u00a0tuberculosis\u00a0clasificado\u00a0de\u00a0la\u00a0A15\u00a0a\u00a0la\u00a0A19\u00a0en\u00a0la\u00a0Clasificaci\u00f3n\u00a0Estad\u00edstica\u00a0Internacional\u00a0de\u00a0Enfermedades\u00a0y\nProblemas\u00a0relacionados\u00a0con\u00a0la\u00a0Salud\u00a0de\u00a0la\u00a0OPS/OMS\u00a0en\u00a0su\u00a010a.\u00a0revisi\u00f3n,\u00a0debe\u00a0registrarse\u00a0en\u00a0los\u00a0establecimientos\u00a0para\natenci\u00f3n\u00a0m\u00e9dica\u00a0de\u00a0los\u00a0sectores\u00a0p\u00fablico,\u00a0social\u00a0y\u00a0privado,\u00a0por\u00a0medio\u00a0de\u00a0un\u00a0expediente\u00a0cl\u00ednico,\u00a0tarjeta\u00a0de\u00a0tratamiento,\u00a0cuaderno\nde\u00a0registro\u00a0y\u00a0seguimiento\u00a0y\u00a0ser\u00a0notificado\u00a0a\u00a0la\u00a0Secretar\u00eda\u00a0de\u00a0Salud\u00a0de\u00a0acuerdo\u00a0a\u00a0lo\u00a0establecido\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\ncitada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n5 . 3\u00a0La\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0de\u00a0la\u00a0tuberculosis\u00a0se\u00a0sustenta\u00a0en\u00a0lo\u00a0establecido\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\npunto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n5 . 3 . 1\u00a0La\u00a0operaci\u00f3n\u00a0del\u00a0subsistema\u00a0de\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0de\u00a0la\u00a0tuberculosis\u00a0se\u00a0sustentar\u00e1\u00a0en\u00a0el\u00a0Manual\u00a0de\nProcedimientos\u00a0Estandarizados\u00a0para\u00a0la\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0de\u00a0las\u00a0Micobacteriosis\u00a0(Tuberculosis\u00a0y\u00a0lepra),\u00a0publicado\u00a0en\u00a0la\np\u00e1gina\u00a0 http://www.epidemiologia.salud.gob.mx/doctos/infoepid/\nvig_epid_manuales/17_2012_Manual_Micobacteriosis_vFinal_9nov12.pdf,\u00a0el\u00a0cual\u00a0incluye\u00a0los\u00a0elementos\u00a0t\u00e9cnicos\u00a0y\nmetodol\u00f3gicos\u00a0necesarios\u00a0para\u00a0orientar\u00a0su\u00a0aplicaci\u00f3n\u00a0en\u00a0todos\u00a0los\u00a0niveles\u00a0e\u00a0instituciones\u00a0del\u00a0SINAVE,\u00a0de\u00a0acuerdo\u00a0con\u00a0lo\nestablecido\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n5 . 3 . 2\u00a0La\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0de\u00a0la\u00a0mortalidad\u00a0por\u00a0tuberculosis\u00a0pulmonar\u00a0y\u00a0tuberculosis\u00a0men\u00edngea\u00a0se\u00a0sustenta\u00a0en\u00a0lo\nestablecido\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma,\u00a0en\u00a0el\u00a0Manual\u00a0de\nvigilancia\u00a0epidemiol\u00f3gica\u00a0de\u00a0tuberculosis\u00a0y\u00a0en\u00a0el\u00a0Manual\u00a0de\u00a0procedimientos\u00a0del\u00a0sistema\u00a0epidemiol\u00f3gico\u00a0estad\u00edstico\u00a0de\u00a0las\ndefunciones,\u00a0publicados\u00a0en\u00a0la\u00a0p\u00e1gina\u00a0www.cenaprece.salud.gob.mx.\n5 . 3 . 3\u00a0Los\u00a0componentes\u00a0de\u00a0informaci\u00f3n,\u00a0laboratorio\u00a0y\u00a0capacitaci\u00f3n\u00a0para\u00a0la\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0de\u00a0la\u00a0tuberculosis\u00a0deben\nestar\u00a0basados\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n5 . 3 . 4\u00a0La\u00a0tuberculosis\u00a0men\u00edngea\u00a0es\u00a0de\u00a0notificaci\u00f3n\u00a0inmediata\u00a0dentro\u00a0de\u00a0las\u00a0siguientes\u00a0veinticuatro\u00a0horas\u00a0de\u00a0que\u00a0se\u00a0tenga\nconocimiento\u00a0del\u00a0caso\u00a0y\u00a0debe\u00a0acompa\u00f1arse\u00a0del\u00a0estudio\u00a0epidemiol\u00f3gico\u00a0correspondiente\u037e\u00a0por\u00a0su\u00a0parte,\u00a0la\u00a0tuberculosis\u00a0del\naparato\u00a0respiratorio\u00a0y\u00a0otras\u00a0formas\u00a0son\u00a0de\u00a0notificaci\u00f3n\u00a0semanal\u00a0y\u00a0mensual\u00a0y\u00a0requieren\u00a0estudio\u00a0epidemiol\u00f3gico,\u00a0conforme\u00a0a\u00a0lo\nestablecido\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n6 . \u00a0 E s p e c i f i c a c i o n e s\n6 . 1\u00a0Medidas\u00a0de\u00a0prevenci\u00f3n\u00a0y\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud:\n6 . 1 . 1\u00a0La\u00a0vacunaci\u00f3n\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0mexicana\u00a0se\u00a0debe\u00a0realizar\u00a0conforme\u00a0a\u00a0lo\u00a0que\u00a0se\u00a0establece\u00a0en\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\ncitada\u00a0en\u00a0el\u00a0apartado\u00a02.6,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma.\n6 . 1 . 2\u00a0La\u00a0terapia\u00a0preventiva\u00a0con\u00a0isoniacida\u00a0(tratamiento\u00a0para\u00a0tuberculosis\u00a0latente\u00a0o\u00a0quimioprofilaxis)\u00a0se\u00a0debe\u00a0realizar\u00a0de\u00a0la\nsiguiente\u00a0manera:\n6 . 1 . 2 . 1\u00a0Se\u00a0administra\u00a0durante\u00a0seis\u00a0meses\u00a0a\u00a0los\u00a0contactos\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os,\u00a0con\u00a0o\u00a0sin\u00a0antecedente\u00a0de\u00a0vacunaci\u00f3n\u00a0con\nBCG\u00a0en\u00a0quienes\u00a0se\u00a0haya\u00a0descartado\u00a0la\u00a0tuberculosis.\n6 . 1 . 2 . 2\u00a0Se\u00a0administra\u00a0durante\u00a0seis\u00a0meses\u00a0a\u00a0los\u00a0contactos\u00a0de\u00a0cinco\u00a0a\u00a0catorce\u00a0a\u00f1os\u00a0de\u00a0edad,\u00a0no\u00a0vacunados\u00a0con\u00a0BCG,\u00a0en\nquienes\u00a0se\u00a0haya\u00a0descartado\u00a0la\u00a0tuberculosis.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 10/236 . 1 . 2 . 3\u00a0Se\u00a0administra\u00a0durante\u00a0seis\u00a0meses\u00a0a\u00a0los\u00a0contactos\u00a0de\u00a0quince\u00a0a\u00f1os\u00a0de\u00a0edad\u00a0o\u00a0m\u00e1s\u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0o\u00a0con\u00a0otra\ncausa\u00a0de\u00a0inmunocompromiso\u00a0(por\u00a0desnutrici\u00f3n\u00a0o\u00a0por\u00a0administraci\u00f3n\u00a0de\u00a0f\u00e1rmacos\u00a0inmunosupresores)\u037e\u00a0con\u00a0la\u00a0posibilidad\u00a0de\nextensi\u00f3n\u00a0a\u00a0nueve\u00a0meses,\u00a0de\u00a0acuerdo\u00a0a\u00a0criterio\u00a0cl\u00ednico\u00a0y\u00a0de\u00a0recuperaci\u00f3n\u00a0inmunol\u00f3gica\u00a0de\u00a0la\u00a0persona\u00a0con\u00a0VIH\u00a0o\u00a0SIDA\u037e\npreviamente\u00a0se\u00a0debe\u00a0realizar\u00a0estudio\u00a0exhaustivo\u00a0para\u00a0descartar\u00a0tuberculosis\u00a0activa\u00a0pulmonar\u00a0o\u00a0extrapulmonar.\n6 . 1 . 2 . 4\u00a0El\u00a0f\u00e1rmaco\u00a0recomendado\u00a0para\u00a0el\u00a0tratamiento\u00a0de\u00a0la\u00a0tuberculosis\u00a0latente\u00a0es\u00a0la\u00a0isoniacida\u00a0a\u00a0dosis\u00a0de\u00a05\u00a0a\u00a010\u00a0mg\u00a0en\nadultos,\u00a0por\u00a0kg\u00a0de\u00a0peso\u00a0por\u00a0d\u00eda,\u00a0sin\u00a0exceder\u00a0de\u00a0300\u00a0mg\u00a0en\u00a0una\u00a0toma\u00a0diaria\u00a0por\u00a0v\u00eda\u00a0oral,\u00a0estrictamente\u00a0supervisada.\n6 . 1 . 2 . 5\u00a0La\u00a0terapia\u00a0preventiva\u00a0con\u00a0isoniacida\u00a0no\u00a0est\u00e1\u00a0indicada\u00a0en\u00a0los\u00a0casos\u00a0de\u00a0contactos\u00a0de\u00a0pacientes\u00a0en\u00a0quienes\u00a0se\nsospecha\u00a0o\u00a0se\u00a0ha\u00a0confirmado\u00a0tuberculosis\u00a0multifarmacorresistente.\n6 . 1 . 2 . 6\u00a0Todos\u00a0los\u00a0pacientes\u00a0que\u00a0presenten\u00a0inmunocompromiso,\u00a0deber\u00e1n\u00a0ser\u00a0valorados\u00a0para\u00a0la\u00a0administraci\u00f3n\u00a0de\u00a0terapia\npreventiva\u00a0con\u00a0isoniacida.\nLa\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud\u00a0debe\u00a0realizarse\u00a0por\u00a0parte\u00a0del\u00a0personal\u00a0de\u00a0salud\u00a0del\u00a0sector\u00a0p\u00fablico,\u00a0social\u00a0y\u00a0privado,\u00a0considerando\nacciones\u00a0alineadas\u00a0al\u00a0servicio\u00a0integrado\u00a0de\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud.\n6 . 1 . 3\u00a0Manejo\u00a0de\u00a0riesgos\u00a0personales:\u00a0corresponde\u00a0a\u00a0los\u00a0Responsables\u00a0Estatales\u00a0y\u00a0Jurisdiccionales\u00a0de\u00a0los\u00a0Programas\u00a0de\nPromoci\u00f3n\u00a0de\u00a0la\u00a0Salud,\u00a0Tuberculosis\u00a0y\u00a0de\u00a0la\u00a0Red\u00a0TAES\u00a0de\u00a0Enfermer\u00eda,\u00a0instruir\u00a0y\u00a0fomentar\u00a0en\u00a0los\u00a0pacientes,\u00a0estilos\u00a0de\u00a0vida\u00a0que\nmejoren\u00a0la\u00a0salud\u00a0individual,\u00a0familiar\u00a0y\u00a0comunitaria\u037e\u00a0promover\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0la\u00a0vacuna\u00a0BCG\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0Norma\u00a0Oficial\nMexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.6,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma\u00a0y\u00a0su\u00a0registro\u00a0en\u00a0las\u00a0Cartillas\u00a0Nacionales\u00a0de\u00a0Salud\nvigentes\u037e\u00a0higiene\u00a0personal\u00a0y\u00a0de\u00a0la\u00a0vivienda,\u00a0alimentaci\u00f3n\u00a0correcta\u00a0y\u00a0saneamiento\u00a0b\u00e1sico.\n6 . 1 . 4\u00a0Promover\u00a0el\u00a0desarrollo\u00a0de\u00a0capacidades\u00a0y\u00a0competencias\u00a0en\u00a0salud\u00a0para\u00a0el\u00a0personal\u00a0de\u00a0salud\u00a0y\u00a0la\u00a0poblaci\u00f3n,\u00a0en\u00a0la\nprevenci\u00f3n,\u00a0protecci\u00f3n\u00a0espec\u00edfica\u00a0con\u00a0la\u00a0vacuna\u00a0BCG,\u00a0la\u00a0detecci\u00f3n\u00a0oportuna\u00a0y\u00a0tratamiento\u00a0supervisado\u00a0y\u00a0efectivo\u00a0que\u00a0garantice\nla\u00a0curaci\u00f3n\u00a0de\u00a0la\u00a0enfermedad\u037e\u00a0higiene\u00a0y\u00a0cuidado\u00a0personal,\u00a0de\u00a0la\u00a0vivienda,\u00a0de\u00a0los\u00a0sitios\u00a0de\u00a0trabajo,\u00a0alimentaci\u00f3n\u00a0correcta\u00a0y\nconsumo\u00a0de\u00a0leche\u00a0y\u00a0sus\u00a0derivados\u00a0pasteurizados,\u00a0mejoramiento\u00a0del\u00a0saneamiento\u00a0b\u00e1sico\u00a0del\u00a0ambiente\u00a0y\u00a0control\u00a0veterinario.\n6 . 1 . 5\u00a0Fomento\u00a0en\u00a0las\u00a0personas\u00a0que\u00a0padecen\u00a0tuberculosis\u00a0del\u00a0empoderamiento\u00a0para\u00a0la\u00a0salud\u00a0(autocuidado),\u00a0incluidas\u00a0las\nmedidas\u00a0de\u00a0prevenci\u00f3n\u00a0en\u00a0todas\u00a0aquellas\u00a0personas\u00a0con\u00a0quienes\u00a0conviven\u00a0de\u00a0manera\u00a0cotidiana.\n6 . 1 . 6\u00a0Se\u00a0promover\u00e1\u00a0que\u00a0las\u00a0casas\u00a0est\u00e9n\u00a0bien\u00a0ventiladas,\u00a0en\u00a0particular\u00a0los\u00a0cuartos\u00a0donde\u00a0el\u00a0paciente\u00a0con\u00a0tuberculosis\u00a0pasa\u00a0un\ntiempo\u00a0considerable.\n6 . 1 . 7\u00a0Las\u00a0personas\u00a0con\u00a0tos\u00a0y\u00a0expectoraci\u00f3n\u00a0y/o\u00a0baciloscopia\u00a0positiva,\u00a0deber\u00e1n\u00a0cubrirse\u00a0la\u00a0nariz\u00a0y\u00a0la\u00a0boca\u00a0al\u00a0toser/estornudar\n(etiqueta\u00a0respiratoria)\u00a0y\u00a0pasar\u00a0el\u00a0menor\u00a0tiempo\u00a0posible\u00a0en\u00a0sitios\u00a0de\u00a0concentraci\u00f3n.\n6 . 2\u00a0Prevenci\u00f3n\u00a0y\u00a0protecci\u00f3n\u00a0en\u00a0establecimiento\u00a0de\u00a0salud:\n6 . 2 . 1Medidas\u00a0gerencialesadministrativas:\n6 . 2 . 1 . 1\u00a0Identificar\u00a0oportunamente\u00a0a\u00a0las\u00a0personas\u00a0con\u00a0sintomatolog\u00eda\u00a0respiratoria\u00a0en\u00a0salas\u00a0de\u00a0espera\u00a0y\u00a0servicios\u00a0de\u00a0urgencias\nantes\u00a0de\u00a0ingresar\u00a0a\u00a0hospitalizaci\u00f3n.\n6 . 2 . 1 . 2\u00a0Priorizaci\u00f3n\u00a0y\u00a0separaci\u00f3n\u00a0de\u00a0sintom\u00e1ticos\u00a0respiratorios\u00a0a\u00a0nivel\u00a0ambulatorio\u00a0y\u00a0de\u00a0hospitalizaci\u00f3n.\n6 . 2 . 1 . 3\u00a0Promover\u00a0que\u00a0los\u00a0sintom\u00e1ticos\u00a0respiratorios\u00a0se\u00a0cubran\u00a0la\u00a0boca\u00a0al\u00a0toser\u00a0cuando\u00a0se\u00a0encuentren\u00a0en\u00a0las\u00a0salas\u00a0de\u00a0espera\no\u00a0en\u00a0los\u00a0servicios\u00a0de\u00a0hospitalizaci\u00f3n.\n6 . 2 . 2Medidas\u00a0de\u00a0control\u00a0ambiental:\n6 . 2 . 2 . 1\u00a0Maximizar\u00a0la\u00a0ventilaci\u00f3n\u00a0natural,\u00a0asegurar\u00a0la\u00a0ventilaci\u00f3n\u00a0cruzada\u00a0y\u00a0evitar\u00a0cortos\u00a0circuitos\u00a0en\u00a0la\u00a0ventilaci\u00f3n\u00a0dentro\u00a0de\u00a0los\nestablecimientos\u00a0de\u00a0salud.\n6 . 2 . 2 . 2\u00a0Reubicar\u00a0el\u00a0mobiliario\u00a0de\u00a0los\u00a0consultorios\u00a0aprovechando\u00a0la\u00a0iluminaci\u00f3n\u00a0y\u00a0la\u00a0ventilaci\u00f3n\u00a0natural.\n6 . 2 . 2 . 3\u00a0Para\u00a0evitar\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0la\u00a0tuberculosis\u00a0en\u00a0\u00e1reas\u00a0de\u00a0alto\u00a0riesgo\u00a0de\u00a0los\u00a0establecimientos\u00a0de\u00a0salud,\u00a0como\u00a0salas\u00a0de\nespera,\u00a0cuartos\u00a0de\u00a0aislamiento,\u00a0entre\u00a0otros,\u00a0se\u00a0debe\u00a0de\u00a0contar\u00a0con\u00a0extractores\u00a0o\u00a0sistemas\u00a0de\u00a0ventilaci\u00f3n\u00a0mec\u00e1nica\u00a0centralizada\nque\u00a0aseguren\u00a0doce\u00a0RAH\u00a0y\u00a0presi\u00f3n\u00a0negativa.\n6 . 2 . 3Medidas\u00a0de\u00a0protecci\u00f3n\u00a0respiratoria:\n6 . 2 . 3 . 1\u00a0Fomentar\u00a0el\u00a0uso\u00a0de\u00a0mascarillas\u00a0quir\u00fargicas\u00a0o\u00a0cubre\u00a0bocas\u00a0en\u00a0los\u00a0pacientes\u00a0sintom\u00e1ticos\u00a0respiratorios\u00a0y\u00a0en\u00a0las\npersonas\u00a0afectadas\u00a0por\u00a0tuberculosis\u00a0durante\u00a0su\u00a0traslado,\u00a0en\u00a0salas\u00a0de\u00a0espera\u00a0o\u00a0cuando\u00a0reciban\u00a0visitas\u00a0en\u00a0su\u00a0cuarto\u00a0de\naislamiento.\n6 . 2 . 3 . 2\u00a0Asegurar\u00a0el\u00a0uso\u00a0de\u00a0respiradores\u00a0N95\u00a0entre\u00a0los\u00a0trabajadores\u00a0de\u00a0salud\u00a0y\u00a0los\u00a0familiares\u00a0que\u00a0se\u00a0encuentran\u00a0en\u00a0\u00e1reas\u00a0de\nalto\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n\u00a0de\u00a0TB.\n6 . 3 \u00a0Participaci\u00f3n\u00a0para\u00a0la\u00a0acci\u00f3n\u00a0comunitaria:\n6 . 3 . 1\u00a0Promover\u00a0la\u00a0participaci\u00f3n\u00a0de\u00a0voluntarios,\u00a0familiares\u00a0y\u00a0grupos\u00a0comunitarios\u00a0organizados\u00a0y\u00a0autoridades\u00a0locales\n(empoderamiento),\u00a0para\u00a0que\u00a0colaboren\u00a0en\u00a0la\u00a0localizaci\u00f3n\u00a0de\u00a0tosedores\u00a0en\u00a0su\u00a0comunidad\u00a0y\u00a0promuevan\u00a0otros\u00a0apoyos\u00a0para\u00a0el\ntransporte,\u00a0alimentarios\u00a0y\u00a0de\u00a0acompa\u00f1amiento\u00a0para\u00a0personas\u00a0afectadas\u00a0por\u00a0tuberculosis\u00a0y/o\u00a0familiares,\u00a0para\u00a0garantizar\u00a0la\nadherencia\u00a0terap\u00e9utica\u00a0cuando\u00a0sea\u00a0necesario.\n6 . 3 . 2\u00a0Impulsar\u00a0el\u00a0desarrollo\u00a0de\u00a0entornos\u00a0favorables\u00a0a\u00a0la\u00a0salud,\u00a0como\u00a0la\u00a0vivienda,\u00a0la\u00a0escuela\u00a0y\u00a0los\u00a0centros\u00a0de\u00a0trabajo,\u00a0entre\notros\u00a0y\u00a0que\u00a0propicien\u00a0la\u00a0adopci\u00f3n\u00a0de\u00a0estilos\u00a0de\u00a0vida\u00a0saludables\u00a0y\u00a0espacios\u00a0para\u00a0la\u00a0recreaci\u00f3n\u00a0con\u00a0\u00e1reas\u00a0verdes.\n6 . 3 . 3\u00a0Propiciar\u00a0el\u00a0fortalecimiento\u00a0de\u00a0las\u00a0redes\u00a0sociales\u00a0y\u00a0la\u00a0coordinaci\u00f3n\u00a0intra\u00a0y\u00a0extrasectorial\u00a0entre\u00a0instituciones\u00a0p\u00fablicas\u00a0y\nprivadas\u00a0para\u00a0el\u00a0desarrollo\u00a0de\u00a0proyectos\u00a0sanitarios\u00a0de\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud\u00a0orientados\u00a0a\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0la\ntuberculosis.\n6 . 4\u00a0Comunicaci\u00f3n\u00a0educativa:\n6 . 4 . 1\u00a0Concertar\u00a0con\u00a0agrupaciones\u00a0de\u00a0profesionales\u00a0en\u00a0los\u00a0campos\u00a0de\u00a0la\u00a0salud\u00a0y\u00a0de\u00a0la\u00a0comunicaci\u00f3n,\u00a0para\u00a0que\u00a0se\u00a0vinculen\u00a0y\nparticipen\u00a0en\u00a0la\u00a0tarea\u00a0de\u00a0informaci\u00f3n\u00a0veraz,\u00a0confiable\u00a0y\u00a0oportuna\u00a0a\u00a0la\u00a0poblaci\u00f3n\u00a0en\u00a0general\u00a0y\u00a0especialmente\u00a0a\u00a0las\u00a0personas\u00a0en\nriesgo.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 11/236 . 4 . 2\u00a0Informar\u00a0a\u00a0la\u00a0poblaci\u00f3n\u00a0en\u00a0forma\u00a0permanente\u00a0del\u00a0riesgo\u00a0que\u00a0significa\u00a0la\u00a0tuberculosis\u00a0y\u00a0dar\u00a0a\u00a0conocer\u00a0los\u00a0datos\u00a0m\u00ednimos\npara\u00a0sospechar\u00a0la\u00a0enfermedad,\u00a0as\u00ed\u00a0como\u00a0para\u00a0acudir\u00a0oportunamente\u00a0al\u00a0servicio\u00a0de\u00a0salud.\n6 . 4 . 3\u00a0Los\u00a0Responsables\u00a0Estatales\u00a0y\u00a0Jurisdiccionales\u00a0del\u00a0Programa\u00a0de\u00a0Acci\u00f3n\u00a0de\u00a0Tuberculosis\u00a0y\u00a0de\u00a0la\u00a0Red\u00a0TAES,\u00a0deben\nrealizar\u00a0actividades\u00a0de\u00a0abogac\u00eda\u00a0para\u00a0la\u00a0salud\u00a0a\u00a0fin\u00a0de\u00a0concertar\u00a0y\u00a0coordinar\u00a0con\u00a0los\u00a0medios\u00a0masivos\u00a0de\u00a0comunicaci\u00f3n,\u00a0para\ninformar\u00a0a\u00a0la\u00a0poblaci\u00f3n\u00a0sobre\u00a0el\u00a0cuidado\u00a0de\u00a0la\u00a0salud,\u00a0la\u00a0prevenci\u00f3n\u00a0y\u00a0el\u00a0tratamiento\u00a0de\u00a0la\u00a0tuberculosis,\u00a0mediante\u00a0la\u00a0difusi\u00f3n\u00a0de\nmensajes,\u00a0as\u00ed\u00a0como,\u00a0para\u00a0colocar\u00a0en\u00a0la\u00a0agenda\u00a0pol\u00edtica\u00a0de\u00a0los\u00a0tomadores\u00a0de\u00a0decisiones\u00a0el\u00a0tema\u00a0de\u00a0la\u00a0tuberculosis\u00a0a\u00a0fin\u00a0de\ngenerar\u00a0los\u00a0apoyos\u00a0necesarios.\n6 . 5\u00a0Medidas\u00a0de\u00a0control:\nComprende\u00a0la\u00a0protecci\u00f3n\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0mediante\u00a0la\u00a0identificaci\u00f3n\u00a0oportuna\u00a0de\u00a0casos\u00a0probables,\u00a0la\u00a0atenci\u00f3n\u00a0integral\u00a0y\nmultidisciplinaria\u00a0del\u00a0paciente,\u00a0el\u00a0diagn\u00f3stico\u00a0eficiente,\u00a0el\u00a0registro\u00a0y\u00a0la\u00a0notificaci\u00f3n\u00a0del\u00a0caso,\u00a0el\u00a0tratamiento\u00a0oportuno\u00a0y\u00a0eficaz\nestrictamente\u00a0supervisado\u00a0y\u00a0el\u00a0seguimiento\u00a0mensual\u00a0del\u00a0paciente,\u00a0as\u00ed\u00a0como,\u00a0el\u00a0estudio\u00a0de\u00a0sus\u00a0contactos\u00a0y\u00a0de\u00a0su\u00a0entorno\u00a0familiar,\nla\u00a0terapia\u00a0preventiva\u00a0con\u00a0isoniacida\u00a0(quimioprofilaxis)\u00a0y\u00a0la\u00a0promoci\u00f3n\u00a0de\u00a0la\u00a0salud.\n6 . 5 . 1 \u00a0Identificaci\u00f3n\u00a0y\u00a0diagn\u00f3stico\u00a0del\u00a0caso.\nLa\u00a0tuberculosis\u00a0pulmonar\u00a0confirmada\u00a0por\u00a0baciloscopia\u00a0es\u00a0la\u00a0fuente\u00a0de\u00a0infecci\u00f3n\u00a0m\u00e1s\u00a0frecuente\u00a0y\u00a0constituye\u00a0el\u00a0objetivo\nfundamental\u00a0de\u00a0las\u00a0actividades\u00a0de\u00a0detecci\u00f3n,\u00a0diagn\u00f3stico\u00a0y\u00a0tratamiento,\u00a0para\u00a0el\u00a0control\u00a0de\u00a0la\u00a0enfermedad.\n6 . 5 . 2\u00a0La\u00a0b\u00fasqueda\u00a0de\u00a0casos\u00a0se\u00a0debe\u00a0realizar\u00a0entre\u00a0consultantes\u00a0sintom\u00e1ticos\u00a0respiratorios,\u00a0sin\u00a0importar\u00a0el\u00a0motivo\u00a0de\u00a0la\ndemanda\u00a0de\u00a0consulta,\u00a0entre\u00a0los\u00a0contactos\u00a0de\u00a0un\u00a0caso\u00a0de\u00a0tuberculosis,\u00a0as\u00ed\u00a0como,\u00a0por\u00a0b\u00fasqueda\u00a0activa\u00a0en\u00a0grupos\u00a0vulnerables\u00a0o\u00a0de\nalto\u00a0riesgo:\u00a0personas\u00a0privadas\u00a0de\u00a0su\u00a0libertad,\u00a0jornaleros,\u00a0migrantes,\u00a0usuarios\u00a0de\u00a0drogas,\u00a0alcoh\u00f3licos,\u00a0personas\u00a0que\u00a0viven\u00a0con\ndiabetes,\u00a0inmunocomprometidos,\u00a0asilos,\u00a0f\u00e1bricas,\u00a0albergues,\u00a0grupos\u00a0ind\u00edgenas,\u00a0personas\u00a0que\u00a0viven\u00a0con\u00a0el\u00a0complejo\u00a0VIH/SIDA,\nentre\u00a0otros.\n6 . 5 . 3\u00a0La\u00a0confirmaci\u00f3n\u00a0de\u00a0la\u00a0presencia\u00a0de\u00a0M.\u00a0tuberculosis\u00a0se\u00a0lleva\u00a0a\u00a0cabo\u00a0mediante\u00a0bacteriolog\u00eda,\u00a0principalmente\u00a0baciloscopia,\ncultivo\u00a0y\u00a0pruebas\u00a0moleculares\u00a0o\u00a0mediante\u00a0cultivo\u00a0de\u00a0fragmento\u00a0de\u00a0tejidos,\u00a0fluidos\u00a0o\u00a0secreciones\u00a0de\u00a0\u00f3rganos\u00a0de\u00a0pacientes\u00a0con\nmanifestaciones\u00a0cl\u00ednicas,\u00a0radiol\u00f3gicas\u00a0y\u00a0datos\u00a0epidemiol\u00f3gicos\u00a0compatibles\u00a0con\u00a0la\u00a0enfermedad.\u00a0Toda\u00a0muestra\u00a0de\u00a0tejido\u00a0u\u00a0\u00f3rgano\npara\u00a0examen\u00a0histopatol\u00f3gico,\u00a0adem\u00e1s\u00a0de\u00a0someterse\u00a0a\u00a0este\u00a0estudio,\u00a0una\u00a0fracci\u00f3n\u00a0se\u00a0debe\u00a0enviar\u00a0al\u00a0servicio\u00a0de\u00a0bacteriolog\u00eda,\u00a0para\nel\u00a0aislamiento\u00a0e\u00a0identificaci\u00f3n\u00a0de\u00a0M.\u00a0tuberculosis\u00a0mediante\u00a0cultivo.\n6 . 5 . 4\u00a0La\u00a0baciloscopia\u00a0se\u00a0debe\u00a0realizar\u00a0de\u00a0acuerdo\u00a0con\u00a0las\u00a0siguientes\u00a0indicaciones:\n6 . 5 . 4 . 1\u00a0En\u00a0cualquier\u00a0muestra\u00a0cl\u00ednica,\u00a0excepto\u00a0orina.\n6 . 5 . 4 . 2\u00a0En\u00a0todos\u00a0los\u00a0sintom\u00e1ticos\u00a0respiratorios\u00a0o\u00a0casos\u00a0probables,\u00a0se\u00a0debe\u00a0realizar\u00a0en\u00a0tres\u00a0muestras\u00a0de\u00a0expectoraci\u00f3n\nseriadas.\u00a0La\u00a0fijaci\u00f3n\u00a0del\u00a0frotis\u00a0debe\u00a0realizarse\u00a0exclusivamente\u00a0en\u00a0el\u00a0laboratorio\u00a0o\u00a0por\u00a0personal\u00a0capacitado\u00a0por\u00a0el\u00a0laboratorio\ncorrespondiente.\n6 . 5 . 4 . 3\u00a0Si\u00a0la\u00a0primera\u00a0serie\u00a0de\u00a0tres\u00a0baciloscopias\u00a0es\u00a0negativa\u00a0y\u00a0no\u00a0se\u00a0confirma\u00a0otro\u00a0diagn\u00f3stico\u00a0y\u00a0en\u00a0quienes2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 12/23cl\u00ednica\u00a0y\u00a0radiol\u00f3gicamente\u00a0se\u00a0sospeche\u00a0tuberculosis,\u00a0se\u00a0debe\u00a0solicitar\u00a0otra\u00a0serie\u00a0de\u00a0tres\u00a0baciloscopias\u00a0y\u00a0cultivo.\n6 . 5 . 4 . 4\u00a0A\u00a0todo\u00a0caso\u00a0de\u00a0tuberculosis\u00a0pulmonar\u00a0que\u00a0haya\u00a0sido\u00a0identificado\u00a0mediante\u00a0baciloscopia\u00a0positiva,\u00a0se\u00a0le\u00a0debe\u00a0realizar\nmensualmente\u00a0baciloscopia\u00a0de\u00a0control\u00a0en\u00a0forma\u00a0estricta\u00a0durante\u00a0su\u00a0tratamiento.\n6 . 5 . 4 . 4 . 1\u00a0Toda\u00a0muestra\u00a0para\u00a0baciloscopia\u00a0de\u00a0control,\u00a0independientemente\u00a0de\u00a0su\u00a0calidad\u00a0y\u00a0apariencia\u00a0macrosc\u00f3pica,\u00a0debe\u00a0ser\nprocesada\u00a0inclusive\u00a0al\u00a0final\u00a0del\u00a0tratamiento.\n6 . 5 . 5\u00a0El\u00a0cultivo\u00a0se\u00a0debe\u00a0solicitar\u00a0en\u00a0las\u00a0siguientes\u00a0situaciones:\n6 . 5 . 5 . 1\u00a0Para\u00a0el\u00a0diagn\u00f3stico,\u00a0en\u00a0caso\u00a0de\u00a0sospecha\u00a0cl\u00ednica\u00a0y\u00a0radiol\u00f3gica\u00a0de\u00a0tuberculosis\u00a0pulmonar\u00a0con\u00a0resultado\u00a0negativo\u00a0de\ntres\u00a0baciloscopias\u00a0de\u00a0expectoraci\u00f3n.\n6 . 5 . 5 . 2\u00a0En\u00a0los\u00a0casos\u00a0de\u00a0sospecha\u00a0de\u00a0tuberculosis\u00a0de\u00a0localizaci\u00f3n\u00a0extrapulmonar.\n6 . 5 . 5 . 3\u00a0En\u00a0todo\u00a0caso\u00a0en\u00a0el\u00a0que\u00a0se\u00a0sospeche\u00a0tuberculosis\u00a0renal\u00a0o\u00a0genitourinaria.\n6 . 5 . 5 . 4\u00a0Para\u00a0el\u00a0diagn\u00f3stico\u00a0en\u00a0caso\u00a0de\u00a0sospecha\u00a0de\u00a0tuberculosis\u00a0en\u00a0casos\u00a0con\u00a0VIH/SIDA.\n6 . 5 . 5 . 5\u00a0En\u00a0caso\u00a0de\u00a0sospecha\u00a0de\u00a0tuberculosis\u00a0en\u00a0ni\u00f1os.\n6 . 5 . 5 . 6\u00a0En\u00a0pacientes\u00a0sujetos\u00a0a\u00a0tratamiento\u00a0estrictamente\u00a0supervisado,\u00a0en\u00a0quienes\u00a0al\u00a0segundo\u00a0mes\u00a0persiste\u00a0la\u00a0baciloscopia\npositiva.\n6 . 5 . 5 . 7\u00a0Para\u00a0confirmar\u00a0el\u00a0fracaso\u00a0de\u00a0tratamiento.\n6 . 5 . 5 . 8\u00a0Para\u00a0el\u00a0seguimiento\u00a0bimensual\u00a0de\u00a0los\u00a0casos\u00a0de\u00a0tuberculosis\u00a0farmacorresistente.\n6 . 5 . 6\u00a0El\u00a0cultivo\u00a0y\u00a0PFS\u00a0se\u00a0deben\u00a0solicitar\u00a0en\u00a0las\u00a0siguientes\u00a0situaciones:\n6 . 5 . 6 . 1\u00a0Para\u00a0el\u00a0diagn\u00f3stico\u00a0en\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0tuberculosis\u00a0pulmonar\u00a0o\u00a0extrapulmonar\u00a0previamente\u00a0tratados.\n6 . 5 . 6 . 2\u00a0En\u00a0todos\u00a0los\u00a0pacientes\u00a0que\u00a0al\u00a0t\u00e9rmino\u00a0de\u00a0la\u00a0fase\u00a0intensiva\u00a0del\u00a0tratamiento\u00a0tienen\u00a0estudio\u00a0de\u00a0baciloscopia\u00a0con\nresultado\u00a0positivo.\n6 . 5 . 6 . 3\u00a0Previo\u00a0al\u00a0inicio\u00a0del\u00a0tratamiento\u00a0para\u00a0tuberculosis\u00a0en\u00a0pacientes\u00a0en\u00a0quienes\u00a0se\u00a0ha\u00a0demostrado\u00a0contacto\u00a0con\u00a0un\u00a0caso\u00a0de\nTB\u00adMFR.\n6 . 5 . 6 . 4\u00a0En\u00a0los\u00a0casos\u00a0de\u00a0reingreso\u00a0por\u00a0reca\u00edda\u00a0o\u00a0fracaso\u00a0de\u00a0tratamiento.\n6 . 5 . 6 . 5\u00a0En\u00a0los\u00a0sintom\u00e1ticos\u00a0respiratorios\u00a0con\u00a0diabetes\u00a0mellitus\u00a0descompensada\u00a0que\u00a0viven\u00a0en\u00a0zonas\u00a0de\u00a0alta\u00a0incidencia\u00a0de\ntuberculosis\u00a0con\u00a0resistencia\u00a0a\u00a0f\u00e1rmacos\u00a0anti\u00a0tuberculosis.\n6 . 5 . 6 . 6\u00a0Para\u00a0el\u00a0diagn\u00f3stico,\u00a0en\u00a0los\u00a0casos\u00a0con\u00a0sospecha\u00a0de\u00a0tuberculosis\u00a0farmacorresistente\u00a0o\u00a0con\u00a0motivo\u00a0de\u00a0investigaciones\nepidemiol\u00f3gicas,\u00a0terap\u00e9uticas\u00a0y\u00a0bacteriol\u00f3gicas.\n6 . 5 . 7\u00a0El\u00a0diagn\u00f3stico\u00a0de\u00a0un\u00a0caso\u00a0de\u00a0tuberculosis\u00a0no\u00a0confirmada\u00a0por\u00a0bacteriolog\u00eda\u00a0o\u00a0pruebas\u00a0moleculares,\u00a0se\u00a0establecer\u00e1\nmediante\u00a0estudio\u00a0cl\u00ednico\u00a0y\u00a0epidemiol\u00f3gico,\u00a0avalado\u00a0por\u00a0el\u00a0m\u00e9dico\u00a0y\u00a0apoyado\u00a0en\u00a0otros\u00a0estudios\u00a0auxiliares\u00a0de\u00a0diagn\u00f3stico.\n6 . 5 . 8\u00a0Para\u00a0precisar\u00a0la\u00a0localizaci\u00f3n\u00a0y\u00a0la\u00a0extensi\u00f3n\u00a0de\u00a0las\u00a0lesiones,\u00a0se\u00a0debe\u00a0realizar\u00a0estudio\u00a0radiogr\u00e1fico,\u00a0cuando\u00a0se\u00a0disponga\ndel\u00a0recurso\u037e\u00a0en\u00a0ni\u00f1os\u00a0es\u00a0indispensable.\n6 . 5 . 9\u00a0En\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0PPD,\u00a0se\u00a0debe\u00a0llevar\u00a0a\u00a0cabo\u00a0de\u00a0acuerdo\u00a0con\u00a0las\u00a0siguientes\u00a0indicaciones:\n6 . 5 . 9 . 1\u00a0Estudio\u00a0de\u00a0contactos.\n6 . 5 . 9 . 2\u00a0Apoyo\u00a0al\u00a0diagn\u00f3stico\u00a0diferencial\u00a0de\u00a0tuberculosis.\n6 . 5 . 9 . 3\u00a0Estudios\u00a0epidemiol\u00f3gicos.\n6 . 5 . 9 . 4\u00a0Dosis,\u00a0administraci\u00f3n,\u00a0e\u00a0interpretaci\u00f3n.\n6 . 5 . 9 . 5\u00a0Un\u00a0d\u00e9cimo\u00a0de\u00a0ml\u00a0equivale\u00a0a\u00a02\u00a0UT\u00a0de\u00a0PPD\u00a0RT\u00ad23\u00a0o\u00a05\u00a0UT\u00a0de\u00a0PPD\u00adS,\u00a0por\u00a0v\u00eda\u00a0intrad\u00e9rmica\u00a0en\u00a0la\u00a0cara\u00a0antero\u00a0externa\u00a0del\nantebrazo\u00a0izquierdo,\u00a0en\u00a0la\u00a0uni\u00f3n\u00a0del\u00a0tercio\u00a0superior\u00a0con\u00a0el\u00a0tercio\u00a0medio.\n6 . 5 . 9 . 6\u00a0Se\u00a0debe\u00a0realizar\u00a0la\u00a0lectura\u00a0de\u00a0la\u00a0induraci\u00f3n\u00a0a\u00a0las\u00a0setenta\u00a0y\u00a0dos\u00a0horas,\u00a0expresada\u00a0siempre\u00a0en\u00a0mil\u00edmetros\u00a0del\u00a0di\u00e1metro\ntransverso.\n6 . 5 . 9 . 6 . 1\u00a0En\u00a0la\u00a0poblaci\u00f3n\u00a0general,\u00a0la\u00a0induraci\u00f3n\u00a0de\u00a010\u00a0mm\u00a0o\u00a0m\u00e1s,\u00a0indica\u00a0reactor\u00a0a\u00a0PPD.\u00a0En\u00a0personas\u00a0con\u00a0inmunocompromiso\n(por\u00a0ejemplo,\u00a0reci\u00e9n\u00a0nacidos,\u00a0desnutridos,\u00a0personas\u00a0infectadas\u00a0por\u00a0VIH)\u00a0se\u00a0considera\u00a0reactor\u00a0al\u00a0que\u00a0presenta\u00a0induraci\u00f3n\u00a0de\u00a05\nmm\u00a0o\u00a0m\u00e1s\u00a0de\u00a0di\u00e1metro\u00a0transverso.\u00a0La\u00a0no\u00a0induraci\u00f3n\u00a0en\u00a0estas\u00a0personas\u00a0no\u00a0descarta\u00a0la\u00a0presencia\u00a0de\u00a0tuberculosis\u00a0activa.\n6 . 5 . 9 . 6 . 2\u00a0En\u00a0ni\u00f1as\u00a0y\u00a0ni\u00f1os\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0reactores\u00a0a\u00a0PPD,\u00a0se\u00a0requiere\u00a0precisar\u00a0el\u00a0diagn\u00f3stico\u00a0y,\u00a0de\u00a0acuerdo\u00a0con\u00a0el\nresultado,\u00a0decidir\u00a0si\u00a0se\u00a0administra\u00a0quimioprofilaxis\u00a0o\u00a0tratamiento.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 13/236 . 6\u00a0Tratamiento\u00a0de\u00a0la\u00a0tuberculosis.\n6 . 6 . 1\u00a0El\u00a0tratamiento\u00a0se\u00a0prescribe\u00a0por\u00a0el\u00a0personal\u00a0m\u00e9dico,\u00a0se\u00a0administra\u00a0en\u00a0cualquiera\u00a0de\u00a0sus\u00a0formas,\u00a0se\u00a0distingue\u00a0en\u00a0primario\nacortado,\u00a0retratamiento\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea,\u00a0retratamiento\u00a0estandarizado\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0para\u00a0TB\u00ad\nMFR\u00a0y\u00a0retratamiento\u00a0individualizado\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0para\u00a0TB\u00adMFR\u00a0o\u00a0de\u00a0acuerdo\u00a0a\u00a0antecedente\u00a0de\u00a0tratamiento.\nTodos\u00a0los\u00a0tratamientos\u00a0deben\u00a0ser\u00a0estrictamente\u00a0supervisados\u00a0por\u00a0personal\u00a0de\u00a0salud.\nF I G U R A \u00a0 1 . \u00a0 P i r \u00e1 m i d e \u00a0 d e \u00a0 \u00c9 x i t o \u00a0 d e \u00a0 T r a t a m i e n t o .\n1a.\u00a0l\u00ednea:\u00a0isoniacida\u00a0(H),\u00a0rifampicina\u00a0(R),\u00a0pirazinamida\u00a0(Z),\u00a0etambutol\u00a0(E),\u00a0estreptomicina\u00a0(S).\n2a.\u00a0l\u00ednea:\u00a0kanamicina\u00a0(Km),\u00a0amikacina\u00a0(Am),\u00a0capreomicina\u00a0(Cm),\u00a0etionamida\u00a0(Eto),\u00a0protionamida\u00a0(Pto),\u00a0ofloxacina\u00a0(Ofx),\nlevofloxacina\u00a0(Lfx),\u00a0moxifloxacina\u00a0(Mfx)y\u00a0ciclocerina\u00a0(Cs).\n*\u00a0Utilizar\u00a0s\u00f3lo\u00a0en\u00a0caso\u00a0de\u00a0reca\u00edda\u00a0o\u00a0reconquista,\u00a0si\u00a0el\u00a0paciente\u00a0cumple\u00a0criterios\u00a0de\u00a0fracaso,\u00a0presente\u00a0el\u00a0caso\u00a0al\u00a0COEFAR.\nNota:\u00a0los\u00a0n\u00fameros\u00a0que\u00a0preceden\u00a0a\u00a0la\u00a0inicial\u00a0del\u00a0f\u00e1rmaco\u00a0indican\u00a0el\u00a0tiempo\u00a0en\u00a0meses\u00a0por\u00a0el\u00a0cual\u00a0hay\u00a0que\u00a0administrarlo\u037e\u00a0las\ndiagonales,\u00a0el\u00a0cambio\u00a0de\u00a0fase\u037e\u00a0los\u00a0sub\u00edndices,\u00a0el\u00a0n\u00famero\u00a0de\u00a0dosis\u00a0del\u00a0medicamento\u00a0por\u00a0semana.\u00a0De\u00a0no\u00a0haber\u00a0ning\u00fan\u00a0n\u00famero\u00a0en\nforma\u00a0de\u00a0sub\u00edndice,\u00a0el\u00a0medicamento\u00a0se\u00a0administra\u00a0diariamente\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado.\n6 . 6 . 2\u00a0Los\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea\u00a0que\u00a0se\u00a0utilizan\u00a0en\u00a0el\u00a0tratamiento\u00a0primario\u00a0de\u00a0la\u00a0tuberculosis\u00a0son:\u00a0H,\u00a0R,\u00a0Z,\u00a0S\u00a0y\u00a0E,\u00a0cuyas\npresentaciones,\u00a0dosis\u00a0y\u00a0reacciones\u00a0adversas\u00a0se\u00a0se\u00f1alan\u00a0en\u00a0la\u00a0TABLA\u00a01,\u00a0de\u00a0esta\u00a0Norma.\u00a0Los\u00a0efectos\u00a0adversos\u00a0se\u00a0deben\u00a0atender\ny\u00a0reportar\u00a0en\u00a0el\u00a0sistema\u00a0de\u00a0informaci\u00f3n\u00a0correspondiente.\nT A B L A \u00a0 1 . \u00a0 F \u00e1 r m a c o s \u00a0 a n t i \u00a0 t u b e r c u l o s i s \u00a0 d e \u00a0 p r i m e r a \u00a0 l \u00ed n e a .\nF\u00e1rmacos\u00a0Acci\u00f3nPresentaci\u00f3nDosis\u00a0diaria: Dosis\u00a0intermitentes:Penetraci\u00f3n\nal\u00a0Sistema\nNervioso\nCentralEx\u00e1menes\u00a0cl\u00ednicos\nde\u00a0monitoreoInteracciones\u00a0y\nefectos\u00a0adversos\nNi\u00f1os\nDosis\nmg/KgAdultos\nDosis\nmg/KgNi\u00f1os\u00a0Dosis\n3\u00a0veces\u00a0por\nsemana\u00a0mg/\nkgAdultos\nDosis\u00a03\nveces\u00a0por\nsemana\nmg/kg\nIsoniacida\u00a0(H)\nBactericida\u00a0extra\ne\u00a0intracelularComprimido\n100\u00a0mg15\nhasta\n300\u00a0mg5\u00ad10\nhasta\n300\u00a0mg20\u00a0hasta\u00a0600\nmg600\u00ad800BuenaPruebas\u00a0de\u00a0funci\u00f3n\nhep\u00e1ticaFenito\u00edna\u00a0Neuritis\nHepatitis\nHipersensibilidad\nS\u00edndrome\u00a0lupoide\nRifampicina\u00a0(R)\nBactericida\u00a0todas\npoblaciones\nEsterilizanteC\u00e1psulas\n300\u00a0mg\nJarabe\u00a0100\nmg/5\u00a0ml15\nhasta\n600\u00a0mg10\u00a0hasta\n600\u00a0mg20\u00a0mg/kg\n600\u00a0a\u00a0900\nmg600 BuenaPruebas\u00a0de\u00a0funci\u00f3n\nhep\u00e1tica\u00a0(Aspartato\namino\u00a0transferasa\u00a0y\nAlanina\u00a0amino\ntransaminasa)Inhibe\nanticonceptivos\norales\u00a0Quinidina\nHepatitis\u00a0Reacci\u00f3n\nfebril\u00a0P\u00farpura\nHipersensibilidad\nIntolerancia\u00a0oral2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 14/23Pirazinamida\u00a0(Z)\nBactericida\nintracelular\nEsterilizanteComprimido\n500\u00a0mg25\u00ad40\nhasta\u00a02\ng20\u00ad30\nhasta\u00a02\u00a0gHasta\u00a050\nmg/kg\u00a0En\n>51\u00a0Kg\nhasta\u00a02.5\u00a0g2,500 BuenaPruebas\u00a0de\u00a0funci\u00f3n\nrenal\u00a0(\u00e1cido\u00a0\u00farico)\nPruebas\u00a0de\u00a0funci\u00f3n\nhep\u00e1tica\u00a0(Aspartato\namino\u00a0transferasa\u00a0y\nAlanina\u00a0amino\ntransaminasa)Hiperuricemia\nHepatitis\u00a0V\u00f3mitos\nArtralgias\nHipersensibilidad\ncut\u00e1nea\nEtambutol\u00a0(E)\nBacteriost\u00e1tico\nextra\u00a0e\nintracelularComprimido\n400\u00a0mg15\u00ad30\nhasta\n1.2\u00a0g15\u00a025\nhasta\u00a01.2\ng50\u00a0mg/kg\nhasta\u00a01.2\u00a0g\ncomo\u00a0dosis\ntope1,200 Buena Agudeza\u00a0visualNeuritis\u00a0\u00f3ptica\nDiscriminaci\u00f3n\u00a0rojo\u00ad\nverde\nEstreptomicina\n(S)\u00a0Bactericida\nextracelular\u00a0(*),\n(**)Frasco\n\u00e1mpula\u00a01\u00a0g15\u00ad30\nhasta\u00a01\ng15\u00a0hasta\n1\u00a0g25\u00ad30\u00a0mg/kg\nhasta\u00a01\u00a0g1,000 PobreFunci\u00f3n\u00a0vestibular\nAudiometr\u00eda\nPruebas\u00a0de\u00a0funci\u00f3n\nrenal\u00a0(creatinina)Bloqueo\nneuromuscular\nLesi\u00f3n\u00a0VIII\u00a0par\nHipersensibilidad\nnefrotoxicidad\n(*)\u00a0Pacientes\u00a0con\u00a0menos\u00a0de\u00a050\u00a0kg\u00a0de\u00a0peso\u00a0y\u00a0mayores\u00a0de\u00a050\u00a0a\u00f1os,\u00a0dar\u00a0la\u00a0mitad\u00a0de\u00a0la\u00a0dosis.\n(**)\u00a0No\u00a0utilizar\u00a0durante\u00a0el\u00a0embarazo.\n6 . 6 . 3 .\u00a0En\u00a0ni\u00f1os\u00a0menores\u00a0de\u00a0ocho\u00a0a\u00f1os\u00a0se\u00a0deben\u00a0administrar\u00a0cuatro\u00a0f\u00e1rmacos\u00a0en\u00a0presentaci\u00f3n\u00a0separada\u00a0de\u00a0acuerdo\u00a0con\u00a0las\ndosis\u00a0indicadas\u00a0en\u00a0la\u00a0TABLA\u00a01,\u00a0sin\u00a0exceder\u00a0la\u00a0dosificaci\u00f3n\u00a0del\u00a0adulto.\n6 . 6 . 4\u00a0El\u00a0tratamiento\u00a0primario\u00a0acortado\u00a0incluye\u00a0los\u00a0siguientes\u00a0f\u00e1rmacos:\u00a0H,\u00a0R,\u00a0Z\u00a0y\u00a0E\u00a0y\u00a0se\u00a0aplica\u00a0a\u00a0todo\u00a0caso\u00a0diagnosticado\u00a0por\nprimera\u00a0vez.\n6 . 6 . 5\u00a0El\u00a0esquema\u00a0de\u00a0tratamiento\u00a0primario\u00a0acortado\u00a0se\u00a0debe\u00a0administrar\u00a0aproximadamente\u00a0durante\u00a0veinticinco\u00a0semanas,\nhasta\u00a0completar\u00a0ciento\u00a0cinco\u00a0dosis,\u00a0dividido\u00a0en\u00a0dos\u00a0etapas:\u00a0fase\u00a0intensiva,\u00a0sesenta\u00a0dosis\u00a0(diario\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0con\u00a0H\u00adR\u00adZ\u00adE)\u037e\ny\u00a0fase\u00a0de\u00a0sost\u00e9n,\u00a0cuarenta\u00a0y\u00a0cinco\u00a0dosis\u00a0(intermitente,\u00a0tres\u00a0veces\u00a0a\u00a0la\u00a0semana,\u00a0con\u00a0H\u00adR),\u00a0seg\u00fan\u00a0se\u00a0indica\u00a0en\u00a0la\u00a0TABLA\u00a02.\nT A B L A \u00a0 2 . \u00a0 T r a t a m i e n t o \u00a0 p r i m a r i o \u00a0 a c o r t a d o .\nFase\u00a0intensiva: Diario,\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado,\u00a0hasta\u00a0completar\u00a0sesenta\ndosis,\u00a0administraci\u00f3n\u00a0en\u00a0una\u00a0toma.\nF\u00e1rmacos:\nRifampicina\u00a0(R)\nIsoniacida\u00a0(H)\nPirazinamida\u00a0(Z)\nEtambutol\u00a0(E)Dosis:\n600\u00a0mg\n300\u00a0mg\n1,500\u00a0a\u00a02,000\u00a0mg\n1,200\u00a0mg\nFase\u00a0de\u00a0sost\u00e9n: Intermitente,\u00a0tres\u00a0veces\u00a0por\u00a0semana,\u00a0lunes,\u00a0mi\u00e9rcoles\ny\u00a0viernes,\u00a0hasta\u00a0completar\u00a0cuarenta\u00a0y\u00a0cinco\u00a0dosis.\nAdministraci\u00f3n\u00a0en\u00a0una\u00a0toma.\nF\u00e1rmacos:\nIsoniacida\u00a0(H)\nRifampicina\u00a0(R)Dosis:\n800\u00a0mg\n600\u00a0mg\nEn\u00a0personas\u00a0que\u00a0pesen\u00a0menos\u00a0de\u00a0cincuenta\u00a0kg,\u00a0la\u00a0dosis\u00a0se\u00a0calcula\u00a0por\u00a0kilogramo\u00a0de\u00a0peso\u00a0en\u00a0dosis\u00a0m\u00e1xima\u00a0y\u00a0se\u00a0maneja\u00a0con\nf\u00e1rmacos\u00a0en\u00a0presentaci\u00f3n\u00a0por\u00a0separado,\u00a0como\u00a0se\u00a0indica\u00a0en\u00a0la\u00a0TABLA\u00a01.\nLa\u00a0presentaci\u00f3n\u00a0en\u00a0comprimido\u00a0\u00fanico\u00a0a\u00a0dosis\u00a0fijas\u00a0combinadas,\u00a0favorece\u00a0el\u00a0apego\u00a0al\u00a0tratamiento.\n6 . 6 . 6\u00a0En\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0tuberculosis\u00a0\u00f3sea,\u00a0se\u00a0aconseja\u00a0que\u00a0el\u00a0tratamiento\u00a0sea\u00a0administrado\u00a0durante\u00a0nueve\u00a0meses,\ndividido\u00a0en\u00a0dos\u00a0etapas:\u00a0fase\u00a0intensiva\u00a0(bactericida),\u00a0dos\u00a0meses\u00a0(diario\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0con\u00a0H,\u00a0R,\u00a0Z\u00a0y\u00a0E\u037e\u00a0en\u00a0ni\u00f1os\u00a0se\u00a0puede\u00a0dar\ndiario)\u00a0y\u00a0fase\u00a0de\u00a0sost\u00e9n\u00a0(esterilizante),\u00a0siete\u00a0meses\u00a0(intermitente,\u00a0tres\u00a0veces\u00a0a\u00a0la\u00a0semana,\u00a0con\u00a0H\u00a0y\u00a0R).\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0tuberculosis\ndel\u00a0sistema\u00a0nervioso\u00a0y\u00a0linfohemat\u00f3gena\u00a0(diseminada),\u00a0el\u00a0tratamiento\u00a0deber\u00e1\u00a0administrarse\u00a0durante\u00a0doce\u00a0meses\u00a0(la\u00a0fase\u00a0de\nsost\u00e9n\u00a0deber\u00e1\u00a0administrarse\u00a0durante\u00a0diez\u00a0meses).\n6 . 6 . 7\u00a0El\u00a0tratamiento\u00a0primario\u00a0acortado\u00a0debe\u00a0ser\u00a0estrictamente\u00a0supervisado\u00a0por\u00a0personal\u00a0de\u00a0salud,\u00a0ajust\u00e1ndose\u00a0a\u00a0las\nsiguientes\u00a0especificaciones:\n6 . 6 . 8\u00a0A\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0tuberculosis\u00a0confirmada\u00a0se\u00a0deber\u00e1\u00a0realizar\u00a0evaluaci\u00f3n\u00a0de\u00a0riesgo\u00a0de\u00a0abandono\u00a0antes\u00a0de\niniciar\u00a0el\u00a0tratamiento\u00a0para\u00a0tomar\u00a0las\u00a0medidas\u00a0pertinentes\u00a0para\u00a0garantizar\u00a0el\u00a0apego\u00a0al\u00a0tratamiento.\n6 . 6 . 9\u00a0Mantener\u00a0el\u00a0tratamiento\u00a0primario\u00a0con\u00a0la\u00a0combinaci\u00f3n\u00a0fija\u00a0de\u00a0H,\u00a0R,\u00a0Z\u00a0y\u00a0E\u00a0o\u00a0H,\u00a0R,\u00a0Z\u00a0m\u00e1s\u00a0E\u00a0para\u00a0fase\u00a0intensiva\u00a0y\u00a0H\u00a0y\u00a0R\u00a0para\nfase\u00a0de\u00a0sost\u00e9n.\n6 . 6 . 1 0\u00a0El\u00a0personal\u00a0de\u00a0salud\u00a0o\u00a0personal\u00a0capacitado\u00a0por\u00a0el\u00a0mismo,\u00a0debe\u00a0vigilar\u00a0la\u00a0administraci\u00f3n\u00a0y\u00a0degluci\u00f3n\u00a0de\u00a0cada\u00a0dosis,\u00a0de\nacuerdo\u00a0a\u00a0lo\u00a0establecido\u00a0en\u00a0esta\u00a0Norma.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 15/236 . 6 . 1 1\u00a0El\u00a0tratamiento\u00a0primario\u00a0para\u00a0tuberculosis\u00a0con\u00a0confirmaci\u00f3n\u00a0bacteriol\u00f3gica\u00a0debe\u00a0tener\u00a0seguimiento\u00a0mensual\u00a0con\nbaciloscopia\u00a0hasta\u00a0el\u00a0t\u00e9rmino\u00a0del\u00a0tratamiento.\u00a0En\u00a0tuberculosis\u00a0no\u00a0confirmada,\u00a0extrapulmonar,\u00a0diseminada\u00a0y\u00a0en\u00a0ni\u00f1os,\u00a0el\nseguimiento\u00a0debe\u00a0ser\u00a0cl\u00ednico\u00a0mensual\u00a0y\u00a0radiol\u00f3gico\u00a0con\u00a0la\u00a0frecuencia\u00a0que\u00a0indique\u00a0el\u00a0m\u00e9dico\u00a0tratante.\n6 . 6 . 1 2\u00a0Cuando\u00a0un\u00a0paciente\u00a0abandona\u00a0el\u00a0tratamiento\u00a0o\u00a0recae\u00a0a\u00a0un\u00a0tratamiento\u00a0primario\u00a0acortado,\u00a0se\u00a0sugiere\u00a0un\u00a0retratamiento\ncon\u00a0cinco\u00a0f\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea\u00a0(v\u00e9ase\u00a0FIGURA\u00a01).\u00a0Cuando\u00a0un\u00a0paciente\u00a0fracasa\u00a0se\u00a0recomienda\u00a0que\u00a0sea\u00a0revisado\u00a0por\u00a0el\nCOEFAR\u00a0para\u00a0dictaminar\u00a0un\u00a0esquema\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea.\n6 . 6 . 1 3\u00a0El\u00a0retratamiento\u00a0primario\u00a0de\u00a0la\u00a0tuberculosis\u00a0incluye\u00a0los\u00a0siguientes\u00a0f\u00e1rmacos:\u00a0H,\u00a0R,\u00a0P,\u00a0E\u00a0y\u00a0S,\u00a0hasta\u00a0completar\u00a0ciento\ncincuenta\u00a0dosis,\u00a0dividido\u00a0en\u00a0tres\u00a0fases:\u00a0fase\u00a0intensiva,\u00a0sesenta\u00a0dosis\u00a0(diario\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0con\u00a0H,\u00a0R,\u00a0Z,\u00a0E\u00a0y\u00a0S)\u037e\u00a0fase\nintermedia,\u00a0treinta\u00a0dosis\u00a0(diario\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0con\u00a0H,\u00a0R,\u00a0Z\u00a0y\u00a0E)\u00a0y\u00a0fase\u00a0de\u00a0sost\u00e9n,\u00a0sesenta\u00a0dosis\u00a0(intermitente\u00a0tres\u00a0veces\u00a0a\u00a0la\nsemana\u00a0con\u00a0H,\u00a0R\u00a0y\u00a0E),\u00a0como\u00a0se\u00a0indica\u00a0en\u00a0la\u00a0TABLA\u00a03.\nT A B L A \u00a0 3 . \u00a0 R e t r a t a m i e n t o \u00a0 p r i m a r i o .\nFase\u00a0intensiva: Diario\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0hasta\u00a0completar\u00a0sesenta\u00a0dosis,\u00a0administraci\u00f3n\u00a0en\nuna\u00a0toma.\nF\u00e1rmacos:\nRifampicina\u00a0(R)\nIsoniacida\u00a0(H)\nPirazinamida\u00a0(Z)\nEtambutol\u00a0(E)\nEstreptomicina\u00a0(S)Dosis\u00a0(separados):\n600\u00a0mg\n300\u00a0mg\n1,500\u00a0a\u00a02,000\u00a0mg\n1,200\u00a0mg\n1,000\u00a0mg\u00a0(IM)\nFase\u00a0intermedia: Diario,\u00a0de\u00a0lunes\u00a0a\u00a0s\u00e1bado\u00a0hasta\u00a0completar\u00a0treinta\u00a0dosis.\nF\u00e1rmacos:\nRifampicina\u00a0(R)\nIsoniacida\u00a0(H)\nPirazinamida\u00a0(Z)\nEtambutol\u00a0(E)Dosis:\n600\u00a0mg\n300\u00a0mg\n1,500\u00a0a\u00a02,000\u00a0mg\n1,200\u00a0mg\nFase\u00a0de\u00a0sost\u00e9n: Intermitente:\u00a0Tres\u00a0veces\u00a0por\u00a0semana,\u00a0lunes,\u00a0mi\u00e9rcoles\u00a0y\u00a0viernes\u00a0hasta\ncompletar\u00a0sesenta\u00a0dosis.\u00a0Administraci\u00f3n\u00a0en\u00a0una\u00a0toma.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 16/23F\u00e1rmacos:\nRifampicina\u00a0(R)\nIsoniacida\u00a0(H)\nEtambutol\u00a0(E)Dosis\u00a0(separados):\n800\u00a0mg\n600\u00a0mg\n1,200\u00a0mg\n\u00a0\nEn\u00a0personas\u00a0que\u00a0pesen\u00a0menos\u00a0de\u00a0cincuenta\u00a0kg\u00a0las\u00a0dosis\u00a0se\u00a0calcular\u00e1n\u00a0por\u00a0kg\u00a0de\u00a0peso\u00a0en\u00a0dosis\u00a0m\u00e1xima\u00a0y\u00a0con\u00a0f\u00e1rmacos\u00a0en\npresentaci\u00f3n\u00a0por\u00a0separado,\u00a0como\u00a0se\u00a0indica\u00a0en\u00a0la\u00a0TABLA\u00a01.\n6 . 6 . 1 4\u00a0Todo\u00a0paciente\u00a0que\u00a0fracase\u00a0al\u00a0tratamiento\u00a0primario,\u00a0los\u00a0que\u00a0abandonen,\u00a0recaigan\u00a0o\u00a0fracasen\u00a0a\u00a0un\u00a0retratamiento\u00a0con\nf\u00e1rmacos\u00a0de\u00a0primera\u00a0l\u00ednea,\u00a0deben\u00a0ser\u00a0evaluados\u00a0por\u00a0el\u00a0COEFAR,\u00a0el\u00a0cual\u00a0definir\u00e1\u00a0el\u00a0manejo,\u00a0seguimiento\u00a0de\u00a0casos\u00a0y\u00a0establecer\u00e1\nlas\u00a0acciones\u00a0de\u00a0prevenci\u00f3n\u00a0y\u00a0control\u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0Gu\u00eda\u00a0para\u00a0la\u00a0atenci\u00f3n\u00a0de\u00a0personas\u00a0con\u00a0tuberculosis\u00a0resistente\u00a0a\u00a0f\u00e1rmacos,\nque\u00a0se\u00a0encuentra\u00a0publicada\u00a0en\u00a0la\u00a0p\u00e1gina\u00a0http://www.cenaprece.salud.gob.mx/programas/interior/portada_manuales.html.\n6 . 7\u00a0Control\u00a0del\u00a0tratamiento\u00a0primario\u00a0acortado\u00a0(casos\u00a0nuevos\u00a0de\u00a0tuberculosis).\n6 . 7 . 1\u00a0Control\u00a0cl\u00ednico:\u00a0se\u00a0debe\u00a0llevar\u00a0a\u00a0cabo\u00a0cada\u00a0mes\u00a0o\u00a0en\u00a0menor\u00a0lapso\u00a0cuando\u00a0la\u00a0evoluci\u00f3n\u00a0del\u00a0enfermo\u00a0lo\u00a0requiera,\u00a0e\nincluye\u00a0revisi\u00f3n\u00a0cl\u00ednica\u00a0integral,\u00a0evoluci\u00f3n\u00a0de\u00a0los\u00a0s\u00edntomas,\u00a0valoraci\u00f3n\u00a0del\u00a0apego\u00a0al\u00a0tratamiento,\u00a0la\u00a0tolerancia\u00a0a\u00a0los\u00a0medicamentos\ny\u00a0presencia\u00a0de\u00a0eventos\u00a0adversos.\n6 . 7 . 2\u00a0Control\u00a0bacteriol\u00f3gico:\u00a0realizar\u00a0estudio\u00a0de\u00a0baciloscopia\u00a0mensual\u00a0hasta\u00a0el\u00a0t\u00e9rmino\u00a0del\u00a0tratamiento.\u00a0Es\u00a0favorable\u00a0cuando\nla\u00a0baciloscopia\u00a0sea\u00a0negativa\u00a0al\u00a0final\u00a0del\u00a0segundo\u00a0mes\u00a0de\u00a0tratamiento\u00a0y\u00a0persista\u00a0negativa\u00a0hasta\u00a0terminar\u00a0las\u00a0dosis\u00a0requeridas\u00a0para\ncada\u00a0esquema\u00a0y\u00a0desfavorable,\u00a0con\u00a0sospecha\u00a0de\u00a0farmacorresistencia\u00a0cuando\u00a0persista\u00a0positiva\u00a0al\u00a0final\u00a0del\u00a0segundo\u00a0mes\u00a0de\ntratamiento\u00a0o\u00a0si\u00a0una\u00a0vez\u00a0que\u00a0es\u00a0negativa\u00a0en\u00a0meses\u00a0consecutivos\u00a0nuevamente\u00a0es\u00a0positiva,\u00a0en\u00a0este\u00a0caso\u00a0se\u00a0debe\u00a0solicitar\u00a0estudio\nde\u00a0cultivo\u00a0con\u00a0PFS.\n6 . 7 . 3\u00a0Control\u00a0radiogr\u00e1fico:\u00a0se\u00a0efect\u00faa\u00a0en\u00a0adultos\u00a0como\u00a0estudio\u00a0complementario,\u00a0al\u00a0inicio\u00a0y\u00a0al\u00a0final\u00a0del\u00a0tratamiento,\u00a0cuando\nexista\u00a0el\u00a0recurso.\u00a0En\u00a0ni\u00f1os\u00a0es\u00a0indispensable,\u00a0si\u00a0es\u00a0posible,\u00a0cada\u00a0dos\u00a0meses.\n6 . 8\u00a0Evaluaci\u00f3n\u00a0del\u00a0tratamiento\u00a0primario:\n6 . 8 . 1\u00a0Al\u00a0completar\u00a0el\u00a0esquema\u00a0de\u00a0tratamiento,\u00a0el\u00a0caso\u00a0se\u00a0clasifica\u00a0como:\u00a0curado,\u00a0t\u00e9rmino\u00a0de\u00a0tratamiento\u00a0o\u00a0fracaso\u00a0de\ntratamiento.\n6 . 8 . 2\u00a0Los\u00a0casos\u00a0que\u00a0no\u00a0terminan\u00a0el\u00a0tratamiento\u00a0se\u00a0clasifican\u00a0como:\u00a0defunciones\u00a0o\u00a0abandonos.\n6 . 8 . 3\u00a0Se\u00a0deber\u00e1\u00a0realizar\u00a0seguimiento\u00a0semestral\u00a0al\u00a0menos\u00a0durante\u00a0dos\u00a0a\u00f1os\u00a0a\u00a0los\u00a0casos\u00a0curados.\n6 . 9\u00a0Estudio\u00a0de\u00a0contactos.\n6 . 9 . 1\u00a0Se\u00a0realizar\u00e1\u00a0a\u00a0todos\u00a0los\u00a0contactos\u00a0inmediatamente\u00a0despu\u00e9s\u00a0de\u00a0conocerse\u00a0el\u00a0caso\u00a0confirmado\u00a0de\u00a0tuberculosis\u00a0y\u00a0durante\nel\u00a0tratamiento\u037e\u00a0se\u00a0deben\u00a0realizar\u00a0los\u00a0siguientes\u00a0estudios:\u00a0cl\u00ednico\u00a0y\u00a0epidemiol\u00f3gico.\u00a0De\u00a0presentarse\u00a0s\u00edntomas\u00a0sugerentes\u00a0de\ntuberculosis\u00a0en\u00a0alguno\u00a0de\u00a0ellos,\u00a0se\u00a0eval\u00faa\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.5.1,\u00a0de\u00a0esta\u00a0Norma.\u00a0Para\u00a0contactos\u00a0pedi\u00e1tricos\u00a0se\u00a0debe\u00a0evaluar\nantecedente\u00a0de\u00a0vacunaci\u00f3n\u00a0con\u00a0BCG\u00a0y\u00a0hacer\u00a0un\u00a0seguimiento\u00a0de\u00a0los\u00a0contactos\u00a0por\u00a0al\u00a0menos\u00a0dos\u00a0a\u00f1os.\n7 . \u00a0 T u b e r c u l o s i s \u00a0 y \u00a0 o t r o s \u00a0 p a d e c i m i e n t o s\n7 . 1\u00a0Todos\u00a0los\u00a0casos\u00a0de\u00a0tuberculosis\u00a0con\u00a0alcoholismo\u00a0y\u00a0tabaquismo\u00a0severo\u00a0u\u00a0otras\u00a0adicciones\u00a0o\u00a0padecimientos\u00a0no\u00a0controlados\ndeben\u00a0ser\u00a0evaluados\u00a0por\u00a0equipo\u00a0multidisciplinario\u00a0y\u00a0la\u00a0red\u00a0de\u00a0apoyo\u00a0social,\u00a0para\u00a0asegurar\u00a0el\u00a0\u00e9xito\u00a0del\u00a0tratamiento.\n7 . 1 . 1\u00a0Tuberculosis\u00a0y\u00a0diabetes\u00a0mellitus.\n7 . 1 . 1 . 1\u00a0Detecci\u00f3n\u00a0de\u00a0diabetes\u00a0mellitus\u00a0en\u00a0personas\u00a0con\u00a0tuberculosis.\n7 . 1 . 1 . 1 . 1\u00a0En\u00a0toda\u00a0persona\u00a0con\u00a0tuberculosis\u00a0se\u00a0deber\u00e1\u00a0realizar\u00a0b\u00fasqueda\u00a0intencionada\u00a0de\u00a0diabetes\u00a0mellitus\u00a0simult\u00e1neamente\nal\u00a0diagn\u00f3stico\u00a0de\u00a0tuberculosis.\n7 . 1 . 1 . 2\u00a0Los\u00a0casos\u00a0complicados\u00a0con\u00a0tuberculosis\u00a0y\u00a0diabetes\u00a0mellitus\u00a0deber\u00e1n\u00a0ser\u00a0evaluados\u00a0por\u00a0el\u00a0COEFAR\u00a0para\u00a0determinar\u00a0el\ntratamiento\u00a0de\u00a0la\u00a0diabetes\u00a0simult\u00e1neamente\u00a0al\u00a0tratamiento\u00a0anti\u00a0tuberculosis.\n7 . 1 . 1 . 3\u00a0En\u00a0las\u00a0personas\u00a0con\u00a0diabetes\u00a0mellitus\u00a0es\u00a0recomendable\u00a0administrar\u00a0piridoxina\u00a0de\u00a010\u00a0a\u00a025\u00a0mg/d\u00eda,\u00a0durante\u00a0el\ntratamiento\u00a0anti\u00a0tuberculosis.\n7 . 1 . 1 . 4\u00a0En\u00a0caso\u00a0de\u00a0que\u00a0el\u00a0paciente\u00a0con\u00a0tuberculosis\u00a0y\u00a0diabetes\u00a0mellitus\u00a0presente\u00a0niveles\u00a0de\u00a0glucosa\u00a0plasm\u00e1tica\u00a0mayores\u00a0a\n250\u00a0mg/dl\u00a0o\u00a0hemoglobina\u00a0glucosilada\u00a0mayor\u00a0a\u00a08.5%\u00a0y/o\u00a0la\u00a0persona\u00a0presente\u00a0complicaciones,\u00a0deber\u00e1\u00a0ser\u00a0referido\u00a0al\u00a0siguiente\nnivel\u00a0de\u00a0atenci\u00f3n\u00a0(UNEME\u00a0EC\u00a0u\u00a0Hospital).\n7 . 1 . 1 . 5\u00a0El\u00a0tratamiento\u00a0para\u00a0tuberculosis\u00a0en\u00a0personas\u00a0con\u00a0diabetes\u00a0mellitus,\u00a0deber\u00e1\u00a0ser\u00a0supervisado,\u00a0preferentemente\u00a0por\npersonal\u00a0de\u00a0salud\u00a0y\u00a0otorgarse\u00a0de\u00a0manera\u00a0permanente\u00a0en\u00a0el\u00a0primer\u00a0nivel\u00a0de\u00a0atenci\u00f3n.\n7 . 1 . 1 . 6\u00a0En\u00a0las\u00a0personas\u00a0con\u00a0diabetes\u00a0mellitus\u00a0que\u00a0desarrollaron\u00a0tuberculosis\u00a0y\u00a0curaron,\u00a0es\u00a0recomendable\u00a0realizar\nseguimiento\u00a0semestral\u00a0posterior\u00a0a\u00a0la\u00a0curaci\u00f3n\u00a0por\u00a0un\u00a0m\u00ednimo\u00a0de\u00a0dos\u00a0a\u00f1os\u00a0para\u00a0identificar\u00a0oportunamente\u00a0reca\u00eddas\u00a0y\u00a0en\u00a0su\u00a0caso\nreinstalar\u00a0el\u00a0tratamiento\u00a0anti\u00a0tuberculosis,\u00a0al\u00a0mismo\u00a0tiempo\u00a0se\u00a0debe\u00a0mantener\u00a0el\u00a0control\u00a0glic\u00e9mico\u00a0de\u00a0manera\u00a0mensual.\n7 . 1 . 1 . 7\u00a0Las\u00a0personas\u00a0con\u00a0diabetes\u00a0mellitus\u00a0que\u00a0tengan\u00a0contacto\u00a0con\u00a0un\u00a0caso\u00a0de\u00a0tuberculosis\u00a0pulmonar\u00a0con\u00a0comprobaci\u00f3n\nbacteriol\u00f3gica,\u00a0se\u00a0recomienda\u00a0dar\u00a0terapia\u00a0preventiva\u00a0con\u00a0H\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.1.2,\u00a0de\u00a0esta\u00a0Norma\u00a0y\u00a0piridoxina\u00a0de\u00a010\u00a0a\u00a025\nmg/d\u00eda,\u00a0durante\u00a0la\u00a0administraci\u00f3n\u00a0de\u00a0la\u00a0terapia\u00a0preventiva\u00a0con\u00a0H.\n7 . 1 . 1 . 8\u00a0Para\u00a0disminuir\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollar\u00a0tuberculosis\u00a0activa\u00a0en\u00a0personas\u00a0con\u00a0diabetes\u00a0mellitus,\u00a0es\u00a0necesario\u00a0que\u00a0estas\npersonas\u00a0lleven\u00a0un\u00a0buen\u00a0control\u00a0metab\u00f3lico\u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0Norma\u00a0Oficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.3,\u00a0del\u00a0cap\u00edtulo\u00a0de\nReferencias,\u00a0de\u00a0esta\u00a0Norma.\n7 . 1 . 1 . 9\u00a0Las\u00a0personas\u00a0que\u00a0viven\u00a0con\u00a0diabetes\u00a0tienen\u00a0mayor\u00a0riesgo\u00a0de\u00a0desarrollar\u00a0tuberculosis\u00a0pulmonar\u037e\u00a0por\u00a0ello,\u00a0se\u00a0debe\u00a0de\nrealizar\u00a0b\u00fasqueda\u00a0intencionada\u00a0de\u00a0sintomatolog\u00eda\u00a0respiratoria\u00a0en\u00a0cada\u00a0consulta.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 17/237 . 1 . 1 . 1 0\u00a0A\u00a0todas\u00a0las\u00a0personas\u00a0con\u00a0diabetes,\u00a0que\u00a0sean\u00a0casos\u00a0probables\u00a0de\u00a0tuberculosis\u00a0(sintom\u00e1ticos\u00a0respiratorios),\u00a0se\u00a0les\ndebe\u00a0realizar\u00a0baciloscopia\u00a0en\u00a0expectoraci\u00f3n\u00a0en\u00a0serie\u00a0de\u00a0tres\u00a0para\u00a0b\u00fasqueda\u00a0intencionada\u00a0de\u00a0tuberculosis,\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\n6.5.4,\u00a0de\u00a0esta\u00a0Norma\u00a0y\u00a0realizar\u00a0diagn\u00f3stico\u00a0mediante\u00a0cultivo,\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.5.6,\u00a0de\u00a0esta\u00a0Norma.\n7 . 1 . 1 . 1 1\u00a0Todos\u00a0los\u00a0pacientes\u00a0con\u00a0diabetes,\u00a0en\u00a0quienes\u00a0se\u00a0demuestre\u00a0tuberculosis\u00a0pulmonar,\u00a0se\u00a0recomienda\u00a0recibir\ntratamiento\u00a0primario\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.6.2,\u00a0de\u00a0esta\u00a0Norma.\n7 . 1 . 1 . 1 2\u00a0Evaluaci\u00f3n\u00a0del\u00a0tratamiento:\n7 . 1 . 1 . 1 2 . 1\u00a0El\u00a0control\u00a0y\u00a0la\u00a0evaluaci\u00f3n\u00a0del\u00a0tratamiento\u00a0se\u00a0debe\u00a0realizar\u00a0de\u00a0acuerdo\u00a0a\u00a0los\u00a0puntos\u00a06.7\u00a0y\u00a06.8,\u00a0de\u00a0esta\u00a0Norma,\nadem\u00e1s\u00a0de\u00a0realizar\u00a0estudios\u00a0de\u00a0control\u00a0glic\u00e9mico\u00a0mensual\u00a0y\u00a0cultivo\u00a0para\u00a0M.\u00a0tuberculosis\u00a0al\u00a0t\u00e9rmino\u00a0del\u00a0tratamiento.\n7 . 1 . 1 . 1 2 . 2\u00a0Los\u00a0pacientes\u00a0con\u00a0diabetes\u00a0mellitus\u00a0y\u00a0sospecha\u00a0de\u00a0TB\u00adMFR\u00a0deben\u00a0ser\u00a0tratados\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a08.1.3,\u00a0de\u00a0esta\nNorma.\n7 . 1 . 2\u00a0Infecci\u00f3n\u00a0por\u00a0VIH/SIDA\u00a0y\u00a0tuberculosis.\n7 . 1 . 2 . 1\u00a0La\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0es\u00a0una\u00a0condici\u00f3n\u00a0predisponente\u00a0para\u00a0adquirir\u00a0tuberculosis\u00a0pulmonar\u00a0y\u00a0extrapulmonar.\n7 . 1 . 2 . 2\u00a0En\u00a0todos\u00a0los\u00a0casos\u00a0de\u00a0tuberculosis\u00a0se\u00a0deber\u00e1\u00a0ofrecer\u00a0la\u00a0prueba\u00a0de\u00a0VIH\u00a0de\u00a0manera\u00a0rutinaria\u00a0(opt\u00a0out\u00a0screening\u037e\u00a0que\nsignifica\u00a0que\u00a0las\u00a0pruebas\u00a0de\u00a0VIH\u00a0se\u00a0realizan\u00a0de\u00a0forma\u00a0rutinaria\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0paciente\u00a0se\u00a0niegue\u00a0expl\u00edcitamente\u00a0a\u00a0realizarse\u00a0la\nprueba\u00a0de\u00a0VIH).\n7 . 1 . 2 . 3 .\u00a0Se\u00a0debe\u00a0realizar\u00a0la\u00a0prueba\u00a0de\u00a0VIH\u00a0despu\u00e9s\u00a0de\u00a0notificar\u00a0a\u00a0la\u00a0persona\u00a0que\u00a0la\u00a0prueba\u00a0se\u00a0llevar\u00e1\u00a0a\u00a0cabo.\n7 . 1 . 2 . 4.\u00a0La\u00a0persona\u00a0puede\u00a0declinar\u00a0o\u00a0diferir\u00a0la\u00a0prueba\u00a0de\u00a0VIH.\u00a0Las\u00a0personas\u00a0que\u00a0resulten\u00a0VIH+\u00a0deber\u00e1n\u00a0referirse\u00a0a\u00a0la\u00a0unidad\nespecializada\u00a0en\u00a0VIH\u00a0para\u00a0su\u00a0atenci\u00f3n.\n7 . 1 . 2 . 5\u00a0En\u00a0todas\u00a0las\u00a0personas\u00a0mayores\u00a0de\u00a0quince\u00a0a\u00f1os\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH,\u00a0deber\u00e1n\u00a0ser\u00a0evaluadas\u00a0integralmente\npara\u00a0descartar\u00a0tuberculosis\u00a0activa\u00a0en\u00a0cualquiera\u00a0de\u00a0sus\u00a0formas.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 18/237 . 1 . 2 . 6\u00a0En\u00a0adultos\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH\u00a0no\u00a0utilizar\u00a0PPD.\u00a0Los\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0de\u00a0edad\u00a0con\u00a0serolog\u00eda\u00a0positiva\npara\u00a0VIH,\u00a0deben\u00a0ser\u00a0sometidos\u00a0a\u00a0una\u00a0prueba\u00a0de\u00a0PPD\u00a0y\u00a0evaluados\u00a0de\u00a0acuerdo\u00a0a\u00a0resultados.\n7 . 1 . 2 . 7\u00a0Los\u00a0ni\u00f1os\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0de\u00a0edad\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH,\u00a0con\u00a0prueba\u00a0de\u00a0PPD\u00a0positiva,\u00a0deben\u00a0ser\nrevisados\u00a0por\u00a0cl\u00ednica,\u00a0gabinete,\u00a0laboratorio\u00a0y\u00a0pruebas\u00a0de\u00a0biolog\u00eda\u00a0molecular,\u00a0si\u00a0est\u00e1n\u00a0disponibles,\u00a0para\u00a0descartar\u00a0tuberculosis\nactiva.\n7 . 1 . 2 . 8\u00a0Los\u00a0ni\u00f1os\u00a0menores\u00a0de\u00a0cinco\u00a0a\u00f1os\u00a0de\u00a0edad,\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH,\u00a0con\u00a0prueba\u00a0de\u00a0PPD\u00a0negativa\u00a0y\u00a0la\u00a0cuenta\nde\u00a0linfocitos\u00a0CD4+\u00a0menor\u00a0de\u00a0200\u00a0c\u00e9lulas/mm3\u00a0y\u00a0en\u00a0quienes\u00a0se\u00a0haya\u00a0descartado\u00a0tuberculosis\u00a0activa,\u00a0deben\u00a0ser\u00a0revisados\u00a0y\u00a0su\ntratamiento\u00a0asesorado\u00a0por\u00a0el\u00a0m\u00e9dico\u00a0especialista.\n7 . 1 . 2 . 9\u00a0Profilaxis\u00a0(terapia\u00a0preventiva\u00a0con\u00a0H).\n7 . 1 . 2 . 9 . 1\u00a0Aquellas\u00a0personas\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH,\u00a0sin\u00a0evidencia\u00a0de\u00a0enfermedad\u00a0activa,\u00a0deben\u00a0recibir\u00a0terapia\npreventiva\u00a0con\u00a0H\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.1.2.3,\u00a0de\u00a0esta\u00a0Norma,\u00a0vigilar,\u00a0atender\u00a0y\u00a0registrar\u00a0los\u00a0efectos\u00a0adversos\u00a0durante\u00a0el\ntratamiento.\n7 . 1 . 2 . 1 0\u00a0Tratamiento.\n7 . 1 . 2 . 1 0 . 1\u00a0Todos\u00a0los\u00a0pacientes\u00a0con\u00a0serolog\u00eda\u00a0positiva\u00a0para\u00a0VIH\u00a0en\u00a0quienes\u00a0se\u00a0demuestre\u00a0tuberculosis\u00a0activa\u00a0en\u00a0cualquier\nlocalizaci\u00f3n,\u00a0se\u00a0recomienda\u00a0que\u00a0reciban\u00a0tratamiento\u00a0primario\u00a0de\u00a0acuerdo\u00a0al\u00a0punto\u00a06.6,\u00a0de\u00a0esta\u00a0Norma.\n7 . 1 . 2 . 1 0 . 2\u00a0La\u00a0coinfecci\u00f3n\u00a0TB/VIH\u00a0es\u00a0indicaci\u00f3n\u00a0formal\u00a0de\u00a0inicio\u00a0de\u00a0tratamiento\u00a0antirretroviral\u00a0y\u00a0se\u00a0deber\u00e1\u00a0implementar\ndependiendo\u00a0de\u00a0la\u00a0cantidad\u00a0de\u00a0CD4.\u00a0Se\u00a0recomienda\u00a0iniciar\u00a0la\u00a0terapia\u00a0antirretroviral\u00a0entre\u00a0dos\u00a0y\u00a0ocho\u00a0semanas\u00a0despu\u00e9s\u00a0de\u00a0iniciar\nel\u00a0tratamiento\u00a0de\u00a0la\u00a0tuberculosis,\u00a0para\u00a0reducir\u00a0la\u00a0probabilidad\u00a0de\u00a0efectos\u00a0adversos\u00a0del\u00a0tratamiento,\u00a0interacciones\u00a0farmacol\u00f3gicas\u00a0y\nel\u00a0s\u00edndrome\u00a0inflamatorio\u00a0de\u00a0reconstituci\u00f3n\u00a0inmune.\n8 . \u00a0 T u b e r c u l o s i s \u00a0 f a r m a c o r r e s i s t e n t e\nLa\u00a0mejor\u00a0forma\u00a0de\u00a0prevenir\u00a0la\u00a0farmacorresistencia\u00a0en\u00a0la\u00a0tuberculosis\u00a0es\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0detecci\u00f3n\u00a0oportuna\u00a0y\u00a0curaci\u00f3n\u00a0de\u00a0todos\nlos\u00a0casos\u00a0nuevos,\u00a0con\u00a0esquemas\u00a0primarios\u00a0estrictamente\u00a0supervisados.\n8 . 1\u00a0Diagn\u00f3stico.\n8 . 1 . 1\u00a0Se\u00a0sospecha\u00a0farmacorresistencia\u00a0en\u00a0todo\u00a0paciente\u00a0con\u00a0tuberculosis\u00a0que\u00a0curse\u00a0con\u00a0reca\u00edda,\u00a0m\u00faltiples\u00a0abandonos\u00a0y\nfracaso\u00a0a\u00a0un\u00a0esquema\u00a0de\u00a0tratamiento\u00a0y\u00a0retratamiento\u00a0primario.\u00a0Asimismo,\u00a0en\u00a0contactos\u00a0con\u00a0casos\u00a0de\u00a0TB\u00adMFR.\n8 . 1 . 2\u00a0En\u00a0todos\u00a0los\u00a0casos\u00a0se\u00a0debe\u00a0realizar\u00a0el\u00a0llenado\u00a0del\u00a0formato\u00a0de\u00a0historial\u00a0farmacol\u00f3gico\u00a0de\u00a0los\u00a0tratamientos\u00a0previos,\u00a0que\u00a0se\nencuentra\u00a0en\u00a0la\u00a0Gu\u00eda\u00a0para\u00a0la\u00a0atenci\u00f3n\u00a0de\u00a0personas\u00a0con\u00a0Tuberculosis\u00a0Resistente\u00a0a\u00a0F\u00e1rmacos,\u00a0que\u00a0se\u00a0encuentra\u00a0publicada\u00a0en\u00a0la\np\u00e1gina\u00a0de\u00a0internet\u00a0http://www.cenaprece.salud.gob.mx/\u00a0programas/interior/portada_manuales.html.\n8 . 1 . 3\u00a0En\u00a0la\u00a0TB\u00adMFR\u00a0y\u00a0casos\u00a0sospechosos,\u00a0se\u00a0debe\u00a0demostrar\u00a0por\u00a0PFS\u00a0la\u00a0presencia\u00a0de\u00a0microbacterias\u00a0tuberculosas\nresistentes\u00a0a\u00a0H\u00a0y\u00a0R\u00a0en\u00a0forma\u00a0simult\u00e1nea,\u00a0independientemente\u00a0de\u00a0la\u00a0resistencia\u00a0concomitante\u00a0a\u00a0otros\u00a0f\u00e1rmacos.\n8 . 2\u00a0Retratamiento\u00a0con\u00a0medicamentos\u00a0de\u00a0segunda\u00a0l\u00ednea.\n8 . 2 . 1\u00a0Todos\u00a0los\u00a0casos\u00a0se\u00a0sugieren\u00a0ser\u00a0evaluados\u00a0por\u00a0el\u00a0COEFAR.\n8 . 2 . 2\u00a0Antes\u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento,\u00a0se\u00a0debe\u00a0asegurar\u00a0la\u00a0disponibilidad\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0anti\u00a0tuberculosis\u00a0que\u00a0se\u00a0utilizar\u00e1n\npara\u00a0todo\u00a0el\u00a0periodo\u00a0de\u00a0tratamiento.\n8 . 2 . 3\u00a0Se\u00a0debe\u00a0explicar\u00a0al\u00a0enfermo\u00a0de\u00a0manera\u00a0clara\u00a0y\u00a0completa\u00a0las\u00a0caracter\u00edsticas\u00a0del\u00a0tratamiento\u00a0farmacol\u00f3gico,\u00a0el\u00a0tiempo\u00a0que\nrecibir\u00e1\u00a0tratamiento,\u00a0los\u00a0posibles\u00a0efectos\u00a0adversos\u00a0del\u00a0mismo\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0interrumpirlo.\u00a0El\u00a0paciente\u00a0o\u00a0su\u00a0representante\u00a0legal,\u00a0en\nsu\u00a0caso,\u00a0debe\u00a0firmar\u00a0una\u00a0carta\u00a0de\u00a0consentimiento\u00a0informado,\u00a0donde\u00a0se\u00a0responsabilice\u00a0a\u00a0seguir\u00a0el\u00a0tratamiento\u00a0hasta\u00a0finalizarlo.\n8 . 2 . 4\u00a0Se\u00a0debe\u00a0garantizar\u00a0la\u00a0supervisi\u00f3n\u00a0directa\u00a0del\u00a0tratamiento\u00a0por\u00a0personal\u00a0de\u00a0salud\u00a0debidamente\u00a0capacitado.\n8 . 2 . 5\u00a0Los\u00a0pacientes\u00a0con\u00a0adicci\u00f3n\u00a0al\u00a0alcohol\u00a0y\u00a0otras\u00a0sustancias,\u00a0deben\u00a0ingresar\u00a0a\u00a0un\u00a0programa\u00a0de\u00a0rehabilitaci\u00f3n\u00a0antes\u00a0de\niniciar\u00a0el\u00a0tratamiento\u00a0de\u00a0tuberculosis.\n8 . 2 . 6\u00a0El\u00a0tratamiento\u00a0recomendado\u00a0para\u00a0TB\u00adMFR\u00a0es\u00a0un\u00a0esquema\u00a0de\u00a0retratamiento\u00a0estandarizado\u00a0o\u00a0individualizado.\n8 . 3\u00a0Los\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0que\u00a0se\u00a0utilizan\u00a0en\u00a0el\u00a0retratamiento\u00a0estandarizado\u00a0y\u00a0retratamiento\u00a0individualizado\u00a0se\nespecifican\u00a0en\u00a0las\u00a0TABLAS\u00a04\u00a0y\u00a05,\u00a0de\u00a0esta\u00a0Norma.\nT A B L A \u00a0 4 . \u00a0 F \u00e1 r m a c o s \u00a0 a n t i \u00a0 t u b e r c u l o s i s \u00a0 d e \u00a0 s e g u n d a \u00a0 l \u00ed n e a \u00a0 c l a s i f i c a d o s \u00a0 p o r \u00a0 g r u p o .\nG R U P O S G r u p o \u00a0 d e\nm e d i c a m e n t o sM e d i c a m e n t o \u00a0 ( a b r e v i a t u r a ) O b s e r v a c i o n e s\nGRUPO\u00a01F\u00e1rmacos\u00a0orales\u00a0de\nprimera\u00a0l\u00ednea\u00a0\u00fatiles\nen\u00a0Tx\u00a0TB\u00adMFR.Etambutol\u00a0(E)\u037e\u00a0Pirazinamida\u00a0(Z).Son\u00a0f\u00e1rmacos\u00a0potentes,\u00a0pero\u00a0s\u00f3lo\u00a0se\nemplean\u00a0si\u00a0hay\u00a0datos\u00a0cl\u00ednicos\u00a0o\u00a0de\nlaboratorio\u00a0que\u00a0apunten\u00a0su\u00a0eficacia.\nGRUPO\u00a02F\u00e1rmacos\ninyectables.Estreptomicina\u00a0(S)*\u037e\u00a0Kanamicina\n(Km)\u037e\u00a0Amikacina\u00a0(Am)\u037e\nCapreomicina\u00a0(Cm).No\u00a0existe\u00a0ninguna\u00a0diferencia\u00a0en\ncuanto\u00a0a\u00a0eficacia\u00a0entre\u00a0los\naminogluc\u00f3sidos\u00a0(Km\u00a0y\u00a0Am)\u00a0y\u00a0la\ncapreomicina.\nGRUPO\u00a03Fluoroquinolonas.Ofloxacino\u00a0(Ofx)\u037e\u00a0Levofloxacino\n(Lfx)\u037e\u00a0Moxifloxacino\u00a0(Mfx).No\u00a0hay\u00a0evidencia\u00a0de\u00a0resistencia\ncruzada\u00a0entre\u00a0quinolinas.\nGRUPO\u00a04Bacteriost\u00e1ticos\norales\u00a0de\u00a0segunda\nl\u00ednea.Etiinamida\u00a0(Eto)\u037e\u00a0Protionamida\n(Pto)\u037e\u00a0Cicloserina\u00a0(Cs)\u037e\u00a0Terizidona\n(Trd)\u037e\u00a0Acido\u00a0.\u00a0p\u00adaminosalic\u00edlico\n(PAS).No\u00a0todos\u00a0tienen\u00a0el\u00a0mismo\u00a0grado\u00a0de\nefectividad.\nGRUPO\u00a05F\u00e1rmacos\u00a0de\u00a0eficaciaClofazimina\u00a0 (Cfz)\u037eNo\u00a0recomendados\u00a0para\u00a0uso\u00a0corriente2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 19/23poco\u00a0clara. Amoxicilina/Clavulanato\n(Amx/Clv)\u037e\u00a0Claritromicina\u00a0(Clr)\u037e\nLinezolid\u00a0(Lzd)\u037e\u00a0Tioacetazona\n(Th)\u037e\u00a0 Imipenem/Cilastat\u00edn\n(Ipm/Cln)\u037e\u00a0dosis\u00a0altas\u00a0de\nIsoniazida\u037e\u00a0Clariromicina\u00a0(Clr)con\u00a0pacientes\u00a0de\u00a0TB\u00adMFR.\n*No\u00a0se\u00a0debe\u00a0utilizar\u00a0estreptomicina\u00a0en\u00a0un\u00a0esquema\u00a0de\u00a0segunda\u00a0l\u00ednea.\nT A B L A \u00a0 5 . \u00a0 F \u00e1 r m a c o s \u00a0 a n t i \u00a0 t u b e r c u l o s i s . \u00a0 D o s i s \u00a0 y \u00a0 E f e c t o s \u00a0 A d v e r s o s .\nF \u00c1 R M A C O D O S I S E F E C T O S\nA D V E R S O SV I G I L A R A C C I O N E S\nG R U P O \u00a0 1 : \u00a0 F \u00c1 R M A C O S \u00a0 O R A L E S \u00a0 D E \u00a0 P R I M E R A \u00a0 L \u00cd N E A \u00a0 \u00da T I L E S \u00a0 E N \u00a0 T R A T A M I E N T O S \u00a0 D E \u00a0 S E G U N D A \u00a0 L \u00cd N E A .\nEtambutol\u00a0(E)25\u00a0mg/kg\nM\u00e1x.\u00a01,600\u00ad2,000\u00a0mgNeuritis\u00a0\u00f3ptica. Vigilar\u00a0alteraciones\nvisuales.\nLa\u00a0dosis\u00a0se\u00a0modifica\u00a0en\ninsuficiencia\u00a0renal.Suspender\u00a0 Etambutol.\nUsualmente\u00a0revierte\u00a0al\nsuspender\u00a0el\u00a0f\u00e1rmaco,\u00a0pero\nrequiere\u00a0de\u00a0valoraci\u00f3n\u00a0por\nOftalmolog\u00eda.\nPirazinamida\u00a0(Z)30\u00ad40\u00a0mg/d\nM\u00e1x.\u00a02,000\u00ad2,500\u00a0mgArtropat\u00eda\u00a0gotosa,\nhepatitis,\u00a0gastritis.Vigilar\u00a0PFH,\u00a0niveles\u00a0de\n\u00e1cido\u00a0\u00farico.\u00a0La\u00a0dosis\u00a0se\nmodifica\u00a0en\u00a0insuficiencia\nrenal.La\u00a0artritis\u00a0habitualmente\ndisminuye\u00a0con\u00a0el\u00a0tiempo\u00a0aun\u00a0sin\ntratamiento.\u00a0Se\u00a0pueden\nadministrar\u00a0antiinflamatorios\u00a0no\nesteroideos\u00a0y/o\u00a0disminuir\u00a0la\ndosis\u00a0en\u00a0caso\u00a0necesario.\nG R U P O \u00a0 2 : \u00a0 F \u00c1 R M A C O S \u00a0 I N Y E C T A B L E S .2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 20/23Capreomicina15\u00ad20\u00a0mg/kg\nM\u00e1x.\u00a01,000\u00a0mg\n\u00a0(El\u00a0perfil\u00a0de\u00a0efectos\nadversos\u00a0 entre\naminogluc\u00f3sidos\u00a0y\u00a0la\nCapreomicina\u00a0es\u00a0muy\nsimilar)\u00a0Nefrotoxicidad,\nla\u00a0cual\u00a0se\u00a0incrementa\ncon\u00a0la\u00a0administraci\u00f3n\u00a0de\notros\u00a0nefrot\u00f3xicos.\nOtotoxicidad\u00a0con\nhipoacusia\u00a0y\u00a0sordera\nirreversible\u037e\u00a0da\u00f1o\nvestibular.\u00a0Alteraciones\nhidroelectrol\u00edticas.Vigilar\u00a0pruebas\u00a0de\nfunci\u00f3n\u00a0renal\u00a0(creatinina,\nBUN,\u00a0urea)\u00a0y\u00a0ES\u00a0en\u00a0el\ncaso\u00a0de\u00a0capreomicina.\nPor\u00a0el\u00a0uso\u00a0prolongado\nse\u00a0requiere\u00a0de\naudiometr\u00eda\u00a0cada\u00a0dos\u00a0o\ntres\u00a0meses.\u00a0Se\u00a0debe\nmodificar\u00a0la\u00a0dosis\u00a0en\ninsuficiencia\u00a0renal.En\u00a0caso\u00a0de\u00a0cursar\u00a0con\u00a0elevaci\u00f3n\nde\u00a0azoados\u00a0se\u00a0puede\nsuspender\u00a0temporalmente\u00a0(no\nm\u00e1s\u00a0de\u00a0dos\u00a0semanas)\u00a0y\nreajustar\u00a0la\u00a0dosis\u00a0de\u00a0acuerdo\u00a0a\nla\u00a0funci\u00f3n\u00a0renal.\u00a0En\u00a0caso\u00a0de\nototoxicidad,\u00a0 valorar\nriesgo/beneficio\u00a0para\u00a0suspender\nel\u00a0tratamiento.Kanamicina15\u00ad20\u00a0mg/kg\nM\u00e1x.\u00a01,000\u00a0mg\n\u00a0\nAmikacina 15\u00ad20\u00a0mg/kg\nM\u00e1x.\u00a01,000\u00a0mg\nG R U P O \u00a0 3 : \u00a0 F L U O R O Q U I N O L O N A S .\nOfloxacino 800\u00a0mg/d\u00eda N\u00e1useas,\u00a0v\u00f3mito,\ngastritis,\u00a0insomnio,\ncefalea,\u00a0v\u00e9rtigo.\u00a0Rara\nvez\u00a0crisis\u00a0convulsiva.Vigilar\u00a0tolerancia\ngastrointestinal\u00a0y\u00a0estado\nneurol\u00f3gico.\u00a0Ofx\u00a0y\u00a0Lfx:\u00a0la\ndosis\u00a0se\u00a0modifica\u00a0en\ninsuficiencia\u00a0renal.Estos\u00a0s\u00edntomas\u00a0por\u00a0lo\u00a0general\nmejoran\u00a0con\u00a0el\u00a0tiempo\u00a0aun\u00a0sin\nintervenci\u00f3n.\u00a0En\u00a0caso\u00a0de\ntoxicidad\u00a0del\u00a0SNC\u00a0suspender\nmodificaci\u00f3n.Levofloxacino750\u00a0\u00ad\u00a01,000\u00a0mg/d\u00eda\nMoxifloxacino400\u00a0mg/d\u00eda\nG R U P O \u00a0 4 : \u00a0 B A C T E R I O S T \u00c1 T I C O S \u00a0 O R A L E S \u00a0 D E \u00a0 S E G U N D A \u00a0 L \u00cd N E A .\nProtionamida\u00a0(Pto)\n/\u00a0Etionamida\u00a0(Eto)15\u00ad20\u00a0mg/kg\nM\u00e1x.\u00a01,000\u00a0mgIntolerancia\ngastrointestinal\n(Gastritis,\u00a0n\u00e1usea,\nv\u00f3mito)\u00a0 dolor\nabdominal,\u00a0sabor\nmet\u00e1lico.\nNeurotoxicidad\n(depresi\u00f3n,\u00a0mareo).\nNeuropat\u00eda\u00a0perif\u00e9rica,\nhepatitis\u00a0hipotiroidismo\n(sobre\u00a0todo\u00a0si\u00a0se\ncombina\u00a0con\u00a0PAS).Vigilar\u00a0PFH\u00a0y\u00a0PFT.\nVigilar\u00a0estado\u00a0de\nhidrataci\u00f3n\u00a0en\u00a0caso\u00a0de\nintolerancia\ngastrointestinal.Los\u00a0s\u00edntomas\u00a0gastrointestinales\nmejoran\u00a0al\u00a0dividir\u00a0las\u00a0dosis\u00a0o\ndisminuirlas.\u00a0Se\u00a0pueden\nadministrar\u00a0antiem\u00e9ticos.\u00a0Se\ndebe\u00a0administrar\u00a0piridoxina\u00a0200\u00ad\n300\u00a0mg\u00a0para\u00a0disminuir\u00a0el\u00a0riesgo\nde\u00a0neurotoxicidad.\nCicloserina\u00a0(Cs)\nTerizidona\u00a0(Trd)10\u00ad15\u00a0mg/kg\nM\u00e1x.\u00a01,000\u00a0mgAlteraciones\npsiqui\u00e1tricas:\nirritabilidad,\u00a0depresi\u00f3n,\nagresividad,\u00a0confusi\u00f3n,\nansiedad.\u00a0Insomnio,\npesadillas\u00a0nocturnas,\ncefalea.\u00a0En\u00a0raras\nocasiones\u00a0ideaci\u00f3n\nsuicida\u00a0y\u00a0crisis\nconvulsivas.Vigilar\u00a0estado.\nLa\u00a0dosis\u00a0se\u00a0modifica\u00a0en\ninsuficiencia\u00a0renal.Se\u00a0debe\u00a0administrar\u00a0piridoxina\n200\u00ad300\u00a0mg\u00a0para\u00a0disminuir\u00a0el\nriesgo\u00a0de\u00a0neurotoxicidad.\nAcido\u00a0P\u00adamino\nsalic\u00edlico\u00a0(PAS)150\u00a0mg/kg\nM\u00e1x.\u00a012\u00a0gGastritis,\u00a0n\u00e1usea,\nv\u00f3mito,\u00a0diarrea.\nHipotiroidismo\u00a0(el\u00a0riesgo\nse\u00a0incrementa\u00a0cuando\nse\u00a0combina\u00a0con\u00a0Pto.).\nEn\u00a0raras\u00a0ocasiones\nHepatitis\u00a0y\u00a0Sx\u00a0de\u00a0mala\nabsorci\u00f3n.Vigilar\u00a0estado\u00a0de\nhidrataci\u00f3n\u00a0en\u00a0caso\u00a0de\nintolerancia\ngastrointestinal\u00a0vigilar\npruebas\u00a0de\u00a0funci\u00f3n\nhep\u00e1tica\u00a0y\u00a0pruebas\u00a0de\nfunci\u00f3n\u00a0tiroideaSe\u00a0pueden\u00a0administrar\nantiem\u00e9ticos.\u00a0Se\u00a0debe\u00a0dividir\u00a0la\ndosis\u00a0en\u00a02\u00a0o\u00a03\u00a0tomas.2017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 21/23G R U P O \u00a0 5 : \u00a0 A N T I \u00a0 T U B E R C U L O S I S \u00a0 C O N \u00a0 E F I C A C I A \u00a0 P O C O \u00a0 C L A R A \u00a0 ( N O \u00a0 R E C O M E N D A D O S \u00a0 P O R \u00a0 L A \u00a0 O M S \u00a0 P A R A \u00a0 U S O\nC O R R I E N T E \u00a0 C O N \u00a0 P A C I E N T E S \u00a0 D E \u00a0 T B \u00ad M F R ) .\n\u00a0\n8 . 4\u00a0El\u00a0retratamiento\u00a0estandarizado\u00a0para\u00a0pacientes\u00a0con\u00a0TB\u00adMFR\u00a0est\u00e1\u00a0indicado\u00a0en\u00a0pacientes\u00a0que\u00a0hayan\u00a0recibido\u00a0s\u00f3lo\u00a0f\u00e1rmacos\nde\u00a0primera\u00a0l\u00ednea\u00a0y\u00a0el\u00a0retratamiento\u00a0individualizado\u00a0se\u00a0recomienda\u00a0ser\u00a0dictaminado\u00a0por\u00a0el\u00a0GANAFAR.\n8 . 5\u00a0Evaluaci\u00f3n.\n8 . 5 . 1\u00a0La\u00a0evaluaci\u00f3n\u00a0del\u00a0tratamiento\u00a0se\u00a0debe\u00a0realizar\u00a0con\u00a0los\u00a0criterios\u00a0cl\u00ednico,\u00a0de\u00a0laboratorio\u00a0y\u00a0bacilosc\u00f3pico\u00a0mensual,\nrealizando\u00a0cultivos\u00a0cada\u00a0dos\u00a0meses\u00a0durante\u00a0todo\u00a0el\u00a0tratamiento,\u00a0y\u00a0radiogr\u00e1fico\u00a0cada\u00a0seis\u00a0meses.\n8 . 5 . 2\u00a0Los\u00a0enfermos\u00a0que\u00a0fracasan,\u00a0abandonan\u00a0o\u00a0recaen\u00a0a\u00a0un\u00a0retratamiento\u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0deben\u00a0ser\nevaluados\u00a0por\u00a0el\u00a0GANAFAR,\u00a0el\u00a0cual\u00a0eval\u00faa\u00a0y\u00a0define\u00a0una\u00a0estrategia\u00a0de\u00a0tratamiento\u00a0y\u00a0los\u00a0f\u00e1rmacos\u00a0recomendados.\n8 . 5 . 3\u00a0Al\u00a0completar\u00a0el\u00a0esquema\u00a0de\u00a0tratamiento,\u00a0el\u00a0caso\u00a0se\u00a0debe\u00a0clasificar\u00a0como:\u00a0curaci\u00f3n,\u00a0t\u00e9rmino\u00a0de\u00a0tratamiento\u00a0o\u00a0fracaso\u00a0de\ntratamiento.\u00a0Las\u00a0definiciones\u00a0son\u00a0diferentes\u00a0a\u00a0las\u00a0empleadas\u00a0para\u00a0pacientes\u00a0con\u00a0tuberculosis\u00a0farmacosensible.\n8 . 5 . 4\u00a0Al\u00a0caso\u00a0que\u00a0no\u00a0completa\u00a0el\u00a0esquema\u00a0de\u00a0tratamiento,\u00a0se\u00a0puede\u00a0clasificar\u00a0como:\u00a0defunci\u00f3n\u00a0o\u00a0abandono.\n8 . 6\u00a0Registro\u00a0y\u00a0notificaci\u00f3n.\n8 . 6 . 1\u00a0Todos\u00a0los\u00a0casos\u00a0de\u00a0TB\u00adMFR\u00a0son\u00a0objeto\u00a0de\u00a0notificaci\u00f3n\u00a0obligada\u00a0por\u00a0parte\u00a0de\u00a0las\u00a0instituciones\u00a0que\u00a0conforman\u00a0el\u00a0Sistema\nNacional\u00a0de\u00a0Salud.\n8 . 6 . 2\u00a0La\u00a0notificaci\u00f3n\u00a0de\u00a0casos\u00a0probables\u00a0de\u00a0TB\u00adMFR\u00a0se\u00a0efect\u00faa\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0formatos\u00a0y\u00a0procedimientos\u00a0de\u00a0concentraci\u00f3n\nque\u00a0establece\u00a0el\u00a0SINAVE\u00a0y\u00a0el\u00a0CENAPRECE.\n8 . 6 . 3\u00a0La\u00a0notificaci\u00f3n\u00a0de\u00a0caso\u00a0nuevo\u00a0de\u00a0TB\u00adMFR\u00a0se\u00a0realiza\u00a0de\u00a0acuerdo\u00a0a\u00a0lo\u00a0que\u00a0se\u00a0establece\u00a0para\u00a0este\u00a0efecto\u00a0en\u00a0la\u00a0Norma\nOficial\u00a0Mexicana\u00a0citada\u00a0en\u00a0el\u00a0punto\u00a02.4,\u00a0del\u00a0cap\u00edtulo\u00a0de\u00a0Referencias,\u00a0de\u00a0esta\u00a0Norma\u00a0y\u00a0dem\u00e1s\u00a0disposiciones\u00a0jur\u00eddicas\u00a0aplicables.\n9 . \u00a0 B i b l i o g r a f \u00ed a\n9 . 1\u00a0Centers\u00a0for\u00a0Disease\u00a0Control.\u00a0Department\u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services,\u00a0Tb\u00a0Care\u00a0Guide,\u00a0Highlights\u00a0from\u00a0care\u00a0Curriculum\non\u00a0Tuberculosis\u00a03rd\u00a0ed.\u00a0Atlanta,\u00a01994.\n9 . 2\u00a0Centers\u00a0for\u00a0Disease\u00a0Control,\u00a01993\u00a0Revised\u00a0Classification\u00a0System\u00a0for\u00a0HIV\u00a0Infection\u00a0and\u00a0Expanded\u00a0Surveillance\u00a0Case\nDefinition\u00a0for\u00a0AIDS\u00a0among\u00a0Adolescents\u00a0and\u00a0Adults.\u00a0MMWR\u00a01992\u037e\u00a041:\u00a0(NO.RR17).\n9 . 3\u00a0Consejo\u00a0Nacional\u00a0de\u00a0Vacunaci\u00f3n,\u00a0Vacunaci\u00f3n.\u00a0Manual\u00a0de\u00a0Procedimientos\u00a0T\u00e9cnicos\u00a0de\u00a0Vacunaci\u00f3n.\u00a0Actualizaci\u00f3n\u00a02002.\n9 . 4\u00a0Cuadro\u00a0b\u00e1sico\u00a0para\u00a0el\u00a0primer\u00a0nivel\u00a0y\u00a0cat\u00e1logo\u00a0de\u00a0f\u00e1rmacos\u00a02008.\n9 . 5\u00a0Farga\u00a0V.,\u00a0Tuberculosis.\u00a0Ed.\u00a0Mediterr\u00e1neo.\u00a0Santiago\u00a0de\u00a0Chile,\u00a01992.\n9 . 6\u00a0Gald\u00f3s\u00a0Tanquis\u00a0H,\u00a0Cayla\u00a0J.A.,\u00a0Tuberculosis\u00a0Infantil.\u00a0Servicio\u00a0de\u00a0Epidemiolog\u00eda,\u00a0Instituto\u00a0Nacional\u00a0de\u00a0la\u00a0Salud\u00a0\"PI\u00a0Lesseps\",\nBarcelona,\u00a01993.\u00a0pp\u00a094.\n9 . 7\u00a0Red\u00a0Book,\u00a0Enfermedades\u00a0infecciosas\u00a0en\u00a0pediatr\u00eda.\u00a024a.\u00a0edici\u00f3n.\u00a0Buenos\u00a0Aires\u00a0Ed.\u00a0Panamericana\u00a02000:\u00a0pp.\u00a0581\u00ad587.\n9 . 8\u00a0Instituto\u00a0Nacional\u00a0de\u00a0Enfermedades\u00a0Respiratorias,\u00a0Cl\u00ednica\u00a0de\u00a0Tuberculosis.\u00a0Lineamientos\u00a0para\u00a0el\u00a0tratamiento\u00a0y\nretratamiento\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0tuberculosis\u00a0en\u00a0el\u00a0Instituto\u00a0Nacional\u00a0de\u00a0Enfermedades\u00a0Respiratorias.\u00a0M\u00e9xico,\u00a02005.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 22/239 . 9\u00a0Iseman\u00a0MD,\u00a0Treatment\u00a0of\u00a0multidrug\u00a0resistant\u00a0tuberculosis.\u00a0N.\u00a0Engl\u00a0Med\u00a0J,\u00a01993\u037e\u00a0329:\u00a0784\u00ad790.\n9 . 1 0\u00a0IUATLD,\u00a0Tuberculosis\u00a0Guide\u00a0for\u00a0Low\u00a0Income\u00a0Countries.\u00a04th\u00a0Ed.,\u00a0Bruselas,\u00a01996.\n9 . 1 1\u00a0Karam\u00a0Bechara\u00a0J,\u00a0Muchinik\u00a0J.,\u00a0Tuberculosis\u00a0en\u00a0el\u00a0ni\u00f1o.\u00a0Bol\u00a0Med.\u00a0Inf.,\u00a0M\u00e9xico,\u00a01995\u037e\u00a032:\u00a0537\u00ad47.\n9 . 1 2 \u00a0Instituto\u00a0de\u00a0Diagn\u00f3stico\u00a0y\u00a0Referencia\u00a0Epidemiol\u00f3gicos.\u00a0Secretar\u00eda\u00a0de\u00a0Agricultura,\u00a0Ganader\u00eda,\u00a0Desarrollo\u00a0Rural,\u00a0Pesca\u00a0y\nAlimentaci\u00f3n,\u00a0Manual\u00a0de\u00a0procedimientos\u00a0de\u00a0laboratorio,\u00a0Tuberculosis.\u00a02002.\n9 . 1 3\u00a0Medical\u00a0section\u00a0of\u00a0the\u00a0American\u00a0Lung\u00a0Association,\u00a0Treatment\u00a0of\u00a0tuberculosis\u00a0and\u00a0tuberculosis\u00a0infection\u00a0in\u00a0adults\u00a0and\nchildren.\u00a0Am\u00a0J\u00a0Respir\u00a0Crit\u00a0Care\u00a0Med,\u00a01994\u037e\u00a0149:\u00a01359\u00ad74.\n9 . 1 4\u00a0World\u00a0Health\u00a0Organization,\u00a0Treatment\u00a0of\u00a0Tuberculosis:\u00a0Guidelines\u00a0for\u00a0National\u00a0Programs.\u00a03d\u00a0ed.,\u00a0Geneva.\u00a0Switzerland,\n2003.\n9 . 1 5\u00a0Organizaci\u00f3n\u00a0Panamericana\u00a0de\u00a0la\u00a0Salud,\u00a0Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud,\u00a0Clasificaci\u00f3n\u00a0Estad\u00edstica\u00a0Internacional\u00a0de\nEnfermedades\u00a0y\u00a0Problemas\u00a0Relacionados\u00a0con\u00a0la\u00a0Salud.\u00a010a.\u00a0Revision,\u00a0109\u00ad113,\u00a01996.\n9 . 1 6\u00a0MMWR,\u00a0Population\u00ad\u00a0Based\u00a0Survey\u00a0for\u00a0drug\u00a0resistance\u00a0of\u00a0tuberculosis,\u00a0M\u00e9xico,\u00a01997:\u00a01997\u037e\u00a047\u00a0(18):371\u00ad375.\n9 . 1 7\u00a0Secretar\u00eda\u00a0de\u00a0Salud,\u00a0Gu\u00eda\u00a0para\u00a0la\u00a0atenci\u00f3n\u00a0de\u00a0la\u00a0Tuberculosis\u00a0Multifarmacorresistente.\u00a0M\u00e9xico,\u00a02009\n9 . 1 8\u00a0Hern\u00e1ndez\u00adCruz\u00a0B,\u00a0Ponce\u00adde\u00adLe\u00f3n\u00adRosales\u00a0S,\u00a0Sifuentes\u00adOsornio\u00a0J,\u00a0Ponce\u00adde\u00adLe\u00f3n\u00adGarduno\u00a0A,\u00a0Diaz\u00ad\u00a0Jouanen\u00a0E.,\nTuberculosis\u00a0prophylaxis\u00a0in\u00a0patients\u00a0with\u00a0steroid\u00a0treatment\u00a0and\u00a0systemic\u00a0rheumatic\u00a0diseases.\u00a0A\u00a0case\u00a0control\u00a0study.\u00a0Clinical\u00a0&\nExperimental\u00a0Rheumathology\u00a01999\u037e\u00a0Jan\u00adFeb\u037e\u00a017(1):\u00a081\u00ad87.\u00a0(Primera\u00a0Secci\u00f3n)\n9 . 1 9\u00a0Garc\u00eda\u00adGarc\u00eda\u00a0ML,\u00a0Ponce\u00adde\u00adLe\u00f3n\u00a0A,\u00a0Jim\u00e9nez\u00adCorona\u00a0ME,\u00a0Jim\u00e9nez\u00adCorona\u00a0A,\u00a0Palacios\u00adMart\u00ednez\u00a0M,\u00a0Balandrano\u00ad\nCampos\u00a0S,\u00a0Ferreira\u00adReyes\u00a0L,\u00a0Ju\u00e1rez\u00adSandino\u00a0L,\u00a0Sifuentes\u00adOsornio\u00a0J,\u00a0Olivera\u00adD\u00edaz\u00a0H,\u00a0Valdespino\u00adG\u00f3mez\u00a0JL,\u00a0Small\u00a0PM,\u00a0Clinical\nConquenses\u00a0and\u00a0Transmissibility\u00a0of\u00a0Drug\u00a0Resistant\u00a0Tuberculosis\u00a0in\u00a0Southern\u00a0M\u00e9xico.\u00a0Archives\u00a0of\u00a0Infernal\u00a0Medicine\u00a02000\u037e\u00a0160,\n630\u00ad636.\n9 . 2 0\u00a0Garc\u00eda\u00adGarc\u00eda\u00a0ML,\u00a0Sifuentes\u00adOsornio\u00a0J,\u00a0Jim\u00e9nez\u00adCorona\u00a0ME,\u00a0Ponce\u00adde\u00adLe\u00f3n\u00a0A,\u00a0Jim\u00e9nez\u00adCorona\u00a0A,\u00a0Bobadilla\u00a0del\u00a0Valle\nM,\u00a0Palacios\u00adMart\u00ednez\u00a0M,\u00a0Canales\u00a0G,\u00a0Sangin\u00e9s\u00a0A,\u00a0Jaramillo\u00a0Y,\u00a0Mart\u00ednez\u00adGamboa\u00a0A,\u00a0Balandrano\u00a0S,\u00a0Valdespino\u00adG\u00f3mez\u00a0JL,\u00a0Small\nPM,\u00a0Resistencia\u00a0de\u00a0Mycobacterium\u00a0tuberculosis\u00a0a\u00a0los\u00a0antimicrobianos\u00a0en\u00a0Orizaba,\u00a0Veracruz.\u00a0Implicaciones\u00a0para\u00a0el\u00a0Programa\u00a0de\nPrevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0la\u00a0Tuberculosis.\u00a0Revista\u00a0de\u00a0Investigaci\u00f3n\u00a0Cl\u00ednica\u00a02001\u037e\u00a053\u00a0(4):\u00a0315\u00ad323.\n9 . 2 1\u00a0Garc\u00eda\u00adGarc\u00eda\u00a0ML,\u00a0Ponce\u00adde\u00adLe\u00f3n\u00a0A,\u00a0Garc\u00eda\u00adSancho\u00a0MC,\u00a0Palacios\u00adMart\u00ednez\u00a0M,\u00a0Ferreira\u00adReyes\u00a0L,\u00a0Kato\u00ad\u00a0Maeda\u00a0M,\nBobadilla\u00a0M,\u00a0Small\u00a0PM,\u00a0Sifuentes\u00adOsornio\u00a0J.,\u00a0Risk\u00a0of\u00a0Death\u00a0in\u00a0a\u00a0Well\u00a0Functioning\u00a0DOTS\u00a0Program.\u00a0Emerging\u00a0Infectious\u00a0Diseases.\n2002\u037e\u00a0Nov\u037e\u00a08\u00a0(11)\u00a0:1327\u00ad33.\n9 . 2 2\u00a0Sifuentes\u00adOsornio\u00a0J,\u00a0Bobadilladel\u00adValle\u00a0M,\u00a0Kato\u00adMaeda\u00a0M,\u00a0Garc\u00eda\u00a0Garc\u00eda\u00a0ML,\u00a0Small\u00a0PM,\u00a0Matus\u00adRu\u00edz\u00a0MG,\u00a0Mart\u00ednez\u00ad\nGamboa\u00a0A,\u00a0Ch\u00e1vez\u00adMazari\u00a0B\u00a0y\u00a0Ponce\u00adde\u00adLe\u00f3n\u00a0A.,\u00a0Epidemiolog\u00eda\u00a0de\u00a0la\u00a0resistencia\u00a0antimicrobiana\u00a0en\u00a0Mycobacterium\ntuberculosis\u00a0en\u00a0M\u00e9xico.\u00a0Gaceta\u00a0M\u00e9dica\u00a0de\u00a0M\u00e9xico\u00a02003\u037e\u00a0139\u00a0(5):\u00a0477\u00ad480.\n9 . 2 3 \u00a0Ponce\u00adde\u00adLe\u00f3n\u00a0A,\u00a0Garc\u00eda\u00adGarc\u00eda\u00a0ML,\u00a0Garc\u00eda\u00adSancho\u00a0MC,\u00a0G\u00f3mez\u00adP\u00e9rez\u00a0F,\u00a0Olaiz\u00adFern\u00e1ndez\u00a0G,\u00a0Valdespino\u00ad\u00a0G\u00f3mez\u00a0JL,\nRojas\u00a0R,\u00a0Ferreira\u00adReyes\u00a0L,\u00a0Cano\u00adArellano\u00a0B,\u00a0Bobadilla\u00a0M,\u00a0Small\u00a0PM,\u00a0Sifuentes\u00adOsornio\u00a0J.,\u00a0Tuberculosis\u00a0and\u00a0diabetes\u00a0mellitus\u00a0in\nSouthern\u00a0Mexico.\u00a0Diabetes\u00a0Care\u00a02004\u037e\u00a0Jul\u037e\u00a027(7):1584\u00ad90.\n9 . 2 4\u00a0De\u00a0Riemer\u00a0K,\u00a0Garc\u00eda\u00adGarc\u00eda\u00a0ML,\u00a0Bobadilla\u00addel\u00adValle\u00a0JM,\u00a0Palacios\u00adMart\u00ednez\u00a0M,\u00a0Mart\u00ednez\u00adGamboa\u00a0A,\u00a0Small\u00a0PM,\u00a0Sifuentes\u00ad\nOsornio\u00a0J,\u00a0Ponce\u00adde\u00ad\u00a0Le\u00f3n\u00a0A.,\u00a0Does\u00a0DOTS\u00a0work\u00a0in\u00a0populations\u00a0with\u00a0drug\u00a0resistant\u00a0tuberculosis?\u00a0Lancet\u00a02004:\u00a0En\u00a0prensa.\n9 . 2 5\u00a0Secretar\u00eda\u00a0de\u00a0Salud,\u00a0Modelo\u00a0Operativo\u00a0de\u00a0Promoci\u00f3n\u00a0de\u00a0la\u00a0salud.\u00a01a.\u00a0edici\u00f3n,\u00a0M\u00e9xico\u00a02006.\n9 . 2 6\u00a0Secretar\u00eda\u00a0de\u00a0Salud,\u00a0Est\u00e1ndares\u00a0para\u00a0la\u00a0atenci\u00f3n\u00a0de\u00a0la\u00a0tuberculosis\u00a0en\u00a0M\u00e9xico,\u00a01a.\u00a0edici\u00f3n,\u00a0M\u00e9xico\u00a02009.\n\u00a02017\u00ad7\u00ad4 DOF\u00a0\u00ad\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n\nhttp://dof.gob.mx/nota_detalle_popup.php?codigo=5321934 23/239 . 2 7\u00a0World\u00a0Health\u00a0Organization,\u00a0Policy\u00a0on\u00a0TB\u00a0infection\u00a0control\u00a0in\u00a0health\u00adcare\u00a0facilities,\u00a0congregate\u00a0settings\u00a0and\u00a0households.\n2009.\n9 . 2 8\u00a0Ministerio\u00a0de\u00a0la\u00a0Salud\u00a0de\u00a0Per\u00fa,\u00a0Control\u00a0de\u00a0infecciones\u00a0de\u00a0tuberculosis\u00a0en\u00a0establecimientos\u00a0de\u00a0salud\u00a0m\u00f3dulo\u00a0de\ncapacitaci\u00f3n.\u00a02005.\n9 . 2 9\u00a0Secretar\u00eda\u00a0de\u00a0Salud\u00a0CENAPRECE,\u00a0Manual\u00a0para\u00a0la\u00a0prevenci\u00f3n\u00a0de\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0la\u00a0tuberculosis\u00a0en\u00a0establecimientos\nde\u00a0salud\u037e\u00a0M\u00e9xico,\u00a02011.\n9 . 3 0\u00a0F.J.\u00a0Curry,\u00a0Tuberculosis\u00a0Infection\u00a0Control.\u00a0A\u00a0practical\u00a0manual\u00a0for\u00a0preventing\u00a0TB.\u00a02007.\n9 . 3 1\u00a0World\u00a0Health\u00a0Organization,\u00a0IMPLEMENTING\u00a0the\u00a0WHO\u00a0Policy\u00a0on\u00a0TB\u00a0Infection\u00a0Control\u037e\u00a02009.\n9 . 3 2\u00a0World\u00a0Health\u00a0Organization,\u00a0Infection\u00a0prevention\u00a0and\u00a0control\u00a0of\u00a0epidemic\u00ad\u00a0and\u00a0pandemic\u00adprone\u00a0acute\u00a0respiratory\u00a0diseases\nin\u00a0health\u00a0care\u00a0\u00ad\u00a0World\u00a0Health\u00a0Organization\u00a0interim\u00a0guidelines\u037e\u00a0Geneva\u037e\u00a02007.\n9 . 3 3\u00a0World\u00a0Health\u00a0Organization,\u00a0Natural\u00a0ventilation\u00a0for\u00a0infection\u00a0control\u00a0in\u00a0health\u00adcare\u00a0settings\u037e\u00a02009.\n9 . 3 4\u00a0Secretar\u00eda\u00a0de\u00a0Salud,\u00a0Manual\u00a0de\u00a0t\u00e9cnicas\u00a0de\u00a0laboratorio\u00a0para\u00a0el\u00a0examen\u00a0bacilosc\u00f3pico\u037e\u00a02003.\n9 . 3 5\u00a0Organizaci\u00f3n\u00a0Panamericana\u00a0de\u00a0la\u00a0Salud/Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud,\u00a0Manual\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0bacteriol\u00f3gico\nde\u00a0la\u00a0Tuberculosis.\u00a0Normas\u00a0y\u00a0Gu\u00eda\u00a0t\u00e9cnica.\u00a0Parte\u00a01.\u00a0Baciloscopia,\u00a02008.\n9 . 3 6\u00a0Organizaci\u00f3n\u00a0Panamericana\u00a0de\u00a0la\u00a0Salud/Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud,\u00a0Manual\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0bacteriol\u00f3gico\nde\u00a0la\u00a0Tuberculosis.\u00a0Normas\u00a0y\u00a0Gu\u00eda\u00a0t\u00e9cnica.\u00a0Parte\u00a02.\u00a0Cultivo,\u00a02008.\n9 . 3 7\u00a0J.\u00a0C.\u00a0Palomino,\u00a0S.\u00a0Cardoso\u00a0Leao,\u00a0V.\u00a0Ritacco\u00a0et\u00a0al.\u00a0Tuberculosis\u00a0from\u00a0Basic\u00a0Science\u00a0to\u00a0Patient\u00a0Care,\u00a02007\n9 . 3 8\u00a0World\u00a0Health\u00a0Organization,\u00a0Treatment\u00a0of\u00a0tuberculosis.\u00a0Guidelines.\u00a0Fourth\u00a0Edition.\u00a0WHO/HTM/TB/2009.\n9 . 3 9\u00a0Cruz\u00adHervert\u00a0LP,\u00a0et\u00a0al,\u00a0Tuberculosis\u00a0in\u00a0ageing:\u00a0high\u00a0rates,\u00a0complex\u00a0diagnosis\u00a0and\u00a0poor\u00a0clinical\u00a0outcomes.\u00a0Age\u00a0Ageing.\n2012\u00a0Jul\u037e\u00a041(4):\u00a0488\u00ad95.\n9 . 4 0\u00a0World\u00a0Health\u00a0Organization.\u00a0International\u00a0Union\u00a0Against\u00a0Tuberculosis\u00a0and\u00a0Lung\u00a0Disease,\u00a0Collaborative\u00a0framework\u00a0for\ncare\u00a0and\u00a0control\u00a0of\u00a0tuberculosis\u00a0and\u00a0diabetes.\u00a02011.\n9 . 4 1\u00a0World\u00a0Health\u00a0Organization,\u00a0Antiretroviral\u00a0therapy\u00a0for\u00a0HIV\u00a0infection\u00a0in\u00a0adults\u00a0and\u00a0adolescents\u00a0in\u00a0resource\u00adlimited\u00a0setting:\nrecommendation\u00a0for\u00a0a\u00a0public\u00a0health\u00a0approach.\u00a0Geneva,\u00a02006.\n9 . 4 2\u00a0World\u00a0Health\u00a0Organization.\u00a0Guidelines\u00a0for\u00a0the\u00a0programmatic\u00a0management\u00a0of\u00a0drugresistant\u00a0tuberculosis.\u00a0Emergency\nupdate\u00a02008.\n9 . 4 3\u00a0Ley\u00a0Federal\u00a0sobre\u00a0Metrolog\u00eda\u00a0y\u00a0Normalizaci\u00f3n.\n9 . 4 4\u00a0World\u00a0Health\u00a0Organization.\u00a0Plan\u00a0to\u00a0stop\u00a0TB,\u00a02006\u00ad\u00a02015.\u00a0Geneva,\u00a02006.\n9 . 4 5\u00a0American\u00a0Thoracic\u00a0Society,\u00a0Diagnostic\u00a0standards\u00a0and\u00a0classification\u00a0of\u00a0tuberculosis\u00a0in\u00a0adults\u00a0and\u00a0children.\u00a0Am\u00a0J\u00a0Respir\nCrit\u00a0Care\u00a0Med\u00a02000.\n9 . 4 6\u00a0Secretar\u00eda\u00a0de\u00a0Salud.\u00a0Gu\u00eda\u00a0de\u00a0Pr\u00e1ctica\u00a0Cl\u00ednica.\u00a0Atenci\u00f3n,\u00a0diagn\u00f3stico\u00a0y\u00a0tratamiento\u00a0de\u00a0la\u00a0Tuberculosis\u00a0Pulmonar\u00a0en\npacientes\u00a0mayores\u00a0de\u00a018\u00a0a\u00f1os\u00a0en\u00a0el\u00a0primer\u00a0nivel\u00a0de\u00a0atenci\u00f3n.\u00a02011.\n9 . 4 7\u00a0R.\u00a0Bryan\u00a0Rock*,\u00a0Michael\u00a0Olin,\u00a0Cristina\u00a0A.\u00a0Baker,\u00a0Thomas\u00a0W.\u00a0Molitor\u00a0and\u00a0Phillip\u00a0K.\u00a0Peterson,\u00a0Central\u00a0Nervous\u00a0System\nTuberculosis:\u00a0Pathogenesis\u00a0and\u00a0Clinical\u00a0Aspects.\u00a0Clin\u00a0Microbiol\u00a0Rev\u00a02008\u037e\u00a021:243\u00ad261.\n1 0 . \u00a0 C o n c o r d a n c i a \u00a0 c o n \u00a0 n o r m a s \u00a0 i n t e r n a c i o n a l e s \u00a0 y \u00a0 n o r m a s \u00a0 m e x i c a n a s\nEsta\u00a0Norma\u00a0es\u00a0parcialmente\u00a0equivalente\u00a0con\u00a0los\u00a0lineamientos\u00a0y\u00a0recomendaciones\u00a0emitidos\u00a0por\u00a0la\u00a0OMS,\u00a0la\u00a0OPS,\u00a0La\u00a0Uni\u00f3n\u00a0y\nno\u00a0tiene\u00a0equivalencia\u00a0con\u00a0normas\u00a0mexicanas\u00a0por\u00a0no\u00a0existir\u00a0referencia\u00a0al\u00a0momento\u00a0de\u00a0su\u00a0elaboraci\u00f3n.\n1 1 . \u00a0 O b s e r v a n c i a \u00a0 d e \u00a0 l a \u00a0 N o r m a\nLa\u00a0vigilancia\u00a0en\u00a0el\u00a0cumplimiento\u00a0de\u00a0la\u00a0presente\u00a0Norma\u00a0corresponde\u00a0a\u00a0la\u00a0Secretar\u00eda\u00a0de\u00a0Salud\u00a0y\u00a0a\u00a0los\u00a0gobiernos\u00a0de\u00a0las\nentidades\u00a0federativas\u00a0en\u00a0el\u00a0\u00e1mbito\u00a0de\u00a0sus\u00a0respectivas\u00a0competencias.\n1 2 . \u00a0 V i g e n c i a\nEsta\u00a0Norma\u00a0entrar\u00e1\u00a0en\u00a0vigor\u00a0al\u00a0d\u00eda\u00a0siguiente\u00a0al\u00a0de\u00a0su\u00a0publicaci\u00f3n\u00a0en\u00a0el\u00a0Diario\u00a0Oficial\u00a0de\u00a0la\u00a0Federaci\u00f3n.\nSufragio\u00a0Efectivo.\u00a0No\u00a0Reelecci\u00f3n.\nM\u00e9xico,\u00a0D.F.,\u00a0a\u00a010\u00a0de\u00a0septiembre\u00a0de\u00a02013.\u00ad\u00a0El\u00a0Subsecretario\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Promoci\u00f3n\u00a0de\u00a0la\u00a0Salud\u00a0y\u00a0Presidente\u00a0del\u00a0Comit\u00e9\nConsultivo\u00a0Nacional\u00a0de\u00a0Normalizaci\u00f3n\u00a0de\u00a0Prevenci\u00f3n\u00a0y\u00a0Control\u00a0de\u00a0Enfermedades,\u00a0 P a b l o \u00a0 A n t o n i o \u00a0 K u r i \u00a0 M o r a l e s.\u00ad\u00a0R\u00fabrica.\n\u00a0\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}